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Multiple sclerosis, a general introduction 
Multiple Sclerosis (MS) is the most common neurodegenerative disease 
among young adults in the Western world affecting about 1 per 1,000. In 
healthy individuals most nerves in the central nervous system (CNS) are 
insulated by a fatty substance called myelin, which permits the efficient 
transmission of electrical impulses signaled by the nerve cell. During MS 
the local occurrence of inflammatory reactions in the CNS white matter 
leads to focal areas of demyelination (lesions or plaques). The insulating 
myelin that is wrapped around axons is degraded. A first attempt to separate 
MS from other neurological diseases was made by Charcot over a hundred 
years ago. Charcot described the pathology of MS in terms of demyelination 
and relative sparing of axons. Nowadays it is known that inflammatory 
demyelination and the production of nitric oxide (NO) result in conduction 
block and axonal damage and eventually in transection of axons and axonal 
loss during disease progression (1). Axonal loss is the pathological hallmark 
of MS and increases in lesions as they age. As a consequence of 
demyelination and axonal loss neuronal signal induction is impaired giving 
rise to many different neurological symptoms. There are two different 
phases of axon degeneration, the first occurring during active myelin 
breakdown and the second in chronic demyelinated plaques in which the 
naked axons appear to be more susceptible to further damage. Although 
myelin can normally repair itself and remyelination has been seen in up to 
70 % of lesions, scarring by the influx and proliferation of astrocytes 
(astrogliosis) happens too rapidly for complete healing to take place. 
Repeated inflammation of the nerves results in many (Multiple) lesions 
which evolve into dysfunctional scars (Sclerosis). Scars are visible 
macroscopically in the CNS of patients upon obduction. MS is often chronic 
and progressive due to repetitive inflammatory reactions. 
 
Clinical and pathological features of MS 
A person may live for years with MS before a diagnosis is set. The initial 
attack of MS occurring sometimes as early as the teen-age years may be 
brief and mild, and may not even be recognized. Generally the first major 
attack, lasting for weeks or months, takes place between the age of 20 and 
40, and further attacks follow at erratic intervals. The symptoms temporarily 
abate or disappear for unknown reasons, but recurrence is highly likely 
although usually after a long latency period. The first attack is followed by a 
period of remission of perhaps years before the next episode. The symptoms 
of the disease are diverse, depending on where in the brain, spinal cord or 
optic nerve these patches of demyelination and axonal damage are located. 
General Introduction   
 9 
Symptoms range from relatively minor physical annoyances to major 
disabilities such as loss of muscular coordination, stiffness (spasticity), 
impaired vision or even loss of vision, bowel or bladder incontinence and 
general tiredness or extreme exhaustion. As a result of the lasting CNS 
damage, 77 % of MS patients are limited to some degree in their activities 
and about 25 % become wheelchair-bound. 
There are four clinical subgroups of MS. Relapsing-remitting (RR) MS is 
the most common one, following a relapsing-remitting course with transient 
neurological deficits that tend to resolve completely at the beginning of the 
disease. With time RR-MS may change into a more progressive subtype; 
secondary-progressive (SP) MS which is characterized by incomplete 
recovery or steady progression of the disease. Patients with the primary-
progressive (PP) MS subtype have an overall poorer prognosis. They do not 
experience an initial attack since the disease progresses from onset, with 
occasional plateaus with an absence of relapsing-remitting periods. 
Progressive disease from onset but associated with clear acute relapses 
followed by full or partial recovery is called progressive-relapsing (PR) MS. 
Periods between relapses are characterized by continuing progression. Only 
5 % of MS patients have this very rare clinical PR course. Sometimes 
exacerbations in MS patients are preceded by special events like physical 
exercise, mental tension or a bacterial or viral infection, but most of the time 
they appear without any traceable direct cause. The clinical course of MS is 
rather unpredictable. To be certain of the diagnosis of MS different clinical 
and laboratory tests are necessary including electrophysiological tests, 
magnetic resonance imaging (MRI) of the brain and the spinal cord as well 
as analysis of the cerebrospinal fluid (CSF) for the presence of oligoclonal 
immunoglobulins (2). Since many MRI signals are non-specific to MS 
reliance on these data alone is not sufficient for the diagnosis and can lead 
to diagnostic errors. This becomes an important issue in epidemiological 
surveys and participation in clinical trials using very expensive disease 
modifying drugs. Confirming the diagnosis signs and symptoms have to be 
present disseminated in time and space. Episodes of symptoms have to last 
for 24 h and must be separated by at least one month. Signs of MS must be 
attributable to involvement of at least two parts of the brain or spinal cord 
(3). MS neuropathology may appear in any CNS region and even in grey 
matter, but some areas are more frequently affected including perivascular 
white matter, the periphery of cerebral gyri, optic nerve, chiasm, pons,  
cerebellar peduncles, medulla oblongata and the spinal cord (4,5). 
Furthermore, there is a high incidence of active lesions in the hypothalamus 
which might form the basis for autonomic and endocrine alterations in MS 
patients (6). 
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There are different forms of lesions including pre-active, active, chronic 
active and chronic inactive lesions. These different lesion stages are 
suggested to reflect stages in disease progression (7). The two most 
common lesion types are chronic active and chronic inactive lesions. In 
chronic active lesions the number of T-cells and macrophages increase from 
the center to the edge of the lesion and penetrate white matter adjacent to 
the lesion. Inflammatory reactions are characterized by foci of myelin 
degeneration. In inactive chronic lesions T-cells and macrophages are fewer 
and more demyelination is seen. The age of the lesion can be established by 
the presence of myelin degradation products in macrophages (8). 
Lesions of different MS patients show a profound heterogeneity in the 
structural and immunopathological patterns of demyelination and 
oligodendrocyte pathology (9). However, for a given individual, multiple 
lesions show the same pattern regardless of the localization or the stage of 
the lesion. Lucchinetti et al. investigated brain samples from biopsies (a rare 
procedure sometimes necessary to exclude other possible diseases) as well 
as from post mortem MS brain (10). Four distinct patterns of demyelination 
are detected based on myelin damage and the presence of immune cells. 
This finding suggests that MS is a group of similar clinical diseases that 
have different causes and involvement of different myelin destruction 
mechanisms. In contrast to these findings Barnett et al. showed that 
heterogeneity may also exist among lesions in a single patient (11). Some 
lesions show the involvement of antibodies in the demyelination process 
while others show more evidence for a primary oligodendrocyte defect (e.g. 
viral infection) (12). Different lesion types among patients or within a single 
patient might be due to individual disease progression, age of disease as 
well as perhaps to infiltrated T-cells reacting against different antigens (13). 
Remyelination in MS lesions is promoted by neurotrophic factors and 
growth factors.  Various experimental models of demyelination and 
remyelination have shown an increased presence of growth factors 
including insulin-like growth factor I (IGFI), fibroblast growth factor 1 
(FGF-1), FGF-2, platelet-derived growth factor A (PDGF-A), TGF-β1, 
nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF). 
Increased production of NGF and other trophic factors can suppress 
inflammation by switching the immune response to an anti-inflammatory, 
suppressive mode in a brain-specific environment (14). Growth factors are 
expressed during the early stages of remyelination and promote recruitment, 
proliferation and motility of adult oligodendrocyte progenitors (OP). The 
presence of these adult OP in lesions is necessary to start remyelination. 
Growth factors and neurotrophins play a role in orchestrating the behavior 
and survival of the adult OP in remyelination and may be used as a 
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therapeutic approach to promote remyelination in clinical disease (15). A 
clearer path to achieve therapeutic remyelination might emerge from careful 
dissection of the roles performed by growth factors and other key mediators 
of this important repair process in MS.  
  
MS Therapies  
MS is associated with enormous direct and indirect costs for the patient, the 
health care system and society. The patients carry most of the economic 
burden of the disease including earnings loss and equipment needed in 
normal daily life. Results of cost-effectiveness studies provide a basis for 
analyses of new therapeutic interventions for MS (16). 
There is currently no cure available for MS and most of the therapies are 
based on drugs that suppress the immune response in a non-antigen specific 
manner. Suppression of the inflammatory process and restoration and 
protection of glial and neuron functions are the major subjects in MS 
treatment. Glucocorticoids are widely used in the treatment of a variety of 
autoimmune diseases because of their anti-inflammatory and 
immunosuppressive properties. Synthetic glucocorticoids including 
prednisone and methylprednisone are given during severe relapses in RR 
MS patients. Several immunosuppressants including azathioprine and 
cyclophosphamide show beneficial effects in terms of reducing 
exacerbations and clinical progression (17). However, all of these drugs 
have serious side-effects when used for a longer period of time. Treatment 
with interferon-β (IFN-β) results in 30 % reduction of the relapse rate and 
the lesion frequency on MRI is decreased in RR MS patients. IFN-
β treatment is also effective in SP MS patients (18). IFN-β probably acts 
through immunomodulatory rather than immunosuppressive effects. 
Copaxone is an alternative drug that appears to have both immunological 
and potential neuroprotective effects along with a favorable side effect 
profile, similar to that of IFN-β. Its efficacy is stable or may even increase 
in time (19). Furthermore, various experimental treatments for MS are 
evaluated in small clinical trials (20). However, the mechanisms by which 
these drugs affect MS progression are unknown. 
 
Genetic, environmental and hormonal factors 
The etiology of MS remains largely unknown despite intensive scientific 
and clinical research. The involvement of genetic and environmental factors 
in the initiation and progression of the disease is generally accepted. MS is 
not only unpredictable in its on-again, off-again patterns and its broad 
symptom spectrum it also strikes the population in uneven ways. Women 
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are twice as susceptible as men and the disease is twice as common among 
Caucasians as among African-Americans (21,22). Although MS is found in 
Japan, China and some other temperate, eastern countries, it is much rarer 
than it is in the West. The incidence of MS is even higher in northerly 
regions: the frequency of MS in Canada for example is twice that of the 
United States. Risks for first degree relatives are increased by 20 fold as 
compared to the general population. Twin studies show that in 26 % of 
monozygotic twins both twin pairs are affected as compared to 4 % of 
dizygotic twins and 1.9 % of non-twin siblings with MS (23). The genetic 
influence on the susceptibility to MS is modulated by several genes. Certain 
human leukocyte antigen (HLA)-class I genes are weakly associated with 
MS (HLA-A3 and HLA-B7) while HLA-class II genes show stronger 
association. HLA-DR associations may differ in certain geographically 
distinct populations. Association with MS is found for HLA-DR4 (Italian 
and Arab population), HLA-DR6 (Mexican and Japanese population), HLA-
DR2 and HLA-DR15 (Caucasian population) as well as for HLA-DQ genes 
(24). Studies have also revealed a weak association of other genes of the 
HLA gene cluster on chromosome 6 with MS (25).  
Studies on the genetic susceptibility for MS also include establishment of 
MS-associated gene sequence polymorphisms. Many polymorphisms have 
presently been associated with MS. Recent MS-associated polymorphisms 
include for example those in the matrix metalloproteinase (MMP)-9 gene, in 
pigmentation related genes, in the CCL2 promoter, in the CTLA-4 gene as 
well as in the FAS-640 gene and αB-crystallin (26,27,28,29,30). A CD95 
polymorphism associated with MS is found to be restricted to women which 
is in line with their higher susceptibility to this disease (31). These 
polymorphisms appear to suggest that the immune system is involved in MS 
since most of these genes involved are immunologically relevant. However, 
it should be taken into account that this bias might be due to specific 
selection of immunologically relevant genes for these studies. Also, 
comparing all information on polymorphisms linked to MS reveals that 
there are much less data on unlinked polymorphisms, consistent with a 
publication bias. Despite genome wide mapping it is still not clear which 
genes are involved in the pathogenesis of MS. 
Geographic differences in prevalence may be explained by genetic make-up. 
However, they have also been attributed to nutrition and Ultraviolet (UV) 
dose. Sunlight and especially vitamin D3 are suggested as environmental 
factors in MS disease (32,33). High vitamin D levels are associated with 
low lesion activity in RR and SP MS patients and vice versa (34). The nadir 
in vitamin D supplies correlates with both the peak of MS lesions activity in 
German MS patients and the peak of MS disease onset in Switzerland 
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(35,36). Furthermore individuals who had the highest residential and 
occupational sunlight exposure were shown to have a lower mortality risk 
from MS (37). The beneficial effects of sunlight exposure are independent 
of country, origin, age, sex and socioeconomic status. These findings on the 
association of sunlight and vitamin D with MS might help explain why the 
incidence of this disease around the equator is less as compared to northern 
Europe. Dietary factors including fish might increase vitamin D production. 
Furthermore fish contains omega-3 fatty acids, which are the components of 
anti-inflammatory eicosanoids belonging to a family of hormone-like 
compounds, as well as polyunsaturated fatty acids (PUFAS). Distribution of 
MS cases in Western Norway showed a higher prevalence in the inland 
areas as compared to coastal areas (38). This distribution has been suggested 
to be due to a larger consumption of fish in coastal areas. Nordvik et al. 
reported that daily consumption of fish oil (omega-3 fatty acids) together 
with vitamins improved the disease outcome of newly diagnosed MS 
patients (39). Depletion of fatty acids, zinc, magnesium, selenium and 
vitamins has been correlated with trapped NO and superoxide resulting in 
the free radical peroxinitrite which induces myelin damage. Menstruation 
cycles correlate with depletion of these components which might help 
explain the higher incidence of MS in women (40). Furthermore, the 
increased risk of MS in women is believed to depend in part on the 
influence of sex hormones on the immune system. The mechanism of 
estrogen-induced immune suppression is suggested to play a role (41). The 
rate of relapses declines in women with MS during their pregnancy and 
especially during the third trimester. On the other hand the rate of relapses 
increases during the first three months post partum before returning to the 
pre-pregnancy rate (42,43). Stressful events such as illness, problems with 
close family members, job stress or financial problems are related to the 
increased occurrence of exacerbations in RR MS patients (44). Although 
certain types of psychological stress suppress immune reactions the impact 
of these stressful events was independent of the triggering effect of 
infections on exacerbations. The mechanism behind stressful events and 
increased exacerbations is still unclear. Modulation of the hypothalamic-
pituitary-adrenal axis and the sympathetic system might explain its impact 
on inflammatory reactions in MS pathogenesis. 
 
The role of the immune system in MS 
The human CNS has for a long time been considered an immunologically 
privileged site because of the existence of skull bones, the CSF, the 
meninges and the blood brain barrier (BBB). The existence of a BBB 
restricts immune cell migration and soluble molecule diffusion from the 
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systemic system into the CNS (45). Furthermore, presumed lack of 
lymphatic drainage in the CNS as well as its inability to reject allografts 
appeared to support this idea of immunological privilege (46). However, it 
has become increasingly clear that an activated BBB promotes the influx of 
leukocytes and that (activated) CD4+ and CD8+ T-cells can enter the CNS 
by passing the impaired BBB (47). Infiltrated T-cells are involved in 
regulation of immune responses, inflammation and ultimately repair during 
a variety of CNS diseases. They produce many immunoregulatory mediators 
such as cytokines, chemokines and growth factors (48). Different types of 
CD4+ T-cells are involved and can be distinguished by their cytokine 
production. T-cell subtypes include for example Th(helper) cells and 
regulatory T-cells (Treg). These different T-cell types regulate immunity to 
infection and self-tolerance (49). The various T-cell types express different 
cytokine profiles. Th1 cells for example tend to produce pro-inflammatory 
cytokines while Th2 cells tend to produce anti-inflammatory cytokines. A 
complex network of interactions between microglia, astrocytes and T-cells 
is involved in determining the balance between Th1 and Th2 cells (50). 
Immunohistochemical studies have shown that MS lesions are characterized 
by perivascular infiltrates of T-cells, B-cells and macrophages. Some of 
these infiltrating T-cells are activated (51). The inflammatory reaction in the 
CNS during MS is accompanied by the production of many inflammatory 
mediators. Infiltrating T-cells express cytokines notably including the pro-
inflammatory cytokine IFN-γ, chemokines, MMPs, NO and reactive oxygen 
species. These mediators stimulate a variety of physiological, 
neuroendocrine and behavioral responses of the CNS. The CNS, in turn, 
regulates the immune system via systemic and local routes including 
neuroendocrine pathways and the autonomic and peripheral nervous system 
(52). Figure 1.1 shows the cells and reactions which are involved in MS 
disease and lesion development. The fact that activated T-cells are clearly 
present in MS lesions but have not been found in the periphery at levels 
different from those found in healthy controls suggests that their antigen is 
primarily recognized within the CNS (53). The autoantigens relevant to MS 
are generally believed to reside in myelin. The most abundant proteins in 
myelin are proteolipid protein (PLP) that accounts for 50 % of the total 
protein mass in myelin and myelin basic protein (MBP) that accounts for 10 
to 15 % of all proteins. Minor myelin proteins include myelin-associated 
glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG) and 2´, 
3´-cyclic nucleotide 3´-phosphohydrolase (CNPase). Comparing myelin 
from healthy controls to that from MS patients indicates that MS-affected 
 myelin contains higher levels of αB-crystallin (54).
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Figure 1.1. Likely events in lesion development during multiple sclerosis 
The first event in lesion development probably involves a local endogenous insult in 
the CNS of unknown origin that leads to apoptotic stress in oligodendrocytes and 
activates microglia either directly or indirectly. Activated microglia develop into 
phagocytic macrophages that begin to sample myelin. At the same time they will 
activate the blood-brain barrier (BBB) to some extent by production of IL-1β and TNF-
α. This will promote non-specific leukocyte infiltration and leads to a mild 
inflammatory reaction. When, however, sufficient numbers of myelin-reactive memory 
T-cells are contained in the emerging infiltrate this initially mild reaction may 
‘explode’ by myelin-triggered production of IFN-γ. This will strongly amplify 
phagocytosis and infiltration by yet more leukocytes. A demyelinating lesion develops.  
Note that lesion development is likely driven by events within the CNS itself, and not 
by the peripheral immune system  that –instead- acts simply in response to these 
events. Microglia and astrocytes are important regulators of the local inflammatory 
process. 
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Interestingly, human peripheral blood T-cell responses to the complete 
collection of myelin from MS patients are dominated by the specific 
response against αB-crystallin. The absence of αB-crystallin from lymphoid 
tissues in humans, allowing autoimmune responsiveness to develop may 
account for this (55). This responsiveness appears to be unique to humans 
since several other mammalian species examined showed expression of αB-
crystallin in secondary lymphoid tissues and even in the thymus, and these 
species are characterized by profound tolerance for self αB-crystallin. As 
this is clearly different in humans, the protein is therefore considered as a 
candidate autoantigen in multiple sclerosis (56). 
An animal model for inflammatory CNS demyelination is experimental 
autoimmune encephalomyelitis (EAE). This model, most frequently studied 
in rodents or non-human primates, is in line with an autoimmune etiology of 
MS. EAE is induced by active immunization with myelin-derived antigens 
in a powerful adjuvant or by transfer of myelin specific T-cells (57,58). 
EAE is thus based on introduction or activation of peripheral T-cells against 
myelin antigens resulting in CNS infiltrates and myelin damage.  
 
Viral associations with MS 
Many epidemiological, clinical and neuropathological data are suggestive 
for an association between MS and viral infections. A viral infection has 
long been suggested to play a role in MS largely because most other 
demyelinating CNS disorders of known origin are virus induced. Also, 
animal model data confirm that a virus could in principle trigger disease 
with characteristics similar to MS. Active infection of mice with for 
example the neurotrophic picornavirus Theiler´s murine encephalomyelitis 
virus (TMEV) or with Semliki Forest virus (SFV) results in inflammatory 
demyelination. Furthermore, the beneficial effects of treatment with the 
anti-viral agent IFN-β also supports involvement of viral infection in the 
pathology of MS (59). It has been well established that viral or bacterial 
infections may trigger MS exacerbations, once the disease has manifests 
itself, as reported for upper airway infections which might be caused by 
influenza virus (60,61). Exacerbations with onset around the time of clinical 
infections result in more sustained neurological damage as compared to 
non-infection-associated exacerbations (62). However, there is no indication 
that this sustained damage is associated with enhanced opening of the BBB. 
Many viruses have been proposed as a potential causative agent in MS 
 (Table 1.1). 
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Table 1.1. Viruses during the years associated with multiple sclerosis 
   Virus                                                                  Reference 
 
Rabies virus      63 
Parainfluenza virus     64 
Herpes simplex virus     65 
Measles virus      66 
Varicella zoster      65 
Mumps virus      67 
Rubella       67 
Canine distemper virus     68 
SMON-like virus     69 
Tick borne encephalitis    70 
Epstein-Barr virus (EBV)     71 
human T-lymphotropic virus type I (HTLV-I)  72 
Simian virus 5      73 
LM7 (retroviruses)     74 
Human herpesvirus-6 (HHV-6)   75 
MS-associated retrovirus (MSRV)    76 
Polyomavirus (JCV)     77 
Human endogenous retroviruses (HERV)   78 
Human coronavirus     79 
morbillivirus      80 
Picornavirus                                                         81 
Chickenpox virus    82 
 
Yet, a role of viral infection as a causative factor in MS remains to be 
established. Viruses can, especially upon reactivation, interfere at various  
levels with antigen presentation and co-stimulation functions as well as with 
cytokine and chemokine signaling. Such effects could provide a basis for 
understanding how even ubiquitous viruses could play a role in the 
pathogenesis of MS or other neurological diseases and CNS inflammation. 
For no single virus, a conclusive and specific association with MS has been 
found so far. Recently, childhood infections, occurring at the age of ≤ 7 
years, including measles, chickenpox, rubella, whooping cough and mumps 
were reported to be significantly higher in MS patients than in controls (82). 
To make it even more complex bacterial pathogens such as Chlamydia 
pneumonia have also been associated with MS (83).  
The association between MS and Epstein-Barr virus (EBV) in particular has 
attracted much attention, and this viral association can be considered the 
strongest known. The most striking findings so far (84) were that essentially 
all MS patients are EBV seropositive versus 90-95 % of the general 
population and that anti EBV immunoglobulin (Ig) serum titers are usually 
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higher in MS patients (85). Also a delayed primary infection with EBV 
resulting in a history of infectious mononucleosis is clearly associated with 
an increased risk of MS later on in life (84,86). Intriguing is the fact that 
EBV infection in B-cells enhances the expression of αB-crystallin, the 
above-mentioned candidate autoantigen in CNS myelin of MS patients (54). 
Presentation of αB-crystallin by major histocompatibility complex (MHC) 
class II molecules in EBV-infected human B-cells to T-cells leads to 
activation of pro-inflammatory αB-crystallin-specific Th cells (55). In this 
way a memory T-cell pool against  αB-crystallin could be established as a 
side effect of EBV infection. Later on in life, these memory T-cells could 
help trigger an ‘explosive’ inflammatory reaction in the CNS when another 
event would induce BBB impairment and oligodendroglial stress (56). 
Migrant studies appear to be consistent with a role of EBV as a necessary 
co-factor in MS. Most studies among migrant populations that relate 
alterations in the risk to developing MS to the age of migration suggest that 
the critical age is before puberty (the age of 15) (87). Moving from high-
prevalence areas to low-prevalence areas shows that these migrants attain 
the lower risk if they move before puberty but retain the high risk status if 
they migrate after puberty. For example Dean and Elian have reported that 
immigrants to England from India and Pakistan at an age younger than 15 
years had a higher risk of developing MS than those immigrating after that 
age (88). Data from a study among North African immigrants to France 
show that their onset of MS is at an earlier age as compared to French-born 
patients. This suggests that MS is primarily an environmental disease 
acquired after childhood (89). These data indicate that there is a co-factor 
before puberty mediating the risk to acquire MS. Young children in high 
risk areas are not affected (yet) by this co-factor, consistent with the idea 
that this co-factor could include delayed primary infection with EBV. Yet, 
not all studies are equally clear on this subject (90,91). For example, a 75 % 
reduction was seen in the risk to develop MS among British and Irish 
immigrants in Australia as compared to the risk of their native countrymen 
(92). The reduction affected both adult and child immigrants.  
 
The association between HHV-6 and MS  
Apart from EBV that can be considered the strongest viral link in MS, 
several observations have also been reported during the years that point to 
an association of human herpesvirus-6 (HHV-6) with MS. However, a 
distinct controversy exists as to the possible involvement of this virus in MS 
(93,94). Studies that associate HHV-6 with MS have for example revealed 
HHV-6 nuclear staining in oligodendrocytes and neurons from MS patients 
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but not in material from control donors (95). HHV-6 infection has been 
found more in MS patients as compared to healthy controls and in more 
active plaques than in inactive ones (96,97). Furthermore, active HHV-6 
infections have been reported to be more frequent in lymphoid tissues, 
peripheral blood lymphocytes, serum and urine of MS patients as compared 
to these tissues from healthy control donors (98,99,100,101). Finally, HHV-
6 antibody titers have been reported to be elevated in serum and CSF from 
MS patients as compared to serum and CSF from healthy controls 
(75,99,102). On the other hand several other studies have failed to produce 
evidence in support of a specific association of HHV-6 with MS 
(103,104,105,106,107,108). These studies show that reactivities to HHV-6 
and levels of HHV-6 DNA in serum and CSF were similar in MS patients as 
compared to healthy controls. Furthermore, Rodriguez et al. reported no 
signs of HHV-6 DNA in CSF from MS patients (109). Moore and co-
workers compared 28 studies on the association between HHV-6 and MS 
(111). In their review they concluded that although many studies prove 
evidence for a relationship between HHV-6 and MS none of the studies 
showed a causative association.The conflicting results on a possible 
association between HHV-6 and MS do not necessarily rule out a role of 
HHV-6. Negative results may be due to different population studies, 
different sensitivities of the technique used, or a different DNA sequence 
target for PCR amplification. The existence of two different variants of 
HHV-6 may also account for discrepant results (110) and also, HHV-6 may 
not be relevant to all stages in MS or all stages in lesion development.  
A major challenge in further clarifying a possible association between 
HHV-6 and MS is identification of molecular mechanisms by which the 
virus could influence cell-biological processes that are specifically relevant 
to MS. While for EBV such mechanisms have been suggested (see below), 
no data or models are currently available to indicate how HHV-6 could 
influence either T-cell functions, CNS pathways or other processes in ways 
that would be consistent with a presumed role as etiological agent in MS. 
 
Ways for viruses to influence autoimmunity 
Many mechanisms have been suggested by which a virus infection can lead 
to an autoimmune response against myelin, as is supposed to play a crucial 
role in MS (112). The most straightforward way for a virus to influence MS 
would be viral infection of the CNS itself. This could initiate a virus-
specific inflammatory response resulting in demyelination as bystander 
damage without necessarily involving an autoimmune response. The 
pathology of MS lesions, largely reflecting a classic host defense response, 
would be consistent with this theory, if it would not be for one crucial issue: 
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a virus specifically associated with active MS has not been identified yet. It 
has been argued that a powerful host defense response against a virus could 
possibly eliminate the pathogen before it could ever be detected in the 
resulting lesion (113). Such a ‘hit-and-run’ model is clearly difficult to 
falsify. In the absence of a well-established causative agent in MS, many 
attempts have been made to explain the development of MS lesions based 
on a virus-associated autoimmune etiology, a line of thinking that is 
strongly supported by animal model data.  
First, cross-reactivity between viral antigens and normal myelin components 
continues to be a popular theory to explain how viral (or bacterial) infection 
could activate autoimmune T-cells. In this model of so-called molecular 
mimicry viral infection does not necessarily need to take place in the CNS 
since structural similarity between pathogen-specific determinants and 
myelin determinants could cause pathogen-activated T-cells to cross react 
against myelin. Even when activated elsewhere in the body, such activated 
T-cells could cross the BBB and set off an autoimmune reaction in the CNS 
similar to what happens during EAE.  Examples of such cross reactions 
between pathogens and self antigens have been documented using 
individual T-cell clones but so far, relevant cross-reactivity between 
pathogens and myelin components at the level of polyclonal responses 
remain to be demonstrated. Also, disease-initiating peripheral T-cell 
reactivity against myelin components in MS patients different from what 
can routinely found also in healthy controls remains to be established, while 
being a crucial element in this model of molecular mimicry.  
Secondly, it has been suggested that a first inflammatory insult caused by 
either a virus or a bacterium could promote subsequent development of 
waves of novel T-cell reactivities to locally released self antigens. In this 
scenario of ‘determinant spreading’, such newly generated responses would 
be largely autoimmune and able to sustain a chronic process of (more or less 
self-perpetuating) autoimmune disease. A major problem with this model, 
however, is the question how such a cascade of spreading responses is to be 
reconciled with organ specificity as seen in MS. After all, most of the 
locally released antigens are also expressed in several other tissues. In 
addition, no evidence has been found so far for any of such spreading 
responses to be detectable in MS patients, nor has any association been 
found between MS and non-specific inflammatory CNS damage such as 
occurs in brain trauma that would similarly be expected to trigger 
determinant spreading (114).  
While still other ideas have been put forward, one final alternative model 
that combines an autoimmune mechanism and viral infection in yet another 
way centers around αB-crystallin. As stated before, EBV infection of B 
General Introduction   
 21 
cells (and perhaps infection by some other viruses as well) is known to 
induce de novo expression of αB-crystallin in infected cells, leading to its 
presentation to helper T-cells. Since in humans this occurs in the pro-
inflammatory environment of active viral infection, and against the 
background of lack of central tolerance, a T-cell response will be mounted 
against αB-crystallin along with that against viral determinants. While not 
the driving force for any autoimmune attack at the time of infection, the 
autoimmune repertoire will persist for life since the triggering virus does so 
too. When later on, oligodendroglial stress for whatever reason occurs, these 
αB-crystallin-specific memory T-cells may find their antigen in 
extracellular myelin of the CNS again, should they find themselves non-
specifically recruited by an activated BBB. In this model, the induction of 
the memory repertoire against a myelin antigen by the virus is not a trigger 
but a necessary co-factor in the development of MS. The association 
between EBV and MS reflects this. 
However intriguing some of the above models may be, none of the above 
mechanisms have been conclusively proven to play any role in MS so far. 
While the almost intuitive conviction remains that viral infection is very 
likely to play a role in MS, more data are required to illustrate how certain 
viruses can impact on the cells and mediators that control lesion formation 
in MS. Clearly, some of the key players are to be found in the CNS itself 
and they include glial cells that are at the very heart of MS in regulating 
 much of the local inflammatory reactions. 
 
The function of astrocytes and microglia in regulating inflammation 
and repair in the CNS 
The human CNS contains two distinct classes of resident cells: neuronal 
cells and glial cells. Glial cells are classified as macroglia and microglia. 
Macroglia can be divided again into oligodendrocytes and astrocytes. 
Oligodendrocytes are responsible for the production of large membrane 
sheaths that are wrapped around axons forming an insulating layer, the 
myelin sheath. Glial cells have long been thought to perform only 
maintenance roles in the CNS providing trophic factors to neurons, 
supporting the BBB, maintaining a healthy balance of ions in the brain, and 
eliminating invading pathogens. Nowadays, it is known that glial cells fulfill 
many more functions. They are far better equipped to play an active role in 
immunological processes as compared to neurons (115). By producing IL-
10, TGF-β and apoptosis-inducing factors, astrocytes form a barrier against 
expansion of pro-inflammatory T-cells and thus limit local inflammation 
(116). They actively regulate BBB functioning and control the structural and 
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functional plasticity of synapses in developing and adult CNS (117). 
Astrocytes also play a role in cell-cell communication through gap 
junctions, and influence neuronal signaling, neuroendocrine interactions and 
even behavioral responses (52). Microglia on the other hand play key roles 
in immune-mediated events in the CNS as resident macrophages but are also 
crucial in repair en regeneration.  
 
Astrocytes and the control of inflammation  
Astrocytes are the largest and most abundantly present glial cell type in the 
CNS. They are coupled by gap junctions that are composed of intracellular 
channels permeable to ions and small molecules. Junctional channels and 
connexins (their molecular constituents) provide the basis for an efficient 
and direct intercellular communication in astrocytic networks (118). 
Astrocytes play a key role in BBB maintenance, control of inflammatory 
responses, the formation of neuronal networks, development, homeostasis, 
repair and signaling networks in the CNS by producing a wide variety of 
cytokines, chemokines, growth factors and by expressing receptors for these 
molecules. Under inflammatory or otherwise pathological conditions 
astrocytes become activated and display enhanced production of several 
cytokines, chemokines and growth factors. Also, astrocytes generally start 
to proliferate and migrate under such conditions. Reactive astrocytes show 
marked induction of glial fibrillary acidic protein (GFAP) and accumulate at 
the border between intact and damaged tissue, a phenomenon known as 
astrogliosis (119). Astrogliosis results in the formation of scar tissue. A 
major function of this glial scar formation is to provide a protective barrier 
around damaged tissue, sealing it off from healthy tissue. Failure in axon 
regeneration and remyelination is often due to the presence of scar tissue. 
The production of many mediators by astrocytes influences T-cell 
responses, monocyte infiltration and microglia effector functions as well as 
aspects of astrogliosis and demyelination. 
The mature BBB is a complex system of different cellular components. 
Highly specialized microvascular endothelial cells and pericytes are 
embedded in the basal membrane and surrounded by perivascular 
macrophages and astrocytic end-feet (120). Interactions with astrocytes 
promote strong interactions between endothelial cells resulting in a compact 
network sealed by tight junctions. Vascular ensheathment by astroglial 
processes is a unique feature of the CNS and is established at the same time 
as the BBB develops (121). Astrocytes and their precursors are implicated 
in the induction of the BBB. The BBB is the main barrier to drug transport 
into the brain and plays an important role in the homeostatic regulation of 
the brain microenvironment necessary for the stable activity of neurons. 
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Astrocytes produce soluble factors which help restrict development of 
inflammation within the CNS. Induction of expression of for example HT7, 
UEA-1 lectin-binding sites, and angiotensin receptors help define the 
phenotype of endothelial cells and induce tight junction formation (45). 
Astrocytes also play a key role in maintaining the ability of the CNS to limit 
the expansion of infiltrating T-cells by inducing apoptosis thus protecting 
the CNS from immune-mediated damage. T-cells that cross the BBB and 
invade the CNS encounter directly astrocytic end-feet that contribute to the 
formation of the BBB . Astrocytes express the death ligand CD95L (APO-
1L, FasL) and induce apoptotic death of infiltrating T-cells by 
CD95/CD95L pathway (122). Defects in this mechanism of T-cell apoptosis 
in T-cell lines from MS patients suggest that the above mechanism of 
elimination is also important in preventing autoimmunity to develop (123). 
While astrocytes express CD95 they are not sensitive to the CD95/CD95L 
apoptosis pathway under normal conditions. Only at late passage (passage 8 
to 10) in culture, astrocytes become sensitive to this pathway and can go 
into apoptosis (124). CD95 triggering in astrocytes leads to induction of 
CXCL8 (IL-8) which contributes to the resistance of astrocytes against 
CD95L. On the other hand IFN-γ results in the sensitization of astrocytes to 
CD95-mediated death suggesting that micro-environmental factors can 
influence this mechanism. Other CNS mechanisms for astrocytes to 
contribute to T-cell apoptosis include the release of glucocorticosteroids and 
NO, deprivation of IL-2 and interaction with CTLA-4 (CD152) on activated 
T-cells. Also, cytokines produced by astrocytes may help modulate the pro-
inflammatory reactions of infiltrated T-cells (125,126).  
Astrocytes also actively participate in several aspects of neuronal growth, 
differentiation maintenance and survival both by cell-cell interactions and 
by secreting neurotrophic factors. Such factors include the NGF subclass, 
brain-derived neurotrophic factor (BDNF) as well as neurotrophins (NT). 
Recently a novel neurotrophic factor has been discovered in astrocytes 
called mesencephalic astrocyte-derived neurotrophic factor (MANF) (127). 
Neuron growth and survival is also supported by astrocytic expression of 
growth factors and their receptors including M-CSF, GM-CSF, MCSFR and 
SCFR (128). Astrocytes capture and remove synaptically released glutamate 
(the major excitatory neurotransmitter) to end its stimulatory action and 
prevent neuronal damage (129). On the other hand intercellular waves of 
Ca2+ in astrocytes result in signaling to neurons as the astrocytes trigger the 
release of glutamate. This glutamate activates receptors on the surrounding 
neurons and modifies their electrical properties and synaptic functions 
(130). In turn, neurons influence the cellular behavior of astrocytes 
primarily by secretion of mediators including neurohormones and 
Chapter 1 
 24 
neurotransmitters. These mediators affect several astrocyte functions such as 
electrophysiological responses, energy metabolism and ionic homeostasis. 
Rapid bidirectional neuroglial interactions are based on their specific mode 
of communication, synaptic transformation for neurons and gap junctional 
communication and Ca2+ waves for astrocytes (131). The impact of neurons 
on astrocyte differentiation seems to depend on neuronal electrical activity 
since it is correlated with neuronal release of GABA. Astrocytes express ion 
channels and receptors by which they can sense and respond to activated 
neurons (132). Astrocytes control neuronal growth and differentiation and 
guide neurons in their migration from birthplace to their final location in the 
CNS during brain development. Neurons and glial cells engage in a two-
way dialogue from embryonic development through old age. Astrocytes 
influence the formation of synapses and help to determine which neural 
connections get stronger or weaker over time. These changes are essential to 
learning and to storing long-term memories (133). Furthermore, astrocytes 
represent a suitable substrate for in vitro neurite outgrowth. Neurons plated 
on monolayers of cultured astrocytes for example grow better, differentiate, 
do not aggregate and survive longer (134). Astrocytes and neurons 
communicate in the protection against reactive oxygen species (ROS) that 
are generated continuously in the human CNS during oxidative metabolism. 
Interactions between astrocytes and neurons and the glutathione system are 
involved in the defense against these ROS (135).  
 
Microglia and the control of inflammation 
Microglia are distributed throughout the CNS as a network of resting 
immunocompetent cells. They compose approximately 5 to 20% of all cells 
in the CNS and represent a distinct cell population with characteristic 
morphology that distinguishes them from other glial cells or neurons 
(136,137). Fully differentiated microglia in the mature human CNS have a 
highly ramified morphology. Microglia are considered as the sentinels or the 
gatekeepers of the brain, and they primarily appear to function as sensor 
cells that are continuously in surveillance of changes or insults in the CNS. 
Microglia provide an first line of defense against CNS-invading pathogens 
and their actions precede peripheral leukocyte infiltration. When activated, 
microglia produce a wide range of cytokines (pro- and anti-inflammatory), 
chemokines, NO, superoxide radicals and proteases. Microglia have the 
ability to present antigens to T-cells, migrate in response to chemotactic 
stimuli and phagocytose cell debris (138). Furthermore, microglia can 
induce T-cell apoptosis by direct ligation of CD95 on T-cells and they 
respond to signals from stressed or damaged cells (139).  
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As stated above, activated microglia undergo morphological and functional 
changes. Resting microglia in a normal CNS show extensive ramification 
but upon activation they loose this ramified structure and become bipolar. 
Upon full activation microglia transform into rounded phagocytes that can 
no longer be discriminated from blood-derived macrophages (140). 
Activated microglia proliferate and migrate through the brain. Chemokines 
including CCL2 (MCP-1), CCL3 (MIP-1α) and CCL4 (MIP-1β) appear to 
play important roles in microglia proliferation and migration (141,142,143). 
In parallel with the morphological changes upon activation microglia 
increase their production of ROS, NO, arachidonic acid derivatives as well 
as immunologically relevant surface markers including MHC class I and 
MHC class II molecules, adhesion molecules such as intercellular adhesion 
molecule (ICAM)-I, complement receptor 3 and other co-stimulatory 
molecules. Consequently, microglia become functional antigen-presenting 
cells (APC) (144,145,146). This is most likely relevant to MS since MHC 
class I and class II molecules are widely expressed by microglial cells in MS 
lesions (147,148,149). While it is known, however, that microglia can 
reactivate T-cells (150) an interesting area of new research is to define the 
functional consequence of this step that may very well contribute to 
controlling T-cell expansion rather than only promoting it.  Antigen-specific 
interaction between APC (microglia) and T-cells is a dialogue in which both 
cell types regulate each other. Production of IFN-γ by T-cells is required for 
the maturation of resting adult microglia into APC, and for the induction of 
for example TNF-α production. Microglia on the other hand can not only 
activate T-cells, but also downregulate or modulate T-cell responses (151, 
152) and they can contribute to apoptotic elimination of T-cells. For 
example, some microglia appear to lack the co-stimulatory molecule CD80 
indicating that they are immature APC and consequently, can trigger anergy 
in T-cells (153) or even apoptosis (139).  
Traditionally, activated microglia have been associated with tissue damage 
in the CNS. However, it has become increasingly clear that the role of 
microglia is that of a double-edged sword. Microglia may be instrumental in 
tissue injury through the damaging potential of their inflammatory 
mediators and by their phagocytic potential, but they are also beneficial in 
promoting homeostasis and repair. Phagocytosis by microglia for example 
removes undesired debris of degraded matrix and apoptotic cells and it helps 
to eliminate serum-derived materials from the CNS (154). In line with this 
function, microglia have been demonstrated to promote oligodendroglial 
proliferation and differentiation which contributes to myelin repair in 
inflammatory demyelinating disease (155) and to support axonal outgrowth 
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when transplanted into the spinal cord of experimental spinal cord lesions in 
rats (156). Also, microglia act as “stand by” glutamate scavengers in case 
astrocytes fail to eliminate glutamate at sufficient levels, which could 
contribute to neurodegeneration. Furthermore, microglia express mediators 
to support cell survival including neurotrophins such as BDNF (157,158, 
159,160) and anti-inflammatory mediators including prostaglandin E2 
(PGE2), TGF-β, and IL-10. These anti-inflammatory mediators inhibit both 
APC functions and T-cell infiltration and they counteract as production of 
pro-inflammatory factors by infiltrated T-cells. A marked protective role of 
microglia rather than only detrimental activities is also in line with the 
notion that brain trauma is not related to MS and certainly not a causative 
factor, which would be expected if microglia activation would have 
damaging effects only (161,162). In conclusion microglia are extremely 
plastic cells that exert dual functions in CNS diseases by promoting either 
deleterious or beneficial processes, depending on the degree, duration and 
context of activation.  
 
Toll-like receptors on glial cells 
Toll like receptors (TLR) were first discovered in Drosophila and later in 
man. TLR have been found to play a critical role in early innate immunity. 
So far 11 mammalian TLR have been identified that show homology to the 
Drosophila Toll receptor (163). Human TLR constitute a protein family 
linking innate and acquired immunity (164). TLR recognize conserved 
structural motifs expressed by microbial pathogens called pathogen-
associated molecular patterns (PAMP). PAMP include various cell-wall 
components such as lipopolysaccharides (LPS), peptidoglycans and 
lipopeptides as well as flagellin, bacterial DNA and double stranded RNA. 
Upon activation TLR initiate a signaling cascade generally involving the 
proteins MyD88 and IRAK. This signaling cascade leads to the activation of 
transcription factors such as NF-κB that controls host defense genes 
including pro-inflammatory cytokines, chemokines and co-stimulatory 
surface molecules that not only represent key elements of innate immune 
responses, but also shape the ensuing adaptive immune response.  
TLR are expressed in a variety of tissues, predominantly in tissues involved 
in immune functions such as spleen and peripheral blood leukocytes as well 
as in tissues exposed to the external environment including lungs and the 
gastrointestinal tract. However, TLR are also expressed in for example liver, 
bladder and kidney. Recently, their expression in the human adult CNS was 
documented for the first time by Bsibsi and co-workers (165). Active brain 
lesions from MS patients express elevated levels of at least TLR3 and TLR4 
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while these receptors are barely detectable in normal-appearing white matter 
brain sections from MS patients or in healthy white matter brain sections 
from controls. TLR are particularly prominent on glial cells and their 
expression is apparently elevated during CNS inflammation. In cell culture 
models human adult microglia express a wide range of different TLR, 
predominantly inside intracellular vesicles. Adult astrocytes in culture on 
the other hand predominantly express TLR4 and, to a lesser extent, TLR3. 
TLR are found to be expressed on the cell surface of astrocytes. TLR5 to 
TLR9 are not expressed at detectable levels in astrocytes, even after 
treatment with different stimuli. Given the dominant function of TLR in 
controlling innate immune responses against invading pathogens in other 
cell types and tissues, TLR may play a crucial role in pathogen control also 
in the human CNS. In this thesis we investigated the expression of TLR1, 
TLR2, TLR3 and TLR4 in human adult astrocytes. TLR1 and TLR2 are 
known to be constitutively expressed at low levels in microglia and are 
enhanced following S. aureus exposure (166). TLR2 is essential in the 
recognition of a variety of PAMP including bacterial lipoproteins, 
peptidoglycan and lipoteichoic. TLR3 is implicated in double-stranded RNA 
and TLR4 is predominantly activated by LPS. While TLR are now known to 
be expressed in human adult glial cells, the way they interact with immune 
regulatory functions in the CNS, however, is still unclear. TLR mediate 
responses to a wide range of pathogen-associated products including 
lipopolysaccharides, lipoproteins, flagellin, bacterial DNA and double-
stranded RNA. Such responses typically involve production of a range of 
inflammatory mediators including TNF-α, IL-1β, IL-6, nitric oxide and type 
I interferons (167). We investigated expression of TLR1, TLR2, TLR3 and 
TLR4 in cultured human adult astrocytes after cytokine treatment as well as 
upon HHV-6 infection.  
 
HHV-6, general features  
HHV-6 is a double stranded DNA β-herpesvirus first isolated in 1986 as 
human B-lymphotropic virus (HBLV) from peripheral blood mononuclear 
cells (PBMC) of adults with AIDS or other lymphoprolipherative disorders 
(168). HHV-6 exists in two distinct variants, viz. the HHV-6A and the 
HHV-6B type. The overall nucleotide sequence identity between the two 
variants is about 90 % (169). The seropositivity for HHV-6 in the human 
adult population is currently estimated to be higher than 95 % (170,171). 
HHV-6 is generally acquired at early childhood, usually within the first two 
years of life (172,173,174). Children with primary HHV-6 infection obtain 
more often fever, diarrhea, rash and roseola as compared to children who 
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never acquired HHV-6 (175). Viral infection shows geographic differences 
with infection percentages ranging from 56 to 100 % (176,177,178,179,180, 
181,182,183,184). A study in Thailand among children from 0 to 12 years 
indicates that the prevalence of HHV-6 infection ranges from 70 to 100 %. 
The highest infection percentages are found among children from 2 to 8 
years and they decline in children from 8 to 12 years, similar to what has 
been reported for a cohort of children in Malaysia. The percentage of HHV-
6 infection appears to differ somewhat in different countries: Malaysia 83 
%, Brazil 77 %, Denmark 78 % (<3 years) and 100 % (>3 years), Eritrea 85 
%, North China 69 %, Spain 56 %, Bratislava and New Guinea 66 %. Yet, 
these data are difficult to compare since the various studies pertain to 
different age groups. In a study of HHV-6 antibody titers rather than 
infection percentages (185) low titers were reported for Australia, Belgium, 
Israel, Japan and the USA, intermediate titers for Mexico and Germany and 
high titers for South Africa. In these data, no distinction could be made 
between the two HHV-6 variants.  
 
HHV-6, life cycle and cell tropism 
HHV-6 consists of three main structural elements: an icosahedrally 
symmetric nucleocapsid (90-110 nm) containing the viral DNA genome, an 
envelope containing the viral glycoproteins involved in receptor recognition 
and the tegument consisting of a protein mixture filling the space between 
nucleocapsid and envelope. HHV-6 is closely related to human 
cytomegalovirus (HCMV) (186) and enters the cell through interaction with 
CD46 that is present on the membrane of all nucleated cells (187). CD46 is 
physiologically involved in complement regulation and also serves as the 
receptor for measles virus (188). After binding of HHV-6 to CD46 the viral 
envelope fuses with the cell membrane. The incoming nucleocapsid is 
transported through the cytoplasm of the target cell to nuclear pore 
complexes and the viral DNA genome is released in the nucleoplasm. After 
infection of the nucleus from the target cell HHV-6 uses the cellular 
transcription and translation machinery to produce three kinetic classes of 
viral proteins: the immediate early (IE), the early (E) and the late (L) 
proteins. IE viral proteins are synthesized within a few hours after infection 
and are necessary for the production of E and L proteins. HHV-6 
transmission commonly takes place through saliva and also older siblings 
appear to serve as a source of virus transmission (189). HHV-6 is currently 
known to latently infect mononuclear cells, salivary glands, lungs, genital 
tract, liver tissue, endothelial cells, early bone marrow progenitor cells and 
brain and HHV-6 proteins are present in CSF (190,191,192,193,194,195, 
196,197,198,199,200). HHV-6 DNA has been detected by PCR in 32-85 % 
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of brain samples derived from healthy adult donors indicating that the virus 
is a CNS commensal (196,197,200,201,202).  
HHV-6 exhibits a predominant CD4+ T-cell tropism (203,204) and is rather 
effective in infecting a range of immortalized T-cell lines as well. The 
ability of the virus to infect particular T-cell lines is dependent on the 
variant type (205,206). Besides T-lymphocytes also fibroblasts, natural 
killer cells, liver cells, endothelial cells and glial cells have been 
successfully infected in vitro. Different levels of CD46 expression could 
possibly relate to differences in cell susceptibility to HHV-6 (207). 
Interestingly, infection of lymphoid tissue and CD4+ T-cells with  HHV-6 
results in downregulation of CD46 surface expression in infected as well as 
in uninfected neighbour cells as assessed by staining and FACS analysis 
(208,209).  
 
Clinical and immunological relevance of HHV-6  
HHV-6 was first discovered in 1986 in patients with AIDS and other 
lymphoprolipherative disorders. HHV-6A has not been etiologically linked 
to any disease while HHV-6B has been implicated in clinical manifestations 
including exanthem subitum, fever, encephalitis, pneumonitis and hepatitis 
(210,211). In many disorders, the virus is suspect as a co-factor rather than a 
direct etiological agent. Previously in this introduction, its presumed 
association with MS has been discussed. In addition, anti-HHV-6 antibodies 
are elevated in Sjögren's syndrome, sarcoidosis, chronic fatigue syndrome as 
well as in AIDS patients, possibly as a secondary result of these disorders 
(212). In HIV infection, HHV-6 is considered as an important co-factor, 
most likely as the result of immunosuppressive effects of infection (see 
below). HHV-6 is capable of establishing latent infection in a variety of cell 
types. Like other latent viruses, HHV-6 can be re-activated by various 
conditions such as superinfection with other viruses or bacteria, 
immunosuppression and stress. Conversely, HHV-6 can also transactivate 
other viruses including HIV, HHV-7, cytomegalovirus (CMV) and EBV 
when these viruses are present in the same cell (213,214,215,216,217). 
TNF-α and IFN-γ trigger activation of latent HHV-6 in monocytes and 
macrophages (218,219). Interestingly, the same factors that may trigger 
herpesvirus reactivation, such as stress and superinfection, have also been 
associated with MS exacerbations (220).  
A feature of HHV-6 that may be particularly relevant for its presumed role 
as a co-factor in several disorders is the fact that the virus codes for multiple 
gene products that can modulate inflammatory pathways in target cells, 
notably including gene products that have similarity to chemokines or their 
receptors (186). Amongst other functions, chemokines are involved in 
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directing tissue invasion by leukocytes. The U12 region of the viral genome 
encodes a beta chemokine receptor for CCL2, CCL3, CCL4 and CCL5 
(221). The U51 region encodes a CCL5 receptor and the U83 region 
encodes a chemokine-like CCR2 agonist (186,222,223). Evidence suggests 
that these chemokine (receptor) mimics are indeed functional. U51 
expression in epithelial cells results in specific binding of CCL5 and 
transcriptional downregulation of CCL5. U83 expressed by HHV-6-infected 
cells attracts cells expressing CCR2 including monocytes and macrophages 
and, in the CNS, astrocytes and microglia. Apart from the ability to encode 
chemokine (receptor) mimics, HHV-6 can influence inflammatory reactions 
also via CD46, its entry receptor. Recent evidence shows that for example in 
macrophages, HHV-6 can selectively downregulate production of the strong 
pro-inflammatory factor IL-12 (224), presumably by first inducing 
production of the anti-inflammatory mediator IL-10 (225). This effect was 
independent on viral replication and shown to be the direct consequence of 
CD46 ligation. Thus, also in this way HHV-6 may very well modulate 
inflammatory pathways.  
 
Goal of the study and experimental approach 
The primary goal of this study was to examine the impact of HHV-6 and 
EBV on inflammatory pathways in human adult glial cells. By clarifying 
this impact, we aimed to collect detailed information on the way these 
viruses may influence the development of MS. Rather than focusing on a 
few selected reporter genes to monitor molecular effects of viral infection, 
we chose a cDNA array-based gene profiling system to analyze expression 
levels of a wide range of 268 cytokines, chemokines, growth factors and 
their receptors. To perform the study, we therefore first had to examine the 
applicability of this comprehensive assay in terms of reproducibility and 
validity. Secondly, we had to optimize ways to experimentally infect 
cultured human glial cells with each virus. While experimental HHV-6 
infection of astrocytes could be achieved at satisfactory levels, the cells 
were refractory to infection with EBV. The effects of HHV-6 infection on 
astrocytes were carefully examined by gene profiling both under normal 
culturing conditions and in the context of inflammatory conditions, 
mimicked in culture by the addition of IL-1β, TNF-α and/or IFN-γ. Also 
microglia could be infected with HHV-6. The gene profile of microglia was 
analyzed, along with the effects of pro-inflammatory conditions but the time 
available to the project precluded an analysis also of the effects of HHV-6 
on microglia.  
As indicated above, the key to our approach was the use of cultured human 
glial cells derived from post-mortem brain samples. In our studies, human 
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adult astrocytes were generally used at passage 4 and human adult microglia 
were used within 1 or 2 weeks after isolation. In this state, these cells are 
expected to mimic authentic glial cells much better than immortalized cell 
lines. This approach therefore appears attractive to model inflammatory 
pathways in the human CNS and in fact, it is the only approach to address 
the above research question involving a virus that only infects humans and 
some primates but no routine laboratory animals such as rodents. Yet, at the 
start of the project it was insufficiently clear to what extent cultured glial 
cells are representative for glial cells in an intact CNS in vivo. Furthermore, 
it was not clear whether glial cells from different donors would display 
similar gene profiles. These issues became part of the research question. 
Glial cells used in this thesis were obtained from post-mortem sub cortical 
white matter kindly provided by the Netherlands brain bank (NBB) 
(www.hersenbank.nl). The NBB operates since 1985 and provides tissue on 
request, after prior submission of research protocols. The NBB supplies post 
mortem material from clinically well documented and neuropathologically 
confirmed cases and serves as a link between clinicians, neuropathologists 
and biomedical researchers. The NBB has three unique features. First, all 
donors and their next of kin are requested to sign an informed consent, when 
joining the program. Secondly, human brain tissue is obtained by means of 
rapid autopsies with a very short post-mortem delay, ranging between two 
to six hours minimizing post-mortem decay. Thirdly, the NBB uses a fresh 
brain dissection procedure, required to obtain high-quality samples for cell 
culture and neurochemical, immunocytochemical and metabolic studies. 
With the assistance of this unique facility, our studies were made possible. 
In present thesis we intend to clarify the impact of HHV-6 infection on glial 
cell functioning, neurodegeneration and demyelination.  
 
Outline of the thesis 
 
Following the General Introduction Chapter 2 describes the gene 
expression profiles in cultured human adult astrocytes using the above-
mentioned cDNA arrays. Astrocytes were chosen as a first target since they 
play key roles in CNS development, inflammation and repair and in 
regulating the blood-brain barrier. Also, it is known that HHV-6 can 
experimentally infect astrocytes in culture. A first important issue to address 
was the sensitivity, robustness and reproducibility of cDNA array-based 
gene profiling in cultured human adult astrocytes. Expression profiles were 
therefore generated eight times over for astrocyte cultures derived from a 
single donor to examine reproducibility, and another two cultures from 
different donors were examined as well. As a next step, the responses of 
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astrocytes to TNF-α, IL-1β and IFN-γ were monitored. This allowed 
comparison of the behavior of cultured astrocytes with data on astrocyte 
responses during inflammation in vivo, for example during MS, and data on 
similar in vitro models of astrocytes reported by others. Chapter 3 
describes the efforts to experimentally infect astrocytes with HHV-6, aiming 
at a maximum level of infection. HHV-6 is somewhat difficult to work with 
since it can only infect cells while “jumping” from one cell to the next. To 
infect astrocytes, another cell therefore had to be used as a source of virus. 
In Chapter 4 experiments are described that led to documentation of the 
gene expression profiles of HHV-6-infected astrocytes. To examine what 
would happen during inflammation, infected astrocytes were next supplied 
with the pro-inflammatory cytokines whose effects had been studied in 
Chapter 2. Apart from cytokines and chemokines, also Toll-like receptor 
(TLR) are key players in regulating inflammatory pathways, also in the 
human CNS. Upon recognizing bacterial or viral structures, TLR tend to 
activate inflammatoryreactions. Previous research in our group had 
documented the presence of TLR on astrocytes and in Chapter 5, the 
possible influence of HHV-6 on these TLR was therefore explored. 
Astrocytes were infected with HHV-6 and expression levels of TLR1 to 
TLR4 were monitored by real-time quantitative PCR and compared to 
cytokine production that was monitored via cDNA array profiling. As a 
final step in the study, attention was directed at another major type of glial 
cell in the human CNS, microglia. Microglia are somewhat more difficult to 
investigate than astrocytes since they do not survive freezing and thus 
cannot be stored. They must therefore be studied in primary cultures, which 
is only possible, over a period of 2 to 3 weeks at most. Also, their yield from 
tissue samples varies considerably from one case to the next. Chapter 6 
describes gene profiling of purified microglia that were all cultured under 
standardized conditions. Presenting a general discussion, Chapter 7 
summarizes the major results of the work, evaluates the suitablity and 
limitations of the currently applied cDNA array gene profiling technology 
 and attempts to put the various results into perspective.
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Abstract 
Astrocytes play key roles in CNS development, inflammation and repair by 
producing a wide variety of cytokines, chemokines and growth factors. 
Understanding the regulation of this network is important for a full 
understanding of astrocyte functioning. In this study, expression levels of 
268 genes encoding cytokines, chemokines, growth factors and their 
receptors were established in cultured human adult astrocytes using cDNA 
arrays. Also, changes in this gene profile were determined following 
treatment with TNF-α, IL-1β and IFN-γ.  
The data obtained reveal a highly reproducible pattern of gene expression 
not only between different astrocyte cultures from a single source, but also 
between astrocytes from different donors. Cultured human adult astrocytes 
were found to express receptors for TNF-α, IL-1β and IFN-γ. We also 
identified several gene products not previously described for human 
astrocytes including for example IL-17, CD70, CD147 and BIGH3. When 
stimulated with TNF-α, astrocytes respond with increased expression of 
several genes notably including those encoding the chemokines CCL2 
(MCP-1), CCL5 (RANTES) and CXCL8 (IL-8), growth factors including 
BMP-2A, BMP-3, neuromodulin (GAP43), BDNF and G-CSF and 
receptors such as the CRF-receptor, the calcitonin receptor (CTR) and TKT. 
The response to IL-1β involves largely the same range of genes, but 
responses were blunted in comparison to the TNF-α response. Treatment 
with IFN-γ had no or only marginal effects on expression of any of the 268 
genes analyzed. Astrocytes treated with a mixture of all three stimuli 
together displayed responses that are largely similar to those found in 
response to TNF-α or IL-1β alone, with only few additional synergistic 
effects.  
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Introduction  
Astrocytes are the most abundant glial cell type in the human brain. They 
play a key role in development, homeostasis, inflammatory responses and 
repair in the CNS by producing a wide variety of cytokines, chemokines, 
growth factors and by expressing receptors for these molecules. Well-
known astrocyte functions include maintenance of the blood-brain barrier 
(BBB), trophic support of neurons and oligodendrocytes and participation in 
the regulation of local inflammatory responses. Cytokines, chemokines and 
their receptors on astrocytes are also key in the cross talk between 
infiltrating cells of the immune system and the brain that determine 
inflammatory, neuroendocrine and even behavioral responses (1). Under 
inflammatory or otherwise pathological conditions astrocytes become 
activated and display enhanced production of several cytokines, chemokines 
and growth factors. Also, astrocytes generally start to proliferate under such 
conditions, a phenomenon known as astrogliosis (2). Under these 
conditions, astrocytes produce a wide variety of cytokines, chemokines and 
growth factors including IL-2, IL-4, IL-10, CCL2 (monocyte chemotactic 
protein-1), CCL5 (RANTES), CXCL8 (IL-8), TGF-β, brain-derived 
neurotrophic factor (BDNF) and TNF-α. Different techniques have been 
used to reveal this (Table2.1).  
Also, data are accumulating to document the functional role of these 
cytokines, chemokines and growth factors in mediating astrocyte functions. 
For example CCL2, CCL5, CXCL8 and TNF-α are associated with 
recruitment of immune cells via induction of adhesion molecule expression, 
and with the activation of such cells, which may lead to inflammatory tissue 
damage as seen in multiple sclerosis (MS) (18,29). On the other hand, IL-4, 
IL-10 and TGF-β promote regulatory roles of astrocytes in local 
inflammatory response and in repair functions (38). Growth factors such as 
for example BDNF and its receptor (gp145trkB) are involved in immune-
mediated neuroprotective interactions (39). 
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Table 2.1. Cytokines, chemokines, growth factors and their receptors expressed in 
human astrocytes 
 
cytokine/chemokine and receptors material reference 
control brain   
CCL2 (MCP-1) adult 3 
IL-4R adult 4 
TGF-βR1, TGF-βR2  adult 5 
FGFR-1 adult 6 
CXCL8 (IL-8) adult 7 
CXCR1 (IL-8R)  adult 8 
CXCR3  adult 9 
CXCR4  adult 7 
CX3CL1, CX3CR1 adult 10 
CCL2, CCR-2 fetal 11 
CX3CL1 (fractalkine) fetal 12 
mesencephalic astrocyte-derived 
neurotrophic factor (MANF) 
fetal 13 
MS brain   
CCL2 adult 14 
CCL3 (MIP-1α)  adult 15 
CCL4 (MIP-1β) adult 16 
CCL5 (RANTES) adult 17 
CCL7 (MCP-3) adult 14 
CCL8 (MCP-2) adult 14 
IL-2 adult 18 
IL-4 adult 19 
IL-6 adult 20 
IL-10  adult 21 
TNF-α adult 21 
TGF-β adult 21 
TGF-β1,  TGF-β2,  TGF-β3 adult 5 
TGF-βR1, TGF-βR2  adult 5 
IFN-γ adult 22 
CCR3 adult 23 
CCR5 adult 23 
CXCL10 (IP-10) adult 24 
CXCL9 (MIG) adult 25 
IL-4R adult 19 
IL-10R adult 19 
BDNF, BDNFR adult 26 
NGFR  adult 27 
CXCR3  adult 28 
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cytokine/chemokine and receptors material reference 
cultured control astrocytes   
CCL2 adult 29 
IL-4 adult 19 
IL-10 adult 19 
IL-1R2 adult 30 
IL-4R adult 4 
TGF-β1, TGF-β2   adult 5 
CXCR2  adult 31 
CXCR4 adult 7 
TNFR adult/fetal 30 
IL-1R1 adult/fetal 30 
IFN-αR, IFN-βR, IFN-γR adult/fetal 30 
MCSFR, SCFR adult/fetal 30 
IL-1β, fetal 32 
TNF-α fetal 32 
IL-6 fetal 32 
CXCL8 fetal 32 
CXCL9 fetal 32 
CXCL10 fetal 32 
CXCL12 fetal 32 
CCL2 fetal 32 
CCL3 fetal 33 
CCL4 fetal 32 
CCL5 fetal 11 
CCR2 fetal 34 
CCR3 fetal 32 
CCR5 fetal 32 
CCR8 fetal 32 
CXCR3 fetal 32 
CXCR5 fetal 32 
CXCR6 fetal 32 
CX3CR1 fetal 32 
BDNF fetal 35 
NGF fetal 35 
M-CSF  fetal 36 
IL-6R fetal 37 
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Much of what is currently known about cytokine and chemokine signaling 
by human astrocytes is derived from immunohistochemical studies of 
cytokines and chemokines in brain samples from cases of MS, Alzheimer's 
disease (AD) and Parkinson's disease. Also, several studies have been 
performed on cultured astrocytes isolated from either fetal or human adult 
brain tissue. In these latter types of studies, TNF-α, IL-1β and IFN-γ are 
frequently used as astrocyte stimulators since these cytokines represent 
major signaling molecules in the CNS (40). Several reports have 
documented the effects of these pro-inflammatory cytokines on the 
production of selected sets of cytokines and chemokines by astrocytes. In 
the discussion section of this paper, results of these studies will be revisited 
in the light of our own data.  Despite the wealth of information on cytokine 
and chemokine production by astrocytes, many questions remain with 
regard to their function and how neurodegenerative processes and viral 
infection modulate this network. Experimental approaches to understand the 
functional roles of astrocytes may be well served by robust in vitro 
approaches that allow experimental manipulation and molecular monitoring 
in ways that would be impossible with intact brains or using experimental 
animal models. A prerequisite for the use of in vitro systems, however, is 
that astrocytes behave in a stable manner when cultured and that astrocytes 
from different healthy control donors behave largely similar. Gene 
expression profiling by cDNA arrays appears a suitable technique to 
evaluate this issue. Array approaches have been applied to an increasing 
variety of cells and tissues (41) including for example rat microglia (42), but 
not yet to cultured human adult astrocytes.  
In this study, we first focused on the issue of robustness and reproducibility 
of cDNA array data. To allow more complex studies on gene expression 
profiles, it is necessary to establish that cultured astrocytes display a stable 
cytokine and chemokine gene expression profile that can serve as a 
reference for future studies. Rather than collecting data for thousands of 
genes, the cDNA array approach we have chosen was aimed at collecting 
reference data only for a relevant functional group of 268 genes encoding 
cytokines, chemokines, growth factors and their receptors, which allows for 
relatively easy data processing. Our results provide such a set of reference 
data and illustrate that cultured human adult astrocytes from different 
healthy control donors display a remarkably stable cytokine profile. As a 
next step we investigated the effects of TNF-α, IL-1β and IFN-γ on cultured 
human adult astrocytes. 
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Material and methods 
Donors 
Astrocytes used in the experiments were obtained from post-mortem sub 
cortical brain white matter provided by the Netherlands Brain Bank after 
rapid autopsy (post-mortem delays of less than 10 h). Three different donors 
were used, each of which was free from any clinical or neuropathological 
sign of CNS disorders. All 3 donors were female with the following 
characteristics: donor 1 (no 00- 022, aged 83, acute myocardial infarction), 
donor 2 (no 00-031, aged 77, cardiac infarction) and donor 3 (no 00-032, 
aged 78, decompensatio cordis). 
 
Isolation and in vitro culture of human adult astrocytes 
Human adult post-mortem astrocytes were obtained as previously described 
(43,44). Briefly, white matter samples were collected and meninges and 
visible blood vessels were removed before mincing the tissue into small 
cubes. The tissue fragments were incubated at 37°C for 20 min in 0.25 % 
trypsin (Sigma, St. Louis, MO) and 0.1 mg/mL bovine pancreatic DNAse I 
(Boehringer Mannheim, Germany). After digestion, cell suspensions were 
gently triturated, washed and taken into culture in medium containing 1:1 
v/v DMEM  : HAM-F10 supplemented with 10 % FCS (Biowhittaker, 
Verviers, Belgium) and pyruvate, glutamine and antibiotics. Astrocyte 
cultures were grown in 75 cm2 culture flasks coated with poly-L-lysine 
(Sigma Chemical Co, St Louis, MO).  Astrocytes were grown until post-
confluent monolayers were obtained at passage 4. The purity of the 
astrocyte culture was verified by staining with rabbit anti-glial fibrillary 
acidic protein (GFAP; ZYMED, San Francisco, CA) as an astrocyte marker, 
murine anti-human CD68 (DAKO, Glostrup, Denmark) as a microglia 
marker, and murine anti-myelin basic protein (MBP; Boehringer Mannheim, 
Germany) as an oligodendrocyte marker. The astrocyte cultures were found 
to be essentially 100 % GFAP-positive. No cells were found to express 
CD68 or MBP.  
Astrocyte treatment  
Post-confluent monolayers of astrocytes (donor 00-022) at passage 4 were 
treated for 48 h with 500 U/mL of either recombinant human TNF-α, IL-1β 
or IFN-γ (PreproTech, Rocky Hill, NY), or with a mixture of each of these 
three cytokines at the above-mentioned concentrations. 
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Analysis of mRNA expression using cDNA arrays 
Analysis of the mRNA profile of astrocytes was performed by hybrid 
selection of radioactive labeled cDNA on high-density Clontech Atlas 
arrays of membrane-bound cDNA probes, according to the manufacturer's 
instructions and using reagents provided by the manufacturer 
(http://www.bdbiosciences.com/clontech). Briefly, total cellular RNA was 
extracted from the astrocytes using denaturing solution and treated with 
RNase-free DNase. Poly A+ RNA was separated from total RNA using 
biotin-labeled oligo (dT) and streptavidin-labeled magnetic beads. Poly A+ 
RNA was incubated with a mixture of primers for all the genes located on 
the array. Radioactive cDNA probes were prepared by adding dNTP-mix 
(for dATP label), DTT, MMLV RT and  [32P]-dATP and incubating for 25 
minutes at 50°C. Hybridization of the radioactive cDNA probes to the 
membrane was carried out overnight at 68°C using continuously turning 
bottles. The membrane was washed in 2x saline sodium citrate (SSC), 1 % 
SDS and in 0.1x SSC, 0.5 % SDS at 68°C. Finally the membrane was once 
washed in 2x SSC at room temperature and directly packed to prevent 
drying. Specifically bound radioactivity was analyzed and quantitated by 
phosphor-imaging.  
 
Data analysis 
The hybridization signal for each gene probe, present in duplicate on the 
array, was calculated as the mean of these duplicates, corrected for 
background intensity and quantified using software provided by the 
manufacturer. Relative hybridization signals were calculated by dividing the 
absolute signals by the mean signal for all 9 housekeeping reference genes 
on the corresponding array, and multiplying this ratio by 1,000. 
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Results  
 
Repeated cytokine and chemokine profiling for astrocytes from a single 
control donor and comparison to other donors 
The first element in our study was to test reproducibility of the cytokine, 
chemokine and growth factor (receptor) gene profile in cultured astrocytes 
as monitored by the cDNA array. To this end, gene profiling was performed 
eight times, each time using a separately prepared post-confluent culture of 
astrocytes seeded from a single frozen stock obtained from one control 
donor. Also, gene profiling was performed on astrocyte cultures from two 
additional control donors, to examine possible donor-to-donor variation. 
Overall, the gene profiles were remarkably similar in all cases. Table 2.2 
lists the twenty most abundantly expressed cytokines, chemokines, growth 
factors and their receptors, standard deviations and coefficients of variation 
for gene expression signals as determined by the eight separate analyses for 
donor 1. Also, Table 2.2 provides a comparison of these data to those 
obtained with astrocytes from two additional donors. The most abundantly 
expressed genes include low affinity nerve growth factor receptor (NGFR), 
insulin-like growth factor binding protein 2 (IGFBP2), thymosin beta-10 
(TMSB10), pleiotrophin (PTN), CD70 (CD27 ligand), CD147 (basigin, 
neurothelin), vascular endothelial growth factor receptor 1 (VEGFR1), 
insulin receptor (INSR) and epidermal growth factor receptor (EGFR). 
These primarily represent soluble mediators for proliferation and their 
receptors, which is not unexpected for normal cultured astrocytes. 
Repeated gene profiling analysis of astrocytes from donor 1 indicated 
excellent reproducibility of the data, with standard deviations in the order of 
5 %. This emphasizes that the gene profile of separate astrocyte cultures 
derived from one donor is a very stable feature. Importantly, an even better 
reproducibility was observed when comparing the data for astrocytes 
derived from donor 1 with those for two additional control donors, as 
evaluated by principal component analysis (PCA). This analysis indicates 
that the agreement between the eight data sets for donor 1 is 80 %, and the 
agreement between the three different donors is 93.7 %. Following 
transformation of the data, these figures are 90.3 % and 97.2 %, respectively 
(45).  
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Signals for a minority of genes including CCL2, IL-4, IL-6, TNF-α and 
BMP-2A show a somewhat higher standard deviation, varying from 10 % 
up to as much as 40 %. Since the vast majority of genes on the arrays 
produce a highly reproducible expression signal, the varying signals for 
these few genes most likely indicate intrinsic variations in the expression 
levels of these particular genes in the astrocyte cultures. Interestingly, 
CCL2, IL-4, IL-6, TNF-α and BMP-2A are known to be highly inducible in 
human astrocytes (see below and Tables 2.3 and 2.4) (46,47). Therefore, it 
seems that these particular inducible genes respond to subtle variations in 
cell culturing conditions and astrocyte densities at the time of RNA 
harvesting. 
 
Cytokine and chemokine profiling of astrocytes treated with TNF-α, 
IL1-β, IFN-γ, or a mixture of these three cytokines together  
Having established reproducibility of the gene profile in cultured astrocytes, 
the effect of pro-inflammatory stimuli including TNF-α, IL1β and IFN-γ 
was examined next. The astrocytes were found to express the receptors for 
these three cytokines. The concentrations of the cytokines used for treatment 
as well as the time for treatment were chosen on the basis of our previous 
and current gene expression studies using cultured human adult astrocytes 
(43). Under the conditions used by us, the most pronounced changes in 
mRNA levels for a variety of cytokine and stress protein genes in astrocytes 
occur over periods of 6 to 72 h. In line with our findings, Croitoru-Lamoury 
and co-workers recently reported that for several chemokines in human fetal 
astrocytes, gene induction effects by TNF-α, IL-1β and IFN-γ generally 
accumulated over 72-h periods (32). Based on this, we considered 48 h as a 
suitable time point allowing us to monitor relevant changes for most genes. 
Gene profiling of IFN-γ treated astrocytes was also performed after 6 or 24 
h to verify that no relevant responses escaped detection by focusing only on 
the results obtained after 48 h (see below).  
 
Genes induced by TNF-α  
Treatment of astrocytes with TNF-α resulted in markedly elevated 
expression of a distinct group of genes fulfilling different functions. No 
genes were found whose expression was markedly decreased as the result of 
treatment.  
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Figure 2.1 depicts a complete overview of the relative levels of expression 
of all genes on the array following treatment as compared to their 
expression in untreated astrocytes. Several genes can be found in the upper 
left part of Figure 2.1, representing genes whose expression is enhanced by 
TNF-α. 
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Figure 2.1. The impact of TNF-α on human astrocyte genes encoding cytokines, 
chemokines, growth factors and their receptors 
Cultured human adult astrocytes were treated with TNF-α for 48 h and using a cDNA 
array, expression levels of 268 cytokines, chemokines, growth factors and their 
receptors were determined and compared to levels found in untreated astrocytes. 
Signals at or around the diagonal line represent genes whose expression is unaffected 
by TNF-α treatment. Signals in the upper left part of Figure 2.1 represent genes whose 
expression is enhanced by the treatment. The data represent the averaged result of two 
separate experiments. For further details, see materials and methods. 
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Table 2.3 shows a summary of genes whose exression was elevated by 
TNF-α (or any of the other stimuli in the present study). As major genes, we 
considered genes with relative signals of at least 300 in untreated astrocytes, 
reflecting a level of expression that is at least 30 % of that of the average for 
all housekeeping genes analyzed as reference. Changes in expression levels 
for these genes are considered meaningful when they exceeded a factor of 2. 
For minor genes of interest, with a minimal relative signal of 250 in treated 
astrocytes, changes in expression levels were considered meaningful when 
they exceeded a factor of 3.  
The most strongly induced major genes after TNF-α treatment include 
CCL2 (MCP-1, a strong chemotactic factor involved for example in 
leukocyte recruitment across the BBB), BMP-2A and BMP-3 (mediators in 
neural development), corticotrophin-releasing factor receptor 1 (CRF-R, a 
neuromodulatory hormone receptor), BDNF (a neurotrophic factor), 
neuromodulin (GAP43, a neuroprotective factor), interferon regulatory 
factor-1 (IRF-1, a transcription factor regulating interferon responses), 
calcitonin receptor (CTR), CCL5 (RANTES, a chemotactic factor) and 
receptor protein tyrosine kinase (TKT).  
Following treatment with TNF-α, several minor genes are induced including 
CD141 (a receptor normally associated with thrombin binding and 
coagulation), cytokine receptor EBI3, tumor necrosis factor receptor 1 
(TNFR1) and TNFR2, interleukin-9 receptor (IL-9R), transforming growth 
factor-alpha (TGF-α), IL-17, CXCL6 (GCP 2), CXCL8 (IL-8), fibroblast 
growth factor 7 (FGF7), CXCL9 (interferon-gamma-induced monokine, 
MIG), CD114 (the G-CSF receptor), CCL4 (MIP-1β), interferon consensus 
binding sequence-protein  (ICSBP), and granulocyte colony-stimulating 
factor (G-CSF). 
 
Genes induced by IL-1β  
Treatment of astrocytes with IL1-β resulted in effects on gene expression 
that are clearly reminiscent of the effects of TNF-α, but that are less 
pronounced. Figure 2.2 depicts a complete overview of the relative levels of 
expression of all genes on the array following treatment as compared to 
their expression in untreated astrocytes. No genes were found whose 
expression was markedly decreased as the result of treatment. Table 2.3 
highlights the most important effects of IL-1β treatment. Concerning the 
major astrocyte genes, only the receptor protein tyrosine kinase (TKT) was 
induced by IL-1β with more than a factor of 2. For the minor genes, 
induction was observed of erythroid differentiation protein (EDF), IL-17, 
CD135 (STK1), CXCL8 (IL-8), vitamin B3 receptor (G-protein-coupled 
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receptor HM74), FGF7 and granulocyte colony-stimulating factor (G-CSF). 
In addition, several other genes displayed modestly enhanced levels of 
expression (yet below the arbitrary threshold of a factor of 2). This group of 
genes is virtually identical to the group of genes induced by TNF-α, 
including again for example CCL2, BMP-2A, BMP3, CRF-R, BDNF and 
CTR.  
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Figure 2.2. The impact of IL-1β on human astrocyte genes encoding cytokines, 
chemokines, growth factors and their receptors 
Cultured human adult astrocytes were treated with IL-1β for 48 h and using a cDNA 
array, expression levels of 268 cytokines, chemokines, growth factors and their 
receptors were determined and compared to levels found in untreated astrocytes. 
Signals at or around the diagonal line represent genes whose expression is unaffected 
by IL-1β treatment. Signals in the upper left part of Figure 2.2 represent genes whose 
expression is enhanced by the treatment. The data represent the averaged result of two 
separate experiments. For further details, see materials and methods. 
Gene profile in cytokine-treated astrocytes 
 47 
 
The effects of IFN-γ  
In contrast to the effects induced by either TNF-α or IL-1β, treatment of 
astrocytes with IFN-γ  had no marked effect on levels of expression of any 
of the genes encoding cytokines, chemokines, growth factors and their 
receptors analyzed in the present study (Figure 2.3 and Table 2.3). In order 
to examine whether the 48-h treatment time would perhaps obscure more 
rapid effects on gene expression, the analysis was repeated with astrocytes 
treated with IFN-γ for only 6 or 24 h. After a 6-h treatment, only the 
abundantly expressed CCL2 (MCP-1) showed a relative increase of more 
than a factor 2, viz. 3.35 (data not shown). After 24 h treatment, only glial 
growth factor and BDNF were induced by a factor of 3.71 and 3.40, 
respectively. This result indicated that marked induction of notably CCL2, 
glial growth factor and BDNF by IFN-γ does occur but that this is a 
relatively rapid response only detectable after 6 or 24 h. No other major 
gene appears to be induced by IFN-γ after 6 or 24 h of treatment any more 
than after 48 h.  
 
The effects of a mixture of TNF-α, IL-1β, and IFN-γ 
Treatment of astrocytes with a mixture of the cytokines TNF-α, IL-1β, and 
IFN-γ resulted in distinct upregulation of several genes. Again, no genes 
were found whose expression was downregulated by the treatment. Figure 
2.4 shows the expression signals for treated astrocytes versus untreated 
ones, revealing a group of genes upregulated by the mixture of cytokines 
that is largely the same as the group induced by the individual cytokines 
TNF-α or IL-1β. Table 2.3 highlights the effects of the combined treatment 
with TNF-α, IL-1β, and IFN-γ. Major genes upregulated by a factor 2 or 
more include for example CRF-R, BDNF, neuromodulin, CTR, BMP-3 and 
TKT that were all already found to be upregulated by either TNF-α or IL-
1β alone. CCL2 was, on the other hand, upregulated by a factor of only 
1.75. Following treatment with TNF-α, IL-1β, and IFN-γ several minor 
genes are upregulated including IL-11, IL-17, CXCL8 (IL-8), CD114 (the 
G-CSF receptor), granulocyte colony-stimulating factor (G-CSF), insulin-
like growth factor II (IGF2), and erythropoietin receptor (EPOR). 
Previous reports have indicated the possibility of synergistic effects of 
cytokines on astrocyte gene expression. Of all 268 genes, only IGFBP3, 
CXCL2 (MIP2-α), ephrin A3, follistatin-related protein, neurotrophin-3, IL-
11, IGF-2 and erythropoietin receptor were found to be markedly induced 
by the mixture of cytokines while being less affected by each of the 
cytokines individually. Overall, however, synergistic effects between TNF-
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α, IL-1β and IFN-γ appear to be limited since the group of genes that is 
induced by the mixture of these mediators primarily reflects additive effects 
of TNF-α and IL-1β alone. 
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Figure 2.3. The impact of IFN-γ on human astrocyte genes encoding cytokines, 
chemokines, growth factors and their receptors 
Cultured human adult astrocytes were treated with IFN-γ for 48 h and using a cDNA 
array, expression levels of 268 cytokines, chemokines, growth factors and their 
receptors were determined and compared to levels found in untreated astrocytes. All 
signals can be found in Figure 3 at or around the diagonal line indicating the absence of 
any gene on the array whose expression is markedly affected by IFN-γ. The data 
represent the averaged result of two separate experiments. For further details, see 
materials and methods. 
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Figure 2.4. The impact of a combined treatment with TNF-α, IL-1β and IFN-γ on 
human astrocyte genes encoding cytokines, chemokines, growth factors and their 
receptors 
Cultured human adult astrocytes were treated with a mixture of TNF-α, IL-1β and IFN-
γ for 48 h and using a cDNA array, expression levels of 268 cytokines, chemokines, 
growth factors and their receptors were determined and compared to levels found in 
untreated astrocytes. Signals at or around the diagonal line represent genes whose 
expression is unaffected by the treatment. Signals in the upper left part of Figure 2.4 
represent genes whose expression is enhanced. The data represent the averaged result 
of two separate experiments. For further details, see materials and methods. 
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Table 2.3. Gene profiles of human adult astrocytes after treatment with different pro-inflammatory 
cytokines 
 treatment
with 
TNF-α 
treatment 
with  
IL-1β  
treatment  
with  
IFN-γ 
treatment with 
TNF-α, IL-1β  
and IFN-γ  
 
 
Gene code 
Major genes      
CCL2 (monocyte chemotactic protein 1, MCP-1) 2.08 1.36 1.00 1.75 M24545 
bone morphogenetic protein 2A (BMP2A) 2.42 1.34 0.93 1.61 M22489 
insulin-like growth factor binding protein 3 
(IGFBP3) 
1.26 1.17 0.88 2.25 M31159 
corticotrophin releasing factor receptor 1 (CRF-R) 2.13 1.47 1.01 2.06 X72304 
brain-derived neurotrophic factor (BDNF) 2.18 1.46 0.99 2.27 M61176 
Neuromodulin (GAP43) 2.27 1.44 1.03 2.02 M25667 
CXCL2 (MIP2-alpha) 1.40 1.61 1.03 2.49 X53799 
interferon regulatory factor 1 (IRF1) 2.07 1.23 1.01 1.49 X14454 
ephrin A3 (EFNA3) 1.33 1.76 0.92 2.64 U14187 
calcitonin receptor (CTR) 2.82 1.61 1.02 2.48 L00587 
CCL5 (RANTES) 3.34 1.31 0.99 1.70 M21121 
follistatin-related protein 1.57 1.93 0.94 2.43 U06863 
bone morphogenetic protein 3 (BMP3) 4.33 1.62 0.91 2.77 M22491 
receptor protein tyrosine kinase (TKT) 2.62 2.86 0.88 2.89 X74764 
neurotrophin-3 (NT-3), NGF-2 1.72 1.73 1.01 2.25 X53655 
Minor genes      
CD141 (thrombomodulin) 3.54 1.89 1.05 2.49 M16552 
erythroid differentiation protein (EDF)  2.41 3.20 0.93 2.91 J03634 
interleukin-11 (IL-11) 1.06 1.41 0.57 3.02 M57765 
cytokine receptor EBI3 3.19 1.85 1.00 2.85 L08187 
tumor necrosis factor receptor (TNFR)  + TNFR2 4.28 2.09 0.98 1.52 M32315 + 
M55994 
interleukin-9 receptor (IL-9R) 3.62 1.64 0.99 2.01 M84747 
transforming growth factor-alpha (TGF-alpha) 3.60 1.57 0.91 2.13 K03222 
interleukin-17 (IL-17) 3.35 4.53 0.96 3.17 U32659 
CD135 (stem cell tyrosine kinase 1, STK1)  3.03 3.92 0.88 2.53 U02687 
CXCL6 (granulocyte chemotactic protein 2, GCP 2) 3.80 2.28 0.97 1.87 X78686 
CXCL8  (IL-8) 7.64 5.30 0.98 3.52 Y00787 
vitamin B3 receptor (G-protein-coupled receptor 
HM74) 
15.23 3.95  0.87 2.98 D10923 
fibroblast growth factor 7 (FGF7) 5.76 3.44 0.99 1.87 M60828 
CXCL9 (interferon-gamma-induced monokine, 
MIG) 
4.50 2.62 1.11 1.84 X72755 
CD114 (GCSF-R) 4.35 1.99 0.94 3.21 M59818 
CCL4 (MIP-1beta) 6.10 5.00 0.69 1.33 J04130 
interferon consensus binding sequence-protein   7.53 2.22 1.11 2.16 M91196 
granulocyte colony-stimulating factor (G-CSF) 17.39 8.90 0.92 4.11 X03438 
insulin-like growth factor II (IGF2) 1.26 1.75 0.63 3.34 M29645 
erythropoietin receptor (EPOR) 2.26 3.75 1.47 3.03 M60459 
Numerical values represent the ratio of expression in treated versus untreated astrocytes. Indicated in bold are 
major genes (relative signals in untreated astrocytes >300) with a ratio of at least 2, and minor genes (relative 
signals in untreated astrocytes <300 and relative signals in treated astrocytes of over 250) with a ratio of at least 3.  
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Discussion 
In this study, cDNA arrays were used to evaluate the expression profile in 
cultured human astrocytes for 268 genes encoding cytokine, chemokines, 
growth factors and their receptors, and the effects of TNF-α, IL-1β and 
IFN-γ on this profile. Gene profiles established for repeated astrocyte 
cultured derived from a single donor as well as for astrocytes from different 
donors are remarkably stable. The vast majority of gene products that are 
relatively abundantly expressed in untreated cultured astrocytes appear to be 
associated with normal regulation of proliferation and either represents 
soluble mediators of growth, or their receptors. Several of these products 
have also been found in vivo in reactive and proliferating astrocytes in 
human brain. This applies to nerve growth factor receptor (NGFR), 
pleiotrophin (PTN), epidermal growth factor receptor (EGFR), IL-6 and 
connective tissue growth factor (CTGF) (20,21,27,48,49). Our study also 
identifies several genes that to the best of our knowledge have not 
previously been documented to be expressed in astrocytes. These novel 
astrocyte gene products include IL-17, CD70, CD147, BIGH3, UFO/Axl 
receptor tyrosine kinase and TEK/TIE-2 receptor tyrosine kinase.  
Treatment of astrocytes with either TNF-α or IL-1β alone leads to induction 
of a remarkably similar set of astrocyte genes including chemotactic factors 
amongst which the predominant ones are CCL2 (MCP-1), CXCL2 (MIP-
2α), CXCL8 (IL-8), CCL5 (RANTES), neuroprotective factors primarily 
including BDNF, neuromodulin (GAP43) (50), BMP-2A and BMP-3, and 
receptors notably including the CRF and calcitonin receptors and receptor 
protein tyrosine kinase (TKT). Somewhat to our surprise, IFN-γ treatment 
under the conditions used by us has no appreciable effect on the level of 
expression of any of the 268 genes examined. We examined the possibility 
that a 48-h treatment time could obscure more rapid effects on gene 
expression. Apart from CCL2, glial growth factor, and BDNF whose 
expression was indeed elevated after 6 or 24 h but not after 48 h, none of the 
other genes were affected by IFN-γ at these earlier time points either. The 
effects of IFN-γ were monitored using two different fresh batches of the 
cytokine, ruling out the possibility that the lack of any major effect could be 
caused by the state of our IFN-γ preparation.  IFN-γ therefore, appears to 
simply have very little effect on the cytokine/chemokine network in cultured 
human adult astrocytes, despite the fact that the IFN-γ receptor is found, by 
us as well as by others, to be expressed by these cells (30). Our finding is in 
line with several other studies that have documented the failure of IFN-γ to 
induce major astrocytic cytokine and chemokine mediators including CCL2, 
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CCL5, CXCL8, BDNF, IL-1β, IL-1α, CCL3 (MIP-1α) and CCL4 
(MIP−1β) in cultured human adult astrocytes (29,33,36,48,51). Many of the 
previously reported effects of IFN-γ on human astrocytes (apart from its 
effect on IL-6, TNF-α and CXCL10) were obtained using fetal rather than 
adult astrocytes (Table 2.4). In particular for IFN-γ this difference has 
previously been shown to be of relevance since several of the stimulatory 
effects on fetal astrocytes did not occur when adult astrocytes were used 
(52,53). Lafortune and co-workers reported an increased number of cultured 
human adult astrocytes with detectable expression of IL-6 and TNF-α in 
response to IFN-γ (53), but levels of expression were not quantified in that 
study, making a comparison to our present data difficult. Our data leave 
open the possibility that IFN-γ induces CXCL10 (IP-10), as has been 
reported by others (29) since the cDNA arrays used in the present study do 
not contain a CXCL10 probe.  
The mixture of all three pro-inflammatory cytokines together induced gene 
expression changes that were very similar to those found in response to 
either TNF-α or IL-1β alone. While examples of synergistic effects by 
cytokines on astrocytes have been reported, our results indicate that overall, 
such synergistic effects are limited and the result of the mixture of cytokines 
is largely a simple addition of the effects of the individual cytokines. The 
only genes with appreciable induction by the mixture of cytokines, while 
being much less affected by individual cytokine stimuli include IGFBP-3, 
CXCL2, follistatin-related protein, ephrin A3 (EFNA3), IL-11 and IGF-2.  
While the technique of cDNA array gene profiling has now been well 
accepted, and has been found to be at least as reliable as other approaches to 
quantify gene expression, it is obviously of relevance to compare our data 
on cytokine responses by human astrocytes to those already reported by 
others, as a validation of the current data. In comparing our data to 
previously published results, it must be kept in mind that treatment times, 
cytokine dosing and, most importantly, the source of astrocytes are 
important variables that can confound direct comparison. In Table 2.4, a 
comparison is presented between our data and previously reported 
stimulatory effects of the cytokines TNF-α, IL-1β, and IFN-γ on cytokine 
and chemokine gene expression in cultured human astrocytes.  
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Table 2.4. Comparison of previously reported findings of gene induction in astrocytes with the present data 
 Material Reference Ratio1 
TNF-α treatment    
CXCL8 (IL-8) adult, fetal 29, 36 7.64 
CCL2 (MCP-1) adult 29 2.08 
CCL5 (RANTES) adult 29 3.34 
CCL2 fetal 55 2.08 
CCL3 (MIP-1α) fetal 56 2.25 
CCL4 (MIP-1β) fetal 56 6.10 
CCL5  fetal 57 3.34 
M-CSF (=CSF-1)  fetal 36 1.53 
G-CSF, GM-CSF fetal 36 17.39, 2.34 
IL-6 fetal 36 1.37 
IL-15 fetal 58 2.80 
CCR2 fetal 32 2.09 
platelet-derived growth factor (PDGF) fetal 59 1.23 
CXCL10 (IP-10) adult 29 not on array 
CX3CR1 fetal 32 not on array 
IL-1β treatment    
CXCL8 adult, fetal 29,36 5.30 
CXCL1 adult 60 not on array 
CCL2 adult 29 1.36 
CCL5  adult, fetal 29, 61 1.31 
CCL3 fetal 56 7.27 
CCL4 fetal 56 5.00 
CCL5 fetal 57 1.31 
M-CSF fetal 36 2.50 
G-CSF, GM-CSF fetal 36 8.90, 1.48 
TNF-α fetal 54 1.04 
IFN-β fetal 61 2.52 
IL-6 fetal 36 1.54 
IL-15 fetal 58 1.35 
IRF7 fetal 61 not on array 
CXCL10 (IP-10) adult, fetal 29,61 not on array 
IFN-γ treatment    
IL-6 adult 53 0.93 
TNF-α  adult 53 0.97 
CCL2, CCL3 fetal 62 1.00/0.69 
CCL4, CCL5 fetal 62 0.69/0.99 
interferon regulatory factor-1 (IRF-1) fetal 48 1.01 
TNFαR1 fetal 63 0.93 
IL-15 fetal 58 0.86 
ICAM-1 fetal 48 not on array 
CXCL10  adult, fetal 60, 29 not on array 
TNF-α and IL-1β treatment    
CCL5 fetal 64 1.702 
CCL2  fetal 32 1.752 
TNF-α and IFN-γ treatment    
CCL5 fetal 64 1.702 
CCR5  fetal 32 not on array 
CXCL8, CXCL9 (MIG) fetal 32 3.522/1.842 
CXCL10 fetal 32 not on array 
CXCR4  fetal 32 not on array 
CX3CL1 (fractalkine)  fetal 65 not on array 
IFN-γ and IL-1β treatment    
CCL2 fetal 29 1.752 
CCL5 fetal 64 1.702 
1 Based on data from the present study, 2 Ratio following treatment with TNF-α, IL-1β and IFN-γ
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Table 2.4 illustrates that almost all cytokines and chemokines previously 
reported by others to be induced by either TNF-α or IL-1β alone, or by a 
mixture of these cytokines, were also found to be upregulated in the present 
study. All TNF-α inducible genes previously documented by others were 
reproduced by the present study, with relative increases of expression 
ranging from 1.37 to 17.39. As the only exception, induction of TNF-α by 
IL-1β as reported by Lee and co-workers (54) could not be reproduced in 
the present study. However, this induction was only observed after 4 to 16 h 
of treatment, and not after 72 h. The apparent discrepancy might therefore 
well be explained by different treatment times. Overall, the correspondence 
between the current data and previously reported effects is very good, 
validating our present data set. 
One of the most abundantly expressed genes in astrocyte cultures, and one 
that is also markedly induced by both TNF-α and IL-1β is CCL2 (MCP-1). 
Also others have already documented the importance of CCL2 for astrocyte 
functions by showing its induction in cultured human astrocytes after 
treatment with TNF-α (66) and its elevated levels of expression under a 
variety of inflammatory or traumatic conditions in vivo in the CNS 
(16,67,68). CCL2 is known to regulate leukocyte transmigration across the 
BBB (69) and it is a prime mediator of astrogliosis (2). Another major 
chemotactic factor that emerges from the present study as well as from 
previous reports as an important inducible astrocyte gene product is CXCL8 
(IL-8). CXCL8 is involved in the activation and chemotaxis of 
polymorphonuclear leukocytes (70) and its induction in adult as well as in 
fetal astrocytes by TNF-α and IL-1β is well documented (29,71).  
It is also interesting to note that treatment with either TNF-α or IL-1β alone, 
as well as treatment with the mixture of cytokines (Table 2.3) consistently 
leads to a 3 - to 4.5-fold induction of IL-17, a pro-inflammatory cytokine 
that has so far been considered as T-cell specific (72). Our data suggest a 
role of IL-17 also in astrocyte functions and thus, in CNS inflammation. 
Interestingly, it was recently reported that IL-17 is strongly upregulated in 
tissue samples of chronic inactive MS plaques, but not in early active 
lesions (73). When combined with our data, this suggests that astrocytes are 
in fact responsible for marked IL-17 production at these late stages of MS 
plaques. As a final note, it should be emphasized that cultured astrocytes as 
used in the present study represents a simplification relative to the state of 
astrocytes in an intact CNS, where additional interactions with other cell 
types and matrix components are likely to influence the cytokine/chemokine 
network. Yet, cultured human astrocytes present a unique system to 
examine in detail the response of astrocytes to defined stimuli at the level of 
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the genome or proteome. It is our conviction that this will help further 
understand the complex molecular interactions that ultimately govern 
development, inflammation and repair in the CNS. 
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Abstract 
Human herpesvirus-6 (HHV-6) is a ubiquitous virus that infects about 90 % 
of the human population and frequently establishes latent infection in 
astrocytes, oligodendrocytes and microglia in the central nervous system 
(CNS). Since the HHV-6 genome encodes several molecules that can act as 
chemokine receptors or as chemokine mimics, the virus may well impact on 
immune regulatory processes in the CNS, such as those relevant to 
inflammatory neurodegenerative disorders in which glial cells play key 
roles.  
To examine the impact of HHV-6 on glial cell functions in vitro models of 
experimental infection appear to be an attractive approach. In the present 
study we therefore investigated the efficiency of experimental infection of 
cultured human adult astrocytes with HHV-6-infected T-cell lines as a 
source of cell-borne virus, as well as with cell-free preparations. While cell-
free preparations of HHV-6 led to infection of only about 10 % of cultured 
astrocytes, cell-borne virus could be reproducibly transferred to about 30-35 
% of astrocytes. This level of infection could be obtained with HSB-2 T-
cells but not with JJHan T-cells as carriers. Infection with HHV-6 was 
apparent from cytopathic effects (CPE) including syncytium formation and 
specific staining for HHV-6 antigen. After 3-5 days following infection, 
death of infected cells started to become apparent. For the first 3 days, 
therefore, HHV-6-infected astrocyte cultures provide a useful in vitro model 
to explore the effects of the virus on inflammatory pathways in human 
astrocytes. 
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Introduction 
Human herpesvirus 6 (HHV-6) is a β-herpesvirus, first discovered in 1989 
as a human B-lymphotropic virus (1) of which two variants are known, viz. 
HHV-6A and HHV-6B (2). Infection with HHV-6 is common in infancy 
and early childhood (3) and the virus persistently infects about 90 % of the 
human population (4,5,6). Following transmission, usually through saliva 
(7), HHV-6 can spread to mononuclear cells, salivary glands, lungs, genital 
tract and the central nervous system (CNS) via its receptor CD46 (8). In 
particular in the CNS,  HHV-6 successfully persists and viral DNA has been 
detected in as many as 85 % of brain samples derived from healthy adult 
donors (9,10,11,12,13). Especially glial cells including astrocytes, 
oligodendrocytes and microglia appear to form life-long reservoirs of virus.   
To date, the role of HHV-6 in human disease remains to be fully clarified. 
To understand the role of the virus in human disease it is therefore 
particularly important to dissect its impact on immune mediated processes. 
While the virus triggers a predominantly pro-inflammatory reaction in 
immortalized T-cell lines that are routinely used to propagate the virus (14), 
the effects in other target cells may be different. In particular in adult CNS 
glial cells, where infection is usually not accompanied by pathogenic 
immune responses, the way HHV-6 affects cell functioning remains to be 
established. In vitro approaches to this issue appear to be attractive. 
Successful infection of cultured human fetal astrocytes and of 
oligodendrocytes and microglia have been reported (15,16,17). In fetal 
astrocytes, infection led to rapid development of CPE and after 1 week to 
total lysis of the culture. In adult oligodendrocytes and microglia on the 
other hand, cell lysis and release of virus was very limited suggesting that 
adult glial cells may respond differently to HHV-6 infection from fetal glial 
cells.  
In this study, we examined HHV-6 infection of cultured human adult 
astrocytes to evaluate whether such a model would allow for further studies 
on immune regulatory aspects of HHV-6 infection in the CNS. The goal 
was therefore to obtain a reproducible level of infection without cell lysis 
that would allow for further experimental manipulation of infected cells. We 
focused on HHV-6A since this variant is more frequently detected in human 
adult CSF and brain samples as compared to HHV-6B (9,18). 
In contrast to fetal human astrocytes, HHV-6-infected adult astrocytes in 
culture did not undergo massive lysis but in the first three days after 
experimental infection, were engaged in syncytium formation only. 
Transmission of HHV-6 from infected to uninfected astrocytes appeared to 
be much less efficient than transmission from infected T-cell lines, limiting 
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viral spread in the culture after an initial dose of T-cell-borne HHV-6. Thus, 
adult astrocyte cultures could be established in which about one third of the 
cells were stably infected as assessed by cytopathic effects (CPE) and 
staining for specific HHV-6 antigen. Such infected cultures may provide a 
useful in vitro research model to explore the effects of HHV-6 on 
inflammatory pathways in the human CNS. 
 
Materials and methods 
 
HHV-6 infection of human T-cell lines  
HHV-6A GS and U1102 were grown using the HSB-2 and the JJHan T-cell 
lines (19,20,21).  HHV-6-infected HSB-2 T-cells were prepared by co-
culturing 5.5 x 106 uninfected cells/mL with one tenth of total cell volume 
HHV-6-infected HSB-2 T-cells (GS strain; multiplicity of infection (MOI) 
0.1) in RPMI 1640 (Biowhittaker, Verviers, Belgium) supplemented with 10 
% FCS (Biowhittaker, Verviers, Belgium) and antibiotics at 37ºC in a 
humidified atmosphere containing 5 % CO2. After 2 h at 37ºC infected T-
cells were collected by centrifugation at 210 g for 10 min, resuspended in 
culture medium and cultured in 75 cm2 flasks kept upright (25 mL/flask). 
After 2 days in culture levels of 40 % infection were reached and cultures 
were split into two equal parts. After an additional culture period of 3 days 
75 % of the HSB-2 T-cells were infected. Infected HSB-2 T-cells from the 
separate cultures were collected centrifuged at 210 g for 10 min and stored 
at 0.5 x 106 cells/mL in 90 % v/v FCS and 10 % v/v dimethylsulfoxide 
(DMSO; Merck, Darmstadt, Germany) at -150ºC.  
HHV-6-infected JJHan T-cells were prepared by infecting 4 x 106 non-
infected cells with HHV-6-infected cells (U1102 strain, tissue culture 
infectious dose 50 (TCID50) = 1 x 106) (19); supplied by U. Gompels, 
London School of Hygiene and Tropical Medicine, London. After 4 days in 
culture levels of 60 % infection were reached. HHV-6-infected T-cells were 
centrifuged at 210 g for 10 min and stored at 0.5 x 106 cells/mL in 90 % v/v 
FCS and 10 % v/v dimethylsulfoxide at -150ºC. 
To determine the levels of infection in cell cultures, as defined by the 
percentage of infected cells rather than by virus titers, samples of infected 
cultures were fixed in acetone supplemented with 0.03 % v/v H2O2 for 10 
min. Cells were incubated overnight at 4ºC in PBS supplemented with 0.1 
% w/v bovine serum albumin (BSA) and the murine monoclonal antibody 
NCL-HHV-6, that is specific for a 105-kD protein for both HHV-6A and 
HHV-6B (Novocastra, Newcastle, UK). After washing with PBS, 
biotinylated horse-anti-mouse Ig antibodies (Vector, Burlingame, CA) were 
added in PBS supplemented with 1 % w/v BSA and 1 % v/v normal human 
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serum (NHS) for 45 min at room temperature. After washing with PBS, 
FITC-conjugated streptavidin (DAKO, Glostrup, Denmark) was added in 
PBS supplemented with 1 % w/v BSA and 1 % v/v NHS for 45 min at room 
temperature. Stained cells were embedded in Vectashield mounting medium 
with 4'6-diamidino-2-phenylindole-2HCl (DAPI; Vector Laboratories, 
Burlingame, CA) for DNA staining. 
 
Infection of astrocytes using infected T-cell lines  
Astrocytes were obtained from post-mortem sub cortical brain white matter 
provided by the Netherlands Brain Bank after rapid autopsy. Autopsies are 
performed on donors with written informed consent from the donor or from 
direct next of kin. Astrocytes were isolated and cultured as described 
previously (22). Astrocytes derived from two different control donors were 
used, both free from any clinical or neuropathological signs of CNS 
disorders. Both donors were females that had succumbed to acute 
myocardial infarction; donor 1 (00- 022, age 83) and donor 2 (00-031, age 
77). Human adult astrocytes were obtained as previously described (23,24). 
Before addition to astrocyte cultures HHV-6-infected T-cells were 
resuspended in fresh astrocyte culture medium (DMEM/HAM-F10 
supplemented with 10 % FCS and pyruvate, glutamine and antibiotics) to 
remove soluble mediators or virus released from infected T-cells. Post-
confluent monolayers of astrocytes in chamberslides were cultured in the 
presence of 0.37 x 104, 0.75 x 104, 1.5 x 104 or 3 x 104 HHV-6-infected T-
cells per 500 µL for a period of 18 h. Astrocytes were washed extensively to 
remove the T-cells, fresh culture medium was added and the astrocytes were 
cultured for an additional period of 1 to 5 days. Infection levels in astrocyte 
cultures were determined as described above for T-cells. 
 
Preparation of cell-free virus   
HHV-6-infected HSB-2 and JJHan T-cells were grown for 8 days to 
maximize viral load. Under these conditions, at least 80 % of the T-cells 
were infected. Previous experiments indicated that the level of infection as 
expressed by HHV-6 antigen positivity produced a more reliable measure 
for infectivity of virus-containing T-cell stocks than the commonly used 
TCID50. Cells were collected by centrifugation at 210 g for 10 min and 
resuspended in a small part of their original culture supernatants 
supplemented with 10 % FCS at 1.5 x 106 cells/mL for storage at -80ºC. To 
prepare cell lysates virus preparations, infected T-cells were subjected to 
three freezing-thawing cycles. This effectively lysed all cells as verified by 
re-culturing the lysate. The cell lysates were added to astrocytes at 
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concentrations of 1.6 x 104, 3.2 x 104, 6.4 x 104 or 12.8 x 104 lysed cells per 
500 µL and astrocytes were cultured for a period of 1 to 5 days. 
As alternatives to the above method to produce a crude total lysate of HHV-
6-infected T-cells, additionally purified variant lysates and cell-free HHV-6 
preparations (free from any viable cells as well as from cell particles) were 
prepared by an additional treatment of total lysates including centrifugation 
at 210 g for 10 min followed by ultracentrifugation of the supernatant (2 h at 
60,000 g), filtration over 0.2 or 0.45 µm filters, or by washing of the crude 
lysate with 150 mM NaCl in the absence or presence of 10 mM 
ethylenediaminetetra-acetic acid (EDTA). 
 
Results 
 
Infection of astrocytes using HHV-6-infected T-cell lines 
Infection of astrocytes was achieved by co-culturing cells with different 
doses of HHV-6 infected T-cells for 18 h, after which T-cells were carefully 
removed from the adherent astrocyte population. This led to successful 
transfer of HHV-6 to cultured astrocytes, as assessed by evaluation of CPE 
and by staining with an HHV-6 specific antibody (Figure 3.1). Astrocytes 
were found to be positive for HHV-6 antigen in their nucleus from the first 
day onward, with CPE such as nucleus swelling and syncytium formation 
perfectly matching the staining for HHV-6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A          B                C 
Figure 3.1. HHV-6-infected astrocytes 
HHV-6-infected human adult astrocytes were stained for GFAP (green channel; Figure 
3.1.A) and the HHV-6 105-kD protein antigen (red channel; Figure 3.1.B). Cytopathic 
effects including syncytium formation and swelling of nuclei (DAPI staining; Figure 
3.1.C) along with the presence of HHV-6 antigen affects between 30 and 35 % of all 
astrocytes in culture. 
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Figure 3.2 illustrates the levels of infection, as expressed by the percentage 
of HHV-6 positive astrocytes over the course of 5 days after using either 
HSB-2 (Figure 3.2.A) or JJHan T-cells (Figure 3.2.B) as virus donor cells.  
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Figure 3.2. Levels of infection in human astrocytes using different HHV-6 donor T-
cell lines 
○ 0.37 x 104 T-cells, ◊  0.75 x 104 T-cells, □ 1.5 x 104 T-cells, ∆ 3 x 104  T-cells. 
Cultured astrocytes were supplied with HHV-6 infected HSB-2 T-cells (A) or JJHan T-
cells (B) and after an overnight incubation, donor T-cells were carefully removed. For the 
first 5 days of continued cultures of T-cell free astrocytes, the percentage of infection was 
determined by specific staining for the common 106 kDa HHV-6 antigen. The 
experiments, using different doses of donor T-cells, were performed three (A) and two (B) 
times; results are given for all experiments separately.  
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Using HSB-2 cells as virus donor cells the percentage of infected astrocytes 
was found to reach levels of 30-35 % in the first two days of culture. As can 
be expected, increasing the dose of virus donor cells also increased the level 
of infection, reaching maximum values with a ratio of T-cells to astrocytes 
of approximately 40:1 to 100:1. At that level, adding more T- cells did not 
increase the level of infection (data not shown). From day 3 onward, the 
percentage of infected astrocytes in the cultures declined. This most likely 
reflects a combination of more rapid growth of uninfected astrocytes in the 
culture relative to infected cells, and cell death in infected astrocytes after 
this period of culturing.  
In Table 3.1, the total numbers of astrocytes in the cultures throughout the 
5-day culture period are given to illustrate this latter point.  The 
combination of these effects reduced the percentage of infected astrocytes to 
about 25 % at day 5. Using JJHan T-cells as virus donors, the maximum 
levels of infection attainable were clearly less, reaching maximum levels of 
only about 15 % in the first two days (Figure 3.2.B). Also in this case, 
reduction in the percentage of infected cells was observed upon continued 
culture, along with increasing levels of cell death after 3 to 5 days following 
addition of the highest dose of infected donor T-cells (Table 3.2). Using the 
same conditions, JJHan T-cells were thus clearly less efficient that HSB-2 
cells in transmitting HHV-6 to human adult astrocytes. 
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Table 3.1. Total cell numbers in astrocyte cultures supplied with increasing doses of 
HHV-6-infected HSB-2 T-cells 
 
 
culture time 
(days) 
 
uninfected 
astrocytes 
plus 
0.37 x 104 
T-cells 
plus 
0.75 x 104 
T-cells 
plus 
1.5 x 104 
T-cells 
plus 
3 x 104  
T-cells 
Experiment 1 
1 394 295  315  386  391  
2 460 380  343  352  360  
3 684 371  306  268  308  
4 996 299  341  214  203 †  
5 1040 498  315  418  236 †  
 
 
 
Experiment 2 
1 366 426  407  383  358  
2 507 549  371  408  386  
3 811 593  426  391  164 †  
4 1198 484  558  263 †  178 †  
5 1340 842  571  482  180 †  
 
 
 
Experiment 3 
1 1049 877  1004  846  823  
2 1047 874  982  970  855  
3 1235 1127  1200  982  830  
4 1560 1541  1182  1063  785  
† = extensive cell death  
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Table 3.2. Total cell numbers in astrocyte cultures supplied with increasing doses of 
HHV-6-infected JJHan T-cells 
 
 
culture time 
(days) 
 
uninfected 
astrocytes 
plus 
0.37 x 104  
T-cells 
plus 
0.75 x 104  
T-cells 
plus 
1.5 x 104 
T-cells 
plus 
3 x 104 
T-cells 
Experiment 1 
1 394 374  451  464  496  
2 460 296  232  479  434  
3 684 671  751  638  569  
4 996 987  823  782  819  
5 1040 1182  1213  1121  327 †  
 
 
Experiment 2 
1 366 325  312  361  541  
2 507 472  440  389  385  
3 811 850  798  735  567  
4 1198 1128  1075  1020  798  
† = extensive cell death  
 
Infection of astrocytes using lysates of HHV-6-infected T-cells 
The goal of our study was to establish an astrocyte cell culture model for 
evaluating the immunomodulatory effects of HHV-6. Cell types other than 
astrocytes, or products derived from such cells could potentially complicate 
such as model. Therefore, we examined the possibility to infect astrocytes 
using a cell-free source of HHV-6. To this end, a lysate was prepared of 
HHV-6-infected HSB-2 or JJHan T-cells by freezing and thawing the 
infected cells. After such a treatment, no viable cells could be detected in 
the lysate as judged by the lack of any T-cell growth under standard 
culturing conditions. When supplied with such a lysate, about 10 % of the 
astrocytes displayed CPE typical for HHV-6 infection including swelling of 
nuclei and syncytium formation and could be successfully stained for 
nuclear HHV-6 antigen in the first 2 days of culture (data not shown). 
Staining of infected astrocytes, however, was complicated by widespread 
staining also of cellular debris non-specifically adhering to astrocyte 
surfaces. Increasing the doses of the lysate or the culture time did not lead to 
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any higher levels of infection in the astrocyte cultures. Finally, several 
additional purification steps were tested for their ability to produce a more 
infectious lysate of HHV-6 carrying HSB-2 or JJHan T-cells. 
Ultracentrifugation to selectively collect viral particles, filtration to remove 
cellular debris, or washing steps to liberate viral particles from subcellular 
organelles, however, were all found ineffective to produce a lysate or cell-
free virus that could infect more than 10 % of cultured astrocytes. 
 
Discussion 
The goal of the present study was to obtain a cell culture model that could 
be used to evaluate the impact of HHV-6 on inflammatory pathways in 
human adult astrocytes. Such a model is considered useful given the ability 
of the virus to encode chemokine receptors and chemokine mimics, which 
could play important roles in inflammatory neurodegenerative disorders 
such as MS. To establish such a model, a reasonable percentage of the 
astrocyte culture should be infected over a suitable period of time, without 
triggering massive cell death. Previously, such massive cell death was 
reported for HHV-6-infected human fetal astrocytes. To the best of our 
knowledge, no reports have appeared that document HHV-6 infection of 
cultured human adult astrocytes.  
Using the HHV-6-infected T-cell line HSB-2 as a carrier, a maximum of 
about 30-35 % of cultured astrocytes could be infected with the virus, as 
judged by specific staining and virus-induced syncytium formation. This 
maximum level of infection was achieved with an excess of T-cells over 
astrocytes in the overnight virus pulse of about 40- to 100-fold. Higher 
numbers of T-cells led to rapid cell death of astrocytes with detectable 
infection percentages over the first 2 days of culture still not exceeding 35 
%. Also initially lower percentages of infection in the culture did not allow 
maximum levels to exceed the 35 % maximum by virus spread to other 
astrocytes (Figure 3.1). A possible increase of infection levels by viral 
spread, should it have occurred at all, is apparently more than compensated 
for by the more rapid proliferation of uninfected cells in the culture as 
compared to infected cells, reducing the overall infection levels again over 
the course of the first 5 days of culture. Together, these data indicate that a 
percentage of infected astrocytes of about 35 appears to be the maximum 
attainable with either of the two donor T-cell lines. Why HSB-2 is markedly 
more efficient than JJHan in transmission of HHV-6 to astrocytes currently 
remains unclear.  
The use of HHV-6-infected T-cell lysates or cell-free HHV-6 preparations 
did not lead to levels of infection in astrocyte cultures comparable to those 
obtained with cell-borne virus. Only about 10 % of the cells could be 
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infected this way. This only poor performance of these  virus preparations is 
in line with a previous report showing more rapid syncytium formation also 
in fetal astrocytes with cell-borne versus cell-free HHV-6 (15). Possibly, 
interactions between the donor T-cell line and the recipient astrocyte 
contribute to productive infection in ways beyond the mere interaction 
between a viral particle and the HHV-6 receptor CD46.  
In conclusion, the use of the HHV-6 carrying T-cell line HSB-2 allows for 
the experimental infection of about one-third of human adult astrocyte 
cultures over a period of 2-3 days. After that period, infected cells start to 
die and overall infection levels decrease. Over these first days, therefore, the 
impact of HHV-6 on inflammatory pathways in astrocytes can be suitably 
studied. 
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Abstract 
Human herpesvirus-6A (HHV-6A) is a common pathogen whose role in 
central nervous system (CNS) disorders including multiple sclerosis remains 
controversial. To understand how HHV-6A could influence inflammatory 
pathways in the CNS, we infected cultured human adult astrocytes and 
examined the expression of 268 cytokines, chemokines, growth factors and 
their receptors by cDNA array gene profiling.  
HHV-6 infection alone had little effect on the astrocyte gene profile but 
strongly altered the astrocyte response to proinflammatory cytokines. Under 
those conditions astrocytes express higher levels of anti-inflammatory 
mediators including IL-10 and IL-11, chemotactic factors, growth factors 
and factors controlling type I interferon production. Our data suggest that 
HHV-6 itself does not evoke a pro-inflammatory response in astrocytes but 
rather triggers immune modulatory factors in the face of inflammation.  
 
Introduction  
Human herpesvirus-6 (HHV-6) is a β-herpes virus of which two variants are 
known, viz. HHV-6A and HHV-6B (1). About 95 % of the human 
population is persistently infected with HHV-6, with infection usually 
occurring within the first two years of life (2,3,4). HHV-6 is present in 
different tissues including mononuclear cells, salivary glands, lungs, genital 
tract, brain and cerebrospinal fluid (CSF) (1,5,6). In the central nervous 
system (CNS) HHV-6 can infect astrocytes, oligodendrocytes and microglia 
(7,8,9,10,11) through CD46, the viral receptor that has been documented on 
various glial and neural cells (12,13). 
HHV-6 has been implicated in clinical manifestations such as exanthem 
subitum, fever, encephalitis, pneumonitis and hepatitis, and it appears to be 
an important co-factor in HIV infection (14,15). HHV-6 infection of the 
CNS is usually silent allowing the virus to persistently remain inside neural 
cells as a normal CNS commensal. Only occasionally does HHV-6 appear 
to be associated with neuroinflammation, febrile seizures, encephalitis or 
encephalopathy (16). For a number of years already, a controversy exists as 
to the possible involvement of HHV-6 in multiple sclerosis (MS) (17,18). 
HHV-6 has been detected in oligodendrocytes of MS patients (19) and signs 
of active HHV-6 infection have been found in CNS tissue, lymphoid tissues, 
peripheral blood lymphocytes, serum and urine of MS patients (20,21,22). 
On the other hand, several other studies have failed to produce evidence in 
support of an association between HHV-6 and MS (23,24,25,26).  
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Even accepting a possible association between HHV-6 and MS, however, it 
has remained obscure how exactly HHV-6 could influence its pathogenesis. 
A striking feature of HVV6 is its ability to modulate inflammatory 
pathways in target cells. The U12 region of the viral genome encodes a beta 
chemokine receptor for CCL2, CCL3, CCL4 and CCL5, and the U51 region 
encodes a CCL5 receptor. Also, a chemokine-like CCR2 agonist is coded 
for by the viral U83 region (27,28,29,30). By introducing these chemokine 
(receptor) mimics into the target cell HHV-6 may well impact on the 
propensity of the infected cell to produce certain mediators or on its 
response to exogenous stimuli such as pro-inflammatory cytokines or 
chemokines. In addition, viral interaction with its CD46 receptor may also 
lead to immune modulatory effects as CD46 ligation influences cytokine 
production. For example, HHV-6 engagement by CD46 on macrophages 
suppresses the production of IL-12 that is normally induced by IFN-γ or 
LPS (31). 
To understand how HHV-6 could influence inflammatory processes in the 
CNS we infected cultured human adult astrocytes and performed gene 
profiling on 268 cytokines, chemokines, growth factors and their receptors. 
Apart from the effect of infection itself, we also examined the response of 
infected astrocytes to additional pro-inflammatory cytokines. Our data 
indicate that HHV-6 infection alone hardly influences expression of 
cytokines, chemokines or growth factors. Yet, following additional 
stimulation with TNF-α, IL-1β or IFN-γ, infected astrocytes respond very 
differently from uninfected cells. Under those conditions astrocytes produce 
elevated levels of anti-inflammatory mediators including IL-10 and IL-11, 
several chemotactic products, growth factors and factors that control type I 
interferons while uninfected cells do not. These data suggest that HHV-6 
infection of astrocytes is unlikely to provoke a host defense response but 
instead, modulates the cytokine network of astrocytes when these are 
 provoked by inflammation.
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Materials and methods 
Donors 
Astrocytes were obtained from post-mortem sub cortical brain white matter 
provided by the Netherlands Brain Bank after rapid autopsy (post-mortem 
delays of less than 10 h). The Netherlands Brain Bank supplies post-mortem 
specimens from clinically well documented and neuropathologically 
confirmed cases. Autopsies are performed on donors with written informed 
consent from the donor or from direct next of kin. All procedures applied in 
the experiments described in this study were approved by the local ethics 
committee. Astrocytes derived from two different control donors were used, 
both free from any clinical or neuropathological signs of CNS disorders. 
Both donors were females that had succumbed to acute myocardial 
infarction; donor 1 (00- 022, age 83) and donor 2 (00-031, age 77).  
 
Isolation and infection of human adult astrocytes with HHV-6 
The human CD4+ T-lymphoblastoid cell line HSB-2 was used as a carrier 
cell line for HHV-6A (Strain GS) as described in Chapter 3. Cells were 
grown in RPMI 1640 (Gibco) supplemented with 10 % FCS and antibiotics 
at 37 ºC in a humidified atmosphere containing 5 % CO2. Viral stocks were 
prepared by freezing HHV-6-infected HSB-2 cells when 75 % HHV-6 
positivity was reached as assessed by cytochemical staining with the murine 
monoclonal antibody NCL-HHV-6 that is specific for a 105-kD protein for 
both HHV-6A and HHV-6B (Novocastra, Newcastle, UK). Previous 
experiments indicated that the level of infection as expressed by HHV-6 
antigen positivity produced a more reliable measure for infectivity of virus-
containing T-cell stocks than the commonly used tissue culture infectivity 
dose (TCID50).  Virus stocks were stored in 90 % v/v FCS and 10 % v/v 
dimethylsulfoxide (DMSO; Merck, Darmstadt, Germany) at -150ºC until 
further use. 
Human adult post-mortem astrocytes were obtained as previously described 
(32,33). The purity of the astrocyte culture was verified by staining with 
rabbit anti-glial fibrillary acidic protein (GFAP; ZYMED, San Francisco, 
CA) as an astrocyte marker, murine anti-human CD68 (DAKO, Glostrup, 
Denmark) as a microglial marker, and murine anti-myelin basic protein 
(MBP; Boehringer Mannheim, Germany) as an oligodendrocyte marker. 
The astrocyte cultures were found to be essentially 100 % GFAP-positive. 
No cells were found to express CD68 or MBP.  
Astrocytes were infected using a HSB-2 carrier cell line. Before adding the 
infected carrier cells to the astrocytes HSB-2 cells were washed and 
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resuspended in fresh astrocyte culture medium to eliminate any pre-existing 
soluble mediators produced by HSB-2. To determine the percentage of 
infection in cultured astrocytes, target cells were cultured in chamber slides 
(Falcon, Becton Dickinson, NY) in the presence of 1.5 x 104 HHV-6-
infected HSB-2 cells per chamber (0.69 cm2) for a period of 18 h. 
Astrocytes were extensively washed to remove HSB-2 cells, fresh culture 
medium was added and the astrocytes were cultured for an additional 48 h 
in the presence or absence of TNF-α, IL-1β or IFN-γ (PreproTech, Rocky 
Hill, NY) or a mixture of these cytokines each at a concentration of 500 
U/mL, as previously described (32,34). Chamberslides were washed with 
PBS and cells were fixed in acetone supplemented with 0.03 % v/v H2O2 
(Merck, Darmstadt, Germany) for 10 min. Chamber slides were air-dried 
and incubated overnight at 4ºC with rabbit polyclonal antibodies against 
glial fibrillary acidic protein (GFAP; ZYMED, San Francisco, CA) and 
NCL-HHV-6 in PBS supplemented with 0.1 % w/v BSA. After washing 
with PBS biotinylated donkey anti-rabbit Ig antibodies (Amersham Life 
Science, Roosendaal, The Netherlands) were added in PBS supplemented 
with 1 % w/v BSA and 1 % v/v normal human serum (NHS) for 45 min at 
room temperature. After washing with PBS, FITC-conjugated streptavidin 
(DAKO, Glostrup, Denmark) and TRITC-conjugated donkey anti-mouse Ig 
(Jackson, West Grove, PA) in PBS supplemented with 1 % w/v BSA and 
1% v/v NHS were added for 45 min at room temperature. Slides were 
embedded in Vectashield mounting medium with 4'6-diamidino-2-
phenylindole-2HCl (DAPI; Vector Laboratories, Burlingame, CA) for DNA 
staining. 
To prepare astrocytes for gene profiling, post-confluent astrocyte cultures 
were supplemented with 1.6 x 106 HHV-6-infected HSB-2 cells per 75 cm2 
flask for a period of 18 h. Astrocytes were extensively washed to remove 
HSB-2 cells, fresh culture medium was added and the astrocytes were 
cultured for an additional 48 h in the presence or absence of TNF-α, IL-1β 
and IFN-γ (PreproTech, Rocky Hill, NY) each at a final concentration of 
500 U/mL. Uninfected and untreated astrocyte cultures were used as 
controls.  
 
mRNA profiling using cDNA arrays 
Analysis of the mRNA profile of astrocytes was performed by hybrid 
selection of radioactively labeled cDNA on high-density Clontech Atlas 
arrays of membrane-bound cDNA probes, as described previously (34). 
Briefly, for each condition total cellular RNA was extracted from the 
astrocytes and poly A+ RNA was separated from total RNA. Radioactive 
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cDNA probes were prepared and hybridization of the probes to the 
membranes was carried out overnight. The hybridization signal for each 
gene probe, present in duplicate on the array, was calculated as the mean of 
these duplicates, corrected for background intensity and quantified using 
software provided by the manufacturer. Relative hybridization signals were 
calculated by dividing the background-corrected hybridization signals for 
each gene by the mean signal for all nine housekeeping reference genes on 
the corresponding array, and multiplying this ratio by 1,000. When 
comparing gene expression signals between different samples, ratios were 
calculated by dividing the relative expression signals. To avoid extreme 
ratio values, a minimum of 10 was applied to very low relative expression 
signals.  
 
Results  
 
HHV-6 infection of cultured human adult astrocytes 
As a first step in this study, we verified whether experimental infection of 
cultured astrocytes with HHV-6 led to a reproducible and stable level of 
infection over the course of the experiments. In this study, we chose to work 
with the HHV-6A variant as this strain is more frequently detected in CSF 
of children and adults and thus, may have a greater neurotropism that the B 
strain (35). Infection of astrocytes was established by co-culturing the cells 
with an HHV-6A-infected HSB-2 carrier T- cell. Attempts to infect 
astrocytes using cell-free preparations such as culture supernatants or cell 
lysates of HSB-2 cells were unsuccessful (see Chapter 3). To monitor the 
percentage of infected astrocytes following co-culture with infected HSB-2 
cells cytopathic effects (CPE) including enlargement of nuclei, cell swelling 
and syncytium formation was evaluated. These CPE were very similar to 
those previously described by others for HHV-6-infected fetal astrocytes, 
oligodendrocytes and microglia in culture (7). Also, astrocytes were stained 
for the 105-kDa antigen common to both the HHV-6A and HHV-6B strain. 
As a confirmation that CPE were the direct consequence of HHV-6 
infection the HHV-6 105-kDa antigen was found to be consistently present 
in cells with marked CPE (Figure 3.1 of Chapter 3) and not in normal-
appearing astrocytes. It should be noted, however, that not all stages of the 
HHV-6 infection cycle may be reflected by CPE and/or the presence of 
sufficient levels of the 105-kDa to allow for immunocytochemical staining. 
In view of the lack of markers for very early stages of HHV-6 infection, 
levels of infection in the culture as assessed by CPE and staining for the 
105-kDa antigen therefore only represent minimum values for the level of 
infection in astrocyte cultures. Over the 48-h culture time of the 
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experiments, between 30 % and 35 % of all astrocytes were visibly affected 
by HHV-6 infection.  Infection levels at the start of the experiment were 
very similar to those observed after 48 h indicating that viral spread in the 
absence of the original HSB-2 carrier cell line was negligible. 
Supplementing astrocyte cultures with TNF-α, IL-1β or IFN-γ had no 
detectable influence on the percentage or morphology of HHV-6-infected 
astrocytes (data not shown).  
 
Gene profiling of HHV-6-infected astrocytes 
Both HHV-6-infected and uninfected astrocyte cultures were evaluated for 
their gene expression profiles after 48 h by cDNA array gene profiling as 
previously described by us (34). In this analysis which was performed three 
times using different astrocyte cultures, 268 genes encoding cytokines, 
chemokines, growth factors and their receptors were monitored. Astrocytes 
from donor 1 were used for experiment 1, while astrocytes from donor 2 
were used for experiments 2 and 3. The data consistently revealed only very 
minor effects of infection, as illustrated in Figure 4.1 and summarized in 
Table 4.1. Only four genes represented on the array were reproducibly 
induced more than two fold by HHV-6 infection. These included leukocyte 
interferon-inducible peptide (LIP), CCL5 (RANTES), insulin-like growth 
factor binding protein 6 (IGFBP6) and vascular endothelial growth factor C 
(VEGF-C). Apart from CCL5, therefore, no distinct pro-inflammatory 
products appeared in the HHV-6-infected astrocyte cultures that would be 
expected to promote a host-defense response. As the result of HHV-6 
infection, some genes were reproducibly suppressed at least two fold. These 
included trk-T3, IGFBP complex acid labile chain (IGFBP), ephrin type-A 
receptor 5, ephrin-B2, transforming growth factor-beta 3 (TGF-β3), colon 
carcinoma kinase 4 (CCK4) and transmembrane receptor PTK7. Yet, these 
effects were minor as expression levels of all these products were already 
rather low in control cultures.
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Figure 4.1. The impact of HHV-6 infection on the cytokine network of astrocytes 
Astrocytes were infected with HHV-6 and after 48 h expression levels of 268 genes 
encoding cytokines, chemokines, growth factors and their receptors were compared to 
those in uninfected control astrocytes. Signals at or around the diagonal represent genes 
whose expression is unaffected by HHV-6 infection. Signals in the upper left part 
represent genes whose expression is enhanced by the infection while signals in the lower 
right part represent genes whose expression is inhibited. Data are shown from a single 
representative experiment.  
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To verify whether the above effects were indeed caused by the infection 
itself and did not result from the presence of residual carrier T-cells in the 
culture system, the effect of adding uninfected instead of infected HSB-2 
carrier T-cells on the astrocyte gene profile was also evaluated. The effect of 
the HSB-2 carrier itself on astrocytes turned out to be minimal and only the 
expression of ephrin type-A receptor 5 and ephrin-B2 were somewhat 
suppressed, both with a factor of 3 (Table 4.1). All other genes that were 
induced or suppressed by infection remained unaffected in their expression 
following addition of only the carrier cell line. 
 
Gene profiling of HHV-6-infected astrocytes upon a pro-inflammatory 
insult   
Next, we investigated the effects on infected astrocytes of a mixture of 
TNF-α, IL-1β and IFN-γ. The combination of HHV-6 infection and these 
cytokines induced extensive and frequently very strong alterations in the 
gene profile after 48 h, as illustrated in Figure 4.2.  
Tables 4.2 and 4.3 present the changes in gene expression levels with regard 
to genes that were either induced or suppressed in their expression at least 
two fold. The gene profile of infected and treated astrocytes can be 
compared to the gene profile of uninfected treated astrocytes as illustrated in 
Figure 2.4 of Chapter 2.  
In HHV-6-infected astrocytes the pro-inflammatory cytokines induced 
markedly elevated levels of IL-10, IL-11, IL-1β, and IL-6. Especially the 
induction of the anti-inflammatory cytokines IL-10 (4-fold) and IL-11 (24-
fold) is striking since in uninfected astrocytes no IL-10 is induced at all, and 
IL-11 only 3-fold. Secondly, TNF-α, IL-1β and IFN-γ induced expression 
of several chemotactic products in HHV-6-infected astrocytes. Whereas 
uninfected astrocytes show strongly elevated levels only of CXCL8 (IL-8) 
in response to the pro-inflammatory cytokines, HHV-6-infected astrocytes 
displayed induction also of CCL3 (MIP-1α), CXCL2 (MIP-2α), CCL5 
(RANTES) and CXCL6 (granulocyte chemotactic protein 2) along with 
CXCL8.  
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Figure 4.2. The impact of pro-inflammatory cytokines on the cytokine network of 
HHV-6-infected astrocytes 
HHV-6-infected human adult astrocytes were treated with a mixture of TNF-α, IL-
1β and IFN-γ and after 48 h expression levels of 268 genes encoding cytokines, 
chemokines, growth factors and their receptors were compared to those in uninfected and 
untreated control astrocytes. Signals at or around the diagonal represent genes whose 
expression is unaffected by cytokine treatment. Signals in the upper left part represent 
genes whose expression is enhanced by the cytokines while signals in the lower right 
part represent genes whose expression is inhibited.  
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Table 4.2. Genes induced after treatment of HHV-6-infected astrocytes  
with TNF-α, IL-1β and IFN-γ 
 
 Gene name HHV-6 infected 
  Exp 1 Exp 2 Exp 3 
 CCL2 (MCP-1) 722 580 788 
 interleukin-6 (IL-6) 342 163 429 
 CCL5 (RANTES) 226 377 321 
 CXCL8 (IL-8) 84 <10 51 
 CXCL2 (MIP2-α)  97 <10 65 
 interleukin-1 beta (IL-1β) 371 465 375 
 CCL3 (MIP1-α) 96 59 91 
 leukocyte interferon-inducible peptide (LIP) 285 38 455 
 interleukin-11 (IL-11) 111 <10 121 
 granulocyte-macrophage colony stimulating factor (GM-CSF) 100 187 49 
 metallothionein-III (MT-III), growth inhibitory factor 214 33 411 
 
ERBB-3 receptor protein-tyrosine kinase (epidermal growth 
factor receptor) 
319 
 
215 
 
256 
 
 interferon regulatory factor 1 (IRF1) 158 173 280 
 CXCL6 (granulocyte chemotactic protein 2, GCP2) 120 <10 27 
 vascular endothelial growth factor C  (VEGF-C) 139 <10 79 
 leukemia inhibitory factor  (LIF) 140 79 172 
 insulin-like growth factor binding protein 6 (IGFBP6) 193 <10 133 
 heparin-binding EGF-like growth factor (HBEGF) 198 <10 77 
 interleukin-10 (IL-10) 248 27 229 
 granulocyte colony-stimulating factor (G-CSF)  93 190 59 
 vascular endothelial growth factor (VEGF) 114 <10 88 
 
neuregulin + neu differentiation factor + heregulin α  
 
109 
 
<10 
 
47 
 
 tumor necrosis factor (TNF-α) 118 330 71 
 erythroid differentiation protein  (EDF) 118 40 83 
 interferon consensus sequence-binding protein (ICSBP) 67 <10 <10 
 cytokine receptor EBI3 85 316 63 
 neuregulin 69 <10 20 
 CD114 (GCSF-R) 83 <10 54 
 interleukin-7 receptor alpha subunit (IL-7R-α) 105 <10 52 
 endothelin receptor type B (EDNRB) 56 <10 46 
Genes are listed when their expression reached relative values of at least 100 in two  
of the three experiments 
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HHV-6 infected plus 
cytokines Mean ratio Gene code 
 Exp 1 Exp 2 Exp 3   
 1844 1487 1677 2.4 M24545 
 1684 1162 1512 5.2 X04602 
 1293 1254 1363 4.4 M21121 
 1269 938 1471 45.8 Y00787 
 1547 1043 1064 45.6 X53799 
 1384 1035 1213 3.1 K02770 
 1516 1056 745 14.0 M23452 
 958 615 1012 7.3 X02492 
 1155 561 725 24.2 M57765 
 1296 443 699 9.9 M11220 
 723 836 824 10.2 D13365 
 
926 
 
345 
 
715 
 
2.4 
 
M29366 
 
 321 702 918 3.1 X14454 
 679 386 853 25.4 X78686 
 597 449 812 19.9 U43142 
 716 269 710 4.2 X13967 
 438 404 596 15.7 M62402 
 699 198 427 9.6 M60278 
 675 193 446 4.0 M57627 
 722 118 311 4.6 X03438 
 348 240 546 11.1 M32977 
 
315 
 
103 
 
350 
 
6.9 
 
L12260+U02326+ 
M94165 
 343 165 234 2.2 X01394 
 162 139 299 2.8 J03634 
 138 181 188 13.2 M91196 
 229 70 207 2.1 L08187 
 168 108 198 7.7 L12261 
 213 20 228 3.4 M59818 
 95 104 202 5.1 M29696 
 118 <10 113 2.3 L06623 
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In addition, the pro-inflammatory stimulus triggered a range of gene 
products that play roles in regulation of cellular growth and differentiation 
and that were different from those induced in uninfected cells. These 
included IGFBP6, VEGF and VEGF-C, granulocyte-macrophage colony-
stimulating factor (GM-CSF), neuregulin, heparin-binding EGF-like growth 
factor (HBEGF), leukemia inhibitory factor (LIF), metallothionein III (MT-
III) and the IL-7 receptor α chain. Also induction of granulocyte colony-
stimulating factor (G-CSF) and its receptor was monitored, but this 
induction was also found in uninfected cells. Finally, several products were 
triggered that control interferon type I production. These included interferon 
regulatory factor-1 (IRF1), interferon consensus sequence binding protein 
(ICSBP) and LIP. None of these genes were induced by the cytokines in 
uninfected astrocytes. 
Together, these data clarify that several marked differences exist between 
the response of HHV-6-infected astrocytes to the pro-inflammatory insult as 
compared to uninfected astrocytes. In Figure 4.3, these differences are 
summarized with regard to genes whose expression was enhanced the 
strongest under the various conditions (induction by at least a factor of 3). 
To emphasize the difference in the response of HHV-6-infected astrocytes 
as compared to uninfected cells, several genes were found to be suppressed 
in their expression by TNF-α, IL-1β and IFN-γ, whereas no genes at all are 
suppressed in uninfected cells (compare Figures 4.2 and 2.4 of Chapter 2). 
Suppression, as summarized in Table 4.3, affected among others connective 
tissue growth factor, Flt3 ligand (SL cytokine) and receptors for CCL2, 
VEGF and ephrin type A, gene products that are normally expressed at 
appreciable levels in cultured astrocytes.  
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Figure 4.3. 
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To extend the information on the effects of pro-inflammatory cytokines on 
HHV-6-infected astrocytes, effects were also examined of the individual 
cytokines in the mixture of TNF-α, IL-1β and IFN-γ. The results of these 
analyses are summarized in Table 4.4. Six genes emerged as common 
responders in HHV-6-infected astrocytes to all three cytokines individually. 
These common responders included IL-11, VEGF-C, LIP and MT-III, IL-6 
and CD124 (the IL-4 receptor α subunit). Five out of these six were also 
found after treatment with all three cytokines together (marked in italics in 
Table 4.4). Other genes such as CXCL8, HBEGF, CCL3, CXCL2, LIF and 
neuromodulin (GAP-43) were induced by both TNF-α and IL-1β alone but 
not by IFN-γ. Genes only induced by IFN-γ not only included the five 
above-mentioned common response genes but also IGFBP6, endothelial 
monocyte activating polypeptide II, VEGF, fibroblast growth factor 5 and, 
interestingly, the IFN-γ receptor β subunit. In itself, the observation that 
IFN-γ has any effect at all already emphasizes the difference between HHV-
6-infected and uninfected astrocytes since in the latter, no effect whatsoever 
could be monitored of only IFN-γ. However, HHV-6 infection alone had no 
effect on the expression levels of the IFN-γ receptor. These data suggest that 
the uninfected astrocytes are in some way blocked to respond to IFN-
γ treatment and that infection of astrocytes with HHV-6 dissolves this 
blockade. The intracellular mechanisms which might be responsible are still 
unknown.  
Most of the genes induced by the individual cytokines as listed in Table 4.4 
explain the induction of genes by the mixture of cytokines as listed in Table 
4.2. Of all gene products that were induced at least 10-fold in HHV-6-
infected cells by the mixture of cytokines only GM-CSF, CXCL6 and 
ICSBP were not found to be induced by any of the individual cytokines. 
Thus, the induction only of these three products may be triggered by 
synergistic effects between the cytokines but for the majority of products 
induced, such effects appear to be limited, similar to what we previously 
observed for uninfected astrocytes (34). 
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Gene profiling of HHV-6-infected HSB-2 T-cells 
Finally, we evaluated the gene profile of the carrier HSB-2 T-cell line that 
was used to infect astrocytes, as well as that of the HHV-6-infected T-cell 
line. The gene profile of HHV-6-infected HSB-2 cells is relevant to evaluate 
the extent of possible contamination of infected astrocyte cultures by RNA 
derived from the carrier T-cells. Also, it is of interest to compare the impact 
of HHV-6 on this T-cell line with its impact on astrocytes. 
A comparison between the most abundant gene products in the infected 
HSB-2 cell line with the gene products induced in infected astrocytes either 
in the presence or absence of pro-inflammatory cytokines indicates that 
contamination by T-cell derived RNA is highly unlikely to have affected 
our data. Of the 30 most abundant gene products in the HHV-6-infected 
HSB-2 cells, only one, viz. LIP, was among the products found to be 
elevated in the infected astrocyte cultures. Only for this single gene product, 
therefore, we cannot formally exclude the possibility that its induction could 
be caused by contaminant HSB-2-derived mRNA. For all other gene 
products, such contamination appears highly unlikely as an explanation for 
their induction in astrocytes.  
Furthermore, a comparison between the genes induced in HSB-2 by HHV-6 
infection with those induced in astrocytes reveal that there is very little 
similarity in the response by either cell type. Of all genes induced by a 
factor of at least 3 (Table 4.5), only the response of VEGF-C corresponded 
with what was observed in astrocytes. All other gene responses induced by 
HHV-6 in the HSB-2 T-cell line, including suppression of CXCL8, were 
different from those induced in astrocytes. Clearly, the effects of HHV-6 on 
expression levels of elements of the cytokine network are highly dependent 
on the type of target cell.  
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Table 4.5. Genes with altered expression in HHV-6-infected HSB-2 T-cells 
 
Gene name 
 uninfected 
HHV-6 
infected 
Ratio 
 
Gene code 
 
induction     
neuregulin + neu differentiation factor + 
heregulin alpha   
<10 
 
178 
 
17.83 
 
L12260 + U02326 
+ M94165 
ephrin type-A receptor 3 (tyrosine kinase 
receptor HEK) 
<10 
 
175 
 
17.48 
 
M83941 
 
frizzled 5 <10 171 17.11 U43318 
insulin-like growth factor binding protein 5 
(IGFBP5) 
<10 
 
156 
 
15.63 
 
M65062 
 
migration inhibitory factor-related protein 8 
(MRP8) 
21 
 
218 
 
10.35 
 
X06234 
 
ciliary neuronotrophic factor (CNTF) isoforms 
B & C 
54 
 
356 
 
6.65 
 
A26792 
 
interferon-gamma receptor (IFNR-gamma) 25 151 6.10 J03143 
epidermal growth factor receptor (EGFR) 33 154 4.65 X00588 
low-affinity nerve growth factor receptor 
(NGFR) 
173 
 
788 
 
4.56 
 
M14764 
 
competitive hepatocyte growth factor antagonist 
(HGF antagonist) 
35 
 
156 
 
4.50 
 
M77227 
 
vascular endothelial growth factor (VEGF) 54 226 4.21 M32977 
vascular endothelial growth factor C  (VEGF-C) 39 163 4.16 U43142 
CCL2 (MCP-1) 121 459 3.81 M24545 
insulin-like growth factor binding protein 4 
(IGFBP4) 
48 
 
170 
 
3.58 
 
M62403 
 
interleukin-1 receptor antagonist protein (IL-
1RA) 
204 
 
682 
 
3.34 
 
M63099 
 
endothelin 3 (ET3) 66 214 3.24 J05081 
hepatocyte growth factor (HGF) 52 163 3.17 M60718 
 
suppression     
CXCL8 (IL-8) 410 148 0.36 Y00787 
 
Genes are listed when their expression reached relative values of at least 150 under either 
condition 
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Discussion  
In this study, gene profiling was used to examine the impact of HHV-6 
infection on the cytokine network in cultured human adult astrocytes. To the 
best of our knowledge, ours is the first attempt to document how infection 
of human glial cells by HHV-6 may influence inflammatory pathways. 
Especially for a better understanding of its suggested association with 
inflammatory neurodegenerative disorders such as MS it is important to 
appreciate whether the virus could be expected to elicit a pro-inflammatory 
reaction in the human CNS, or perhaps modulates such reactions. At least 
with regard to infection of astrocytes the latter appears to be more likely.  
As a standard read-out tool in this study we used cDNA arrays which we 
have previously validated as a comprehensive assay that produces reliable 
and reproducible results when applied to cultured human adult astrocytes 
(34). Infection of astrocytes with HHV-6 affected expression of a 
surprisingly limited number of the 268 genes examined. Only CCL5, LIP, 
IGFBP6 and VEGF-C were induced whereas all other gene expression 
levels remained very similar. In sharp contrast, treatment of HHV-6-infected 
astrocytes with a mixture of TNF-α, IL-1β and IFN-γ resulted in a response 
that was markedly different from that of uninfected astrocytes both in a 
quantitative and a qualitative manner. Especially the 4-fold induction of IL-
10 and the 24-fold induction of IL-11 by the cytokine mixture is of interest 
since both are well-known anti-inflammatory cytokines (36,37). IL-11 is 
only induced 3-fold in uninfected astrocyte cultures while IL-10 is not 
induced at all. Interestingly, IL-10 has also been found induced in 
monocytes as the result of HHV-6 infection, ultimately causing IFN-γ-
induced downregulation of IL-12 in these cells (31). In astrocyte cultures 
treated with TNF-α, IL1β or IFN-γ separately, IL-11 consistently emerges 
as one of the most strongly induced genes with levels of induction between 
30- and 50- fold. In uninfected astrocytes, no induction of IL-11 was 
recorded in response to any of these individual cytokines.  
Another gene product that is consistently induced either by individual or 
mixed pro-inflammatory cytokines is VEGF-C, a growth factor involved in 
angiogenesis. While already somewhat elevated in HHV-6-infected 
astrocytes, TNF-α, IL-1β and IFN-γ trigger a further 20- to 40-fold increase 
in expression levels of VEGF-C which it is not induced by either cytokine 
in uninfected astrocytes, nor by a mixture of the three cytokines. The related 
VEGF to which the same applies, is induced 10- to 20-fold, except by TNF-
α. Other factors that are induced by the pro-inflammatory cytokines include 
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the pleiotropic cytokine IL-6 (38,39) and LIP as well as MT-III, both factors 
whose functions in the CNS remains to be fully established. 
It is remarkable that several of the changes effected by HHV-6 is the 
induction in astrocytes of anti-inflammatory and angiogenic factors in 
response to an inflammatory stimulus. Also chemotactic factors appear to be 
induced more prominently by pro-inflammatory cytokines in HHV-6-
infected astrocytes as compared to uninfected cells. Among the chemotactic 
products readily induced in infected cells are CXCL8, CXCL2, CCL3 and 
CXCL6. Whereas these chemokines, as well as CCL5 (RANTES) that is 
induced in unstimulated HHV-6-infected astrocytes, are well known to be 
relevant to leukocyte and granulocyte recruitment it should be pointed out 
that they are also relevant to glial cells themselves. Both human adult 
astrocytes, neurons and microglia express receptors for all these chemokines 
and under the influence of TNF-α astrocytes express even higher levels of 
CCR3 (receptor for CCL5) and CXCR1 (receptor for CXCL6 and CXCL8) 
(40). Thus, the chemokine response modulated by HHV-6 should be 
considered relevant neural cell migration within the CNS as well. Finally, it 
is interesting to note induction in HHV-6-infected astrocytes but not in 
uninfected cells of LIP, IRF-1 and ICSBP all of which play a role in 
controlling production of type I interferons. Such a response appears to be 
fully consistent with induction of an antiviral response in the target cells as 
a component of the total response, which is obviously not unexpected. 
The effects of HHV-6 on astrocytes appear to be cell specific as the virus 
has a completely different impact on the gene profile of the HSB-2 carrier 
T-cell line used by us to infect astrocytes. This profile was examined 
primarily to exclude the possibility that contaminant RNA from this cell line 
could have affected the results. At the same time, our analysis reveals that 
while HHV-6 hardly impacts on astrocytes, the virus does trigger induction 
of several genes in HSB-2 cells. All of these, except for VEGF-C are 
different from those induced in astrocytes. When compared to a previous 
report on the effect of HHV-6 on another T cell line, viz. SupT1 (41) 
differences are again seen. In SupT1 HHV-6 induced IL-18 and the IL-2 
receptor and led to suppression of IL-10, the IL-10 receptor and IL-14. 
None of these changes could be observed in the presently examined cell line 
HSB-2, despite that fact that in both cases the A strain of HHV-6 was used. 
Together, these data underpin the notion that HHV-6 can have very different 
effects in different types of cells.  
In summary, HHV-6 appears unlikely to trigger an immediate host-defense 
response in astrocytes which is consistent with its frequent and silent 
infection of the human CNS. In the face of a pro-inflammatory stimulus, 
however, the presence of HHV-6 in astrocytes profoundly alters their 
Gene profile in HHV-6-infected astrocytes 
 97 
response and leads to elevated expression of anti-inflammatory mediators, 
chemokines and pro-angiogenic factors. This appears to be in line with the 
recent observation of immunosuppressive effects of HHV-6 infection also 
on macrophages, in which the virus blocks inflammation-induced IL-12 
production (31). Clearly, HHV-6 may have additional effects that are 
relevant to inflammatory demyelinating diseases including for example its 
negative effect on proliferation and development of glial precursors as 
recently observed in vitro (42). Based on its effect on astrocytes, however, 
HHV-6 appears unlikely to help trigger a local inflammatory reaction in the 
CNS but rather promotes downregulation of such a reaction. 
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Abstract  
Toll-like receptors (TLR) are key players in innate immune responses in a 
wide range of cell types and tissues including the central nervous system 
(CNS). In particular during inflammation microglia and astrocytes in the 
human brain express marked levels of TLR. To explore their role in the host 
response to neurotropic infections we examined the impact of human 
herpesvirus-6 (HHV-6) on TLR expression in cultured astrocytes. HHV-6 is 
a frequent pathogen in the human adult CNS but does not usually trigger 
inflammatory reactions in the brain or spinal cord.  
Astrocytes derived from post-mortem human adult brain samples were 
infected with HHV-6 in culture and expression levels of TLR1 to TLR4 
were monitored by real-time quantitative PCR and cytokine production was 
monitored via gene profiling. Also, the effects of the pro-inflammatory 
cytokines IL-1β, TNF-α and IFN-γ on TLR expression were examined, both 
in HHV-6 infected and uninfected astrocytes.  
HHV-6 infection of astrocytes led to a modest increase in levels of mRNA 
encoding the dominant TLR4 or the less abundant TLR1 and TLR2, but to a 
strong increase in levels of TLR3-encoding mRNA. Similar effects were 
observed after treatment of astrocytes with pro-inflammatory cytokines. The 
combination of HHV-6 infection and pro-inflammatory cytokines again led 
to strong induction of TLR3 but in this case, also TLR2 was induced 
between 10- to 100-fold. Interestingly, HHV-6 infection of astrocytes did 
not lead to production of any significant amounts of IL-1β, TNF-α, IL-6 or 
other cytokines traditionally marking TLR-mediated responses. These 
results suggest that while HHV-6 does induce elevated expression 
especially of TLR3, it does not appear to provide the ligands necessary to 
activate a TLR-mediated response in astrocytes.  
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Introduction 
The family of mammalian Toll like receptors (TLR) play key roles in innate 
responses against invading pathogens (1,2). TLR mediate responses to a 
wide range of pathogen-associated products including lipopolysaccharides, 
lipoproteins, flagellin, bacterial DNA and double-stranded RNA. Such 
responses typically involve production of a range of inflammatory 
mediators including TNF-α, IL-1β, IL-6, nitric oxide and type I interferons 
(3). Expression of several TLR family members has been documented also 
for the human CNS (4). TLR are particularly prominent on glial cells and 
their expression is elevated during CNS inflammation. In cell culture 
models human adult microglia express a wide range of different TLR, 
predominantly inside intracellular vesicles. Adult astrocytes on the other 
hand predominantly express TLR4 and, to a lesser extent, TLR3. On 
astrocytes TLR are expressed on the cell surface only. 
Given the dominant function of TLR in controlling innate responses against 
invading pathogens in other cell types and tissues, TLR may play a crucial 
role in pathogen control also in the human CNS. Recently, we established a 
cell culture model for infecting human adult astrocytes with a common 
neurotropic human pathogen, viz. human herpesvirus-6 (HHV-6). HHV-6 is 
a ubiquitous DNA β-herpesvirus which persistently infects at least 95 % of 
the human population and can be detected in at least 40 % of normal healthy 
brains. HHV-6 infection in the adult CNS is usually silent and does not 
frequently trigger clinically or pathologically obvious inflammatory 
reactions. Like other herpesviruses, HHV-6 has developed several strategies 
to evade elimination by the host’s immune system. These strategies include 
production of anti-inflammatory cytokine and chemokine mimics, or 
mimics of chemokine receptors to control the host innate immune response.   
Especially in view of the ability of HHV-6 to maintain itself in the human 
adult CNS it is of interest to examine its interaction with the TLR signaling 
network of glial cells. In the present study real-time quantitative PCR was 
used to monitor expression levels of four TLR family members in astrocytes 
under the influence of HHV-6 infection over a period of 2 days. Also, we 
examined the effects of pro-inflammatory cytokines and monitored their 
production as well, as a read-out for possible TLR-mediated responses.  
While the current preliminary study does not allow any far-reaching 
conclusions yet, the data suggest that both HHV-6 and pro-inflammatory 
cytokines trigger preferential induction of TLR3. Levels of mRNA encoding 
the abundant TLR4, or the much less abundant TLR1 and TLR2 were only 
moderately affected. The combination of HHV-6 infection and cytokine 
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treatment again triggered strong TLR3 induction but in this case, also TLR2 
was induced at levels comparable to TLR3. As assessed by cDNA array 
analysis HHV-6 infection did not trigger any appreciable production of IL-
1β, TNF-α, IL-6, type-I interferons or other mediators that are generally 
considered to be markers for TLR-mediated responses, including those for 
TLR3 and TLR4. Thus, in the time frame monitored in the present study 
experimental HHV-6 infection of human adult astrocytes does trigger 
elevated TLR expression but appears to fail to provide the ligands to 
activate these TLR. 
 
Materials and methods 
 
Donors 
Astrocytes were obtained from post-mortem sub cortical white matter 
samples provided by the Netherlands Brain Bank after rapid autopsy. The 
Netherlands Brain Bank supplies post-mortem material from clinically well 
documented and neuropathologically confirmed cases. Autopsies are 
performed on donors with written informed consent from the donor or from 
direct next of kin. All procedures applied in the experiments were approved by 
the local ethics committee. Material from four control donors free from any 
clinical or pathological signs of neurodegenerative diseases was used. 
Additional donor characteristics are given below in Table 5.1.  
 
 
Table 5.1. Donor characteristics 
 
Donor 
nr 
Donor# Sex Age PM delay Clinical history Cause of death 
1 00-022 female 83 7h 45m non-demented control acute myocard infarction 
2 00-031 female 77 9h 15m non-demented control cardiac infarction 
3 00-032 female    78 6h 30m non-demented control decompensatio cordis 
4 01-104 female 77 5h 30m non-demented control lung metastases from a 
mammacarcinoma 
PM = post mortem  
 
 
Isolation and in vitro culture of human adult astrocytes 
Human adult post-mortem astrocytes were obtained as previously described 
(5,6). Briefly, white matter samples were collected and meninges and 
visible blood vessels were removed before mincing the tissue into small 
cubes. The tissue fragments were incubated at 37°C for 20 min in 0.25 % 
trypsin (Sigma, St. Louis, MO) and 0.1 mg/mL bovine pancreatic DNAse I 
(Boehringer Mannheim, Germany). After digestion cell suspensions were 
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gently triturated, washed and taken into culture in medium containing 1:1 
v/v DMEM : HAM-F10 supplemented with 10 % FCS (Biowhittaker, 
Verviers, Belgium) and pyruvate, glutamine and antibiotics. Astrocyte 
cultures were grown in 25 cm2 culture flasks or 6-well plates (Costar, NY, 
USA) coated with poly-L-lysine (Sigma Chemical Co, St Louis, MO) until 
post-confluent monolayers were obtained at passage 4. The purity of the 
astrocyte cultures was verified by staining with rabbit anti-glial fibrillary 
acidic protein (GFAP; ZYMED, San Francisco, CA) as an astrocyte marker, 
murine anti-human CD68 (DAKO, Glostrup, Denmark) as a microglial 
marker, and murine anti-myelin basic protein (MBP; Boehringer Mannheim, 
Germany) as an oligodendrocyte marker. The astrocyte cultures were found 
to be at least 99% GFAP-positive. No cells were found to express CD68 or 
MBP.  
 
Cytokine treatment of cultured human adult astrocytes 
Previous studies have consistently indicated that changes in the gene 
expression profile of human astrocytes in response to pro-inflammatory 
cytokines are not generally rapid but accumulate over 72-h periods (5,7,8). 
Based on these findings astrocytes were stimulated with pro-inflammatory 
cytokines TNF-α, IL-1β and IFN-γ (PreproTech, Rocky Hill, NY) for 
periods of 2, 6, 24 and 48 h, respectively, in order to monitor TLR 
expression levels . Treatments were performed with each cytokine 
separately added to a final concentration of 500 U/mL, as well as with a 
mixture of the three cytokines at this concentration.  
 
HHV-6 infection of human astrocytes 
Astrocytes from donors 1, 2 and 4 were infected with HHV-6 as previously 
described in Chapter 3 and 4. Briefly, post-confluent astrocyte cultures were 
infected using a HSB-2 carrier cell line of which at least 75 % of the cells 
could be stained for the 105 kDa common antigen of HHV-6A and B (NCL-
HHV-6; Novocastra, Newcastle, UK). Before adding this HHV-6-infected 
HSB-2 cell line to astrocytes, the carrier cells were washed and resuspended 
in fresh culture medium. HHV-6-infected HSB-2 cells and astrocytes were 
co-cultured for a period of 18 h, after which astrocytes were extensively 
washed to remove HSB-2 cells, fresh culture medium was added and the 
astrocytes were cultured for an additional 48 h.  
Cells cultured and infected in chamber slides (Falcon, Becton Dickinson, 
NY) were washed with PBS and  fixed in acetone supplemented with 0.03 
% v/v H2O2 (Merck, Darmstadt, Germany) for 10 min. Chamber slides were 
air-dried and stained for GFAP (GFAP; ZYMED, San Francisco, CA) and 
NCL-HHV-6. Slides were embedded in vectashield mounting medium with 
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4'6-diamidino-2-phenylindole-2HCl (DAPI; Vector Laboratories, 
Burlingame, CA) for DNA staining. Astrocyte cultures obtained from donor 
1 and 4 were infected once and astrocyte cultures obtained from donor 2 
were infected twice using separately prepared post-confluent cultures.  
 
Cytokine treatment of HHV-6-infected astrocytes 
After HHV-6 infection as described above astrocytes were cultured for an 
additional 48 h in the presence of a mixture of TNF-α, IL-1β and IFN-γ, 
each at a concentration of 500 U/mL. Cytokine treatment was performed 
using astrocyte cultures from donor 1 and 4, and two separately prepared 
astrocyte cultures from donor 2. 
 
RNA isolation and cDNA synthesis 
To isolate RNA, cells were washed with PBS and RNA was isolated using 
RNAzol B (Campro Scientific, Veenendaal, The Netherlands) according to 
the manufacturer’s instructions. Briefly, astrocytes were collected in 
RNAzol B and kept on ice. Chloroform was added to a final concentration 
of 10 % (Sigma-Aldrich Chemie, Steinheim, Germany), cells were shaken 
firmly and kept on ice for another 5 min and finally the sample was 
centrifuged for 15 min at 13,600 g at 4°C. RNA in the aqueous supernatant 
was precipitated with an equal volume of ice-cold isopropanol (Sigma-
Aldrich chemie, Steinheim, Germany) and kept overnight at 4°C. RNA was 
collected by centrifugation for 30 min at 13,600 g at 4°C and the pellet was 
washed with 75 % ethanol and centrifuged again. After drying the pellet 
was dissolved in RNA-se free water.  
 
Real-time polymerase chain reaction (RT-PCR) 
Quantification of mRNA encoding β-actin, TLR1, TLR2, TLR3 and TLR4 
was performed by quantitative real-time RT-PCR using an ABI PRISM® 
7700 sequence detection system (Applied Biosystems). Data were analyzed 
using sequence detector version 1.7 software. cDNA was synthesized from 
2.0 µg RNA using reverse transcription system (Promega, Madison, WI). 
Briefly the PCR reaction volume was 25 µL and contained a mixture of 
dNTPs, PCR buffer, Mg2+ (25 mM), beacon (1 µM), sense and anti-sense 
primer and Taq polymerase. Ten µL of cDNA (1:10 diluted in water) was 
added to the reaction mixture. Sequences for the fluorogenic molecular 
beacons and primers (Biolegio) used for β-actin, TLR1, TLR2, TLR3 and 
TLR4 transcription are listed in Table 5.2. PCR amplification reactions were 
conducted with an initial 5 min denaturation step at 95ºC coupled to a 
repeating cycle of 30 s at 95ºC, 40 s at 56ºC and 30 s at 72ºC for 40 cycles. 
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The amount of product was measured during the 20 to 40 s period at 56ºC, 
at this point the maximum amount of beacons is bound to the cDNA. To 
quantify the amount of the target gene we used known quantities of 
plasmids as standards carrying individual target cDNAs. As a positive 
control for the RT-PCR technique we used pooled cDNA from microglia 
cultures obtained from different donors (4). To correct for differences in 
initial cell numbers, as well as in the efficiency of mRNA isolation and 
cDNA synthesis all values were normalised for β-actin levels and TLR 
levels are expressed as the relative amount of transcripts.  
 
The impact of HHV-6 infection on the production of pro-inflammatory 
cytokines and their receptors assessed by cDNA arrays 
Analysis of the mRNA profile of HHV-6-infected astrocytes was performed 
by hybrid selection of radioactive labeled cDNA on high-density Clontech 
Atlas arrays of membrane-bound cDNA probes, as described previously 
(8). Briefly, total cellular RNA was extracted and poly A+ RNA was 
separated from total RNA. Radioactive cDNA probes were prepared by 
adding dNTP-mix, DTT, MMLV RT and [32P]-dATP and incubating for 25 
min at 50°C. Hybridization of the radioactive cDNA probes to the 
membrane was carried out overnight. Specifically bound radioactivity was 
analyzed and quantified by phosphor-imaging. The hybridization signal for 
each gene probe, present in duplicate on the array, was calculated as the 
mean of these duplicates, corrected for background intensity and quantified 
using software provided by the manufacturer. Relative hybridization signals 
were calculated by dividing the absolute signals by the mean signal for all 9 
housekeeping reference genes on the corresponding array, and multiplying 
this ratio by 1,000.  
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Results  
 
The impact of TNF-α, IL-1β or IFN-γ on TLR expression in astrocytes  
First, we examined the effects of pro-inflammatory cytokines on expression 
levels of TLR in astrocytes to establish a suitable time frame to monitor the 
possible effects of HHV-6 infection. Traditional pro-inflammatory 
mediators TNF-α, IL-1β, IFN-γ and a mixture of these three cytokines 
together were used to stimulate cultured astrocytes and TLR expression 
levels were monitored by quantitative real-time PCR over a 48-h period, 
using expression levels of β-actine encoding mRNA as a reference. The 
present analysis was focused on TLR1 through TLR4 since expression 
levels of TLR5 through TLR10 in cultured human astrocytes are very low 
and remain so in the presence of pro-inflammatory cytokines (Bsibsi et al., 
unpublished observations). Astrocytes derived from four different donors 
were used to evaluate possible donor-to-donor variations in the baseline 
values as well in patterns of responsiveness. 
Expression levels of TLR1 (Figure 5.1) were found to be relatively low in 
all four donors. Real time PCR analysis indicated TLR1 transcripts in 
astrocytes at the start of the culture at levels 105 to 106 times lower than 
those encoding β-actin. Donor-to-donor variations in these levels were 
significant and expression levels of TLR1 differed in individual cultures by 
as much as a factor of 10. Upon treatment with either individual cytokines 
or a mixture of cytokines, levels of TLR1 transcripts markedly increased 
only in one culture but not in the other three. It should be noted, however, 
that the increase was observed for the culture with the lowest baseline 
expression of TLR1 and the 5- to 10-fold cytokine-induced increase only 
led to the low TLR1 levels already observed in the other cultures at 
baseline. 
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Figure 5.1. Expression of TLR1 in cytokine-stimulated astrocytes 
Cultured human adult astrocytes were stimulated with either TNF-α (A), IL-1β (B) or 
IFN-γ (C) alone, or with a mixture of all three cytokines together (D). At the start of the 
experiment and after 2, 6, 24 and 48 h, levels of transcripts encoding TLR1 were 
determined by real-time PCR and compared to levels of transcripts encoding β-actin as 
an internal reference.  
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The levels of TLR2-encoding transcripts at baseline were very similar to 
TLR1-encoding transcripts (Figure 5.2). In this case, treatment with either 
TNF-α alone or the combination of TNF-α, IL-1β and IFN-γ together led to 
an increase of TLR2 levels up to 40-fold in three out of four cultures over a 
48-h culture period. No such stimulatory effect was seen after treatment 
with IL-1β or IFN-γ alone, in which case none of the transcripts increased 
more than 4-fold. The amounts of TLR3 transcripts in cultures of untreated 
astrocytes were found to be around 10-5 relative to those of β actin, about 
five to ten times higher than those of TLR1 and TLR2 (Figure 5.3).  
Treatment with either TNF-α alone or the combination of TNF-α, IL-1β 
and IFN-γ together led to a marked (5- to 100-fold) increase of TLR3 levels 
in three out of four cultures. The one astrocyte culture that did not respond 
to cytokine treatment was the same culture that also failed to respond when 
monitored for TLR2. Effects of either IL-1β or IFN-γ alone were more 
modest with markedly (up to 40-fold) increased levels of TLR3 in only two 
cultures. Levels of TLR4-encoding transcripts in the astrocytes cultures 
were about 10 times higher as compared to TLR3-encoding transcripts, 
consistent with previous data illustrating that mRNA expression levels of 
TLR4 are dominant in cultured astrocytes. Effects of pro-inflammatory 
cytokines on these TLR4 expression levels were marginal in all cases, i.e. 
none of the cytokines nor the mixture of cytokines induced levels of TLR to 
change more than 7-fold (Figure 5.4). 
The above data therefore indicate that especially TNF-α exerts a stimulatory 
effect on expression levels of mRNA encoding TLR3 and –albeit to a 
somewhat lesser extent- TLR2 but not TLR1 or TLR4. In general, elevated 
levels of TLR2- and TLR3-encoding transcripts were readily detectable 
after 24 and 48 h but not in the first 6 h.  
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Figure. 5.2. Expression of TLR2 in cytokine-stimulated astrocytes 
Cultured human adult astrocytes were stimulated with either TNF-α (A), IL-1β (B) or 
IFN-γ (C) alone, or with a mixture of all three cytokines together (D). At the start of the 
experiment and after 2, 6, 24 and 48 h, levels of transcripts encoding TLR2 were 
determined by real-time PCR and compared to levels of transcripts encoding β-actin as an 
internal reference.   
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Figure 5.3. Expression of TLR3 in cytokine-stimulated astrocytes 
Cultured human adult astrocytes were stimulated with either TNF-α (A), IL-1β (B) or 
IFN-γ (C) alone, or with a mixture of all three cytokines together (D). At the start of the 
experiment and after 2, 6, 24 and 48 h, levels of transcripts encoding TLR3 were 
determined by real-time PCR and compared to levels of transcripts encoding β-actin as 
an internal reference.   
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Figure 5.4. Expression of TLR4 in cytokine-stimulated astrocytes 
Cultured human adult astrocytes were stimulated with either TNF-α (A), IL-1β (B) or 
IFN-γ (C) alone, or with a mixture of all three cytokines together (D). At the start of the 
experiment and after 2, 6, 24 and 48 h, levels of transcripts encoding TLR4 were 
determined by real-time PCR and compared to levels of transcripts encoding β-actin as 
an internal reference.  
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The impact of HHV-6 infection on TLR expression in astrocytes 
The above data indicate that effects of cytokines on expression levels of 
TLR were apparent after 24 or 48 h but not after shorter periods of 2 to 6 h. 
This relatively slow response of astrocytes at the level of mRNA is fully 
consistent with previous observations of astrocyte cytokine-encoding 
mRNA responses both in our own studies and in those reported by others. 
Together, the data led us to select a period of 48 h to allow the effects of 
experimental HHV-6 infection of astrocytes to develop. In examining the 
effect of HHV-6 on expression levels of TLR-encoding transcripts we also 
included an experimental condition in which HHV-6 infection was 
combined with the addition of a mixture of TNF-α, IL1β and IFN-γ.  This 
mixed condition of HHV-6 infection and pro-inflammatory cytokine 
treatment was chosen since previous studies had indicated that HHV-6 may 
exert very different effects on astrocytes under normal versus pro-
inflammatory culturing conditions (8). 
To investigate the impact of HHV-6 on TLR expression, astrocytes were 
supplied in culture with an HHV-6-infected carrier T-cell line (HSB-2). 
After an overnight co-culture period infected HSB-2 cells were removed 
and astrocytes were cultured for an additional 48 h. Under these conditions, 
between 30 % and 35 % of all astrocytes were infected as revealed by 
immunocytochemical staining for the 105 kDa antigen of HHV-6 in the 
nucleus of infected cells. Also marked cytopathic effects (CPE) including 
enlargement of nuclei, cell swelling and syncytium formation were apparent 
in about one third of the cells. After 48 h expression levels of TLR1-4 were 
measured using real-time PCR, again using β-actin-encoding transcripts as 
an internal reference.  
First of all, the results revealed marked donor-to-donor variations in the 
effects of HHV-6 infection as shown in Figure 5.5.B. As already observed 
after cytokine treatment, the results of which for the 48-h observation period 
are represented again in Figure 5.5.A as a reference, the response levels 
found in individual astrocyte cultures sometimes show marked differences 
making it difficult to draw any far-reaching conclusions. Yet, three out of 
four cultures showed a 10- to 200-fold increase in TLR3-encoding 
transcripts while TLR1, 2 or 4 transcripts were generally affected less than 
10-fold by HHV-6. None of the cultures showed any downregulation of 
TLR-encoding transcripts as the result of HHV-6 infection. These data 
suggest that over the 48-h period following infection, HHV-6 tends to 
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induce expression of TLR, with TLR3 affected more strongly than the other 
TLR.  
We also monitored the effect of a combination of TNF-α, IL-1β and       
IFN-γ on TLR expression in HHV-6-infected astrocytes. After 48 h of 
infection, no change was observed in the percentage of HHV-6-infected 
astrocytes in culture under the influence of the cytokine mixture and again, 
about one third of the cells were infected. Figure 5.5.C shows the levels of 
TLR-encoding transcripts in HHV-6-infected astrocytes treated with the 
cytokine mixture, as compared to uninfected and untreated astrocytes. 
Overall, the combined effects of infection and cytokine treatment on 
expression levels of TLR1, TLR3 and TLR4 were very similar to those 
observed in infected astrocytes only. Again, TLR3 levels were markedly 
induced between 5- and 100-fold for all cultures and also for TLR1 and 
TLR4, the more modest levels of induction (up to maximally 20-fold) were 
very similar to those found in the absence of the combined cytokine 
stimulus. Yet, the effects on TLR-2-encoding transcripts were clearly 
influenced by the cytokines. While HHV-6 infection alone led to only very 
modest effects (10-fold induction in only one of the four cultures) the 
combination of HHV-6 infection with TNF-α, IL-1β and IFN-γ resulted in 
10- to 100-fold induction of TLR2 in three out of the four cultures. Overall, 
the induction levels of TLR2 under these conditions were very similar to 
those for TLR3. 
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Figure 5.5. Expression levels of TLR1-4 in astrocytes under the influence of HHV-
6 infection and cytokines  
Cultured human astrocytes were stimulated with a mixture of TNF-α, IL-1β and IFN-γ 
(A), infected with HHV-6 (B) or infected with virus in the presence of cytokines (C). 
After 48 h levels of transcripts encoding TLR1-4 were determined by real-time PCR 
using transcripts encoding β-actin as an internal reference, and expressed relative to the 
levels found in an untreated control culture of astrocytes from the same source kept for 
48 h under identical conditions. For each condition four separate astrocyte cultures 
from different donors were used to generate data.  
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The impact of HHV-6 infection on the production of pro-inflammatory 
cytokines  
Next, we examined HHV-6-infected astrocytes for levels of expression of a 
range of mRNAs encoding cytokines, chemokines and growth factors. 
Levels of these mediators were evaluated for two reasons. First, TLR 
expression levels in HHV-6 infected astrocyte cultures could be influenced 
indirectly by cytokines or other mediators secreted into the culture medium 
by infected astrocytes. Figures 5.1-5.4 illustrate that soluble mediators 
notably including TNF-α can in fact influence TLR expression levels. 
Secondly, by determining expression levels of the pro-inflammatory 
cytokines and chemokines that are typically triggered by TLR ligation, 
including for example TNF-α, IL-6, IL-1β or type-I interferons, such 
ligation by any possible TLR ligand associated with HHV-6 infection may 
be revealed.  
As reportedly previously, cDNA array analysis of expression of 268 
cytokines, chemokines, growth factors and their receptors in HHV-6 
infected astrocytes revealed marked induction only of a few genes. These 
genes, as listed in Table 4.1 of Chapter 4, include none of the traditional 
TLR activation markers as reported in literature with the only exception 
perhaps of CCL5 (RANTES) that is known as one of the products that could 
–among other factors- be triggered by TLR engagement. CCL5 expression 
is elevated 2- to 4-fold in two out of three cultures. Yet, when a focus is 
chosen on cytokines and chemokines that have been repeatedly found as 
TLR-induced gene products in a variety of cell types, none of these were 
found to be consistently induced by HHV-6 (Table 5.3) over a 48-h period. 
Especially noteworthy is the lack of any induction of IFN-β, a type-I 
interferon that is typically induced by TLR3. Since TLR3 is induced in 
HHV-6-infected astrocytes more strongly than the others, ligation of this 
particular TLR could well have been reflected by an increase in IFN-β, but 
it is not.  
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Discussion 
In the present study we investigated the impact of pro-inflammatory 
cytokines and HHV-6 infection on TLR expression in cultured human adult 
astrocytes. We focussed on the expression of TLR1, TLR2, TLR3 and 
TLR4 since these family members are expressed at detectable levels in 
cultured human adult astrocytes while TLR5 to TLR10 are not detectable, 
also not after treatment with pro-inflammatory cytokines (Bsibsi et al., 
unpublished observations). As a first approach, the present study was based 
on an analysis of astrocyte cultures from four different donors. Since 
marked donor-to-donor variations in levels of TLR-encoding transcripts 
typify results in most cases, a more extended analysis will be required to 
allow for firm conclusions. Also, validation of expression data at the level 
of protein expression will be useful to support the current data. Finally, it 
should be noted that experimental infection of astrocyte cultures leads to 
infection of about one third of the cells, which will probably obscure more 
subtle effects of infection that can only be revealed at higher percentages of 
infection. Bearing these caveats in mind, however, the data collected in the 
present study do allow some trends to be already identified. 
The levels of transcripts encoding TLR1-4 in normal adult astrocyte cultures 
as observed in the present study are consistent with a previous report on 
TLR expression in astrocytes (4) in demonstrating dominant expression of 
TLR4. TLR4 is expressed at levels that about ten times higher than those for 
TLR3, the second dominant TLR in cultured astrocytes. TLR1 and TLR2 
are expressed at only very low levels. In response to TNF-α, TLR3, and to a 
lesser extent TLR2, are induced in astrocytes over a 24- to 48-h period. 
Other pro-inflammatory mediators including IL-1β and IFN-γ appear to 
have much less effect. At earlier points in time following TNF-α treatment, 
levels of TLR-encoding transcripts did not change to any significant level, 
suggesting that the cytokine-induced effects of expression of TLR are 
relatively slow and follow the response course previously documented at the 
level of a large variety of cytokine and chemokine mRNAs. The apparently 
preferential induction of TLR3 by pro-inflammatory cytokines is 
remarkable and deserves follow-up experiments using more donors and 
analyzing TLR expression also at the protein level.  
Also after HHV-6 infection of astrocyte cultures, TLR3 induction appears to 
be the dominant effect. In three out of the four cultures, TLR3 was induced 
by a factor of between 10 and 200, levels of induction that were not attained 
by any other TLR. Bearing in mind that only one third of the cells are 
actually infected with HHV-6, and that the effect is most likely not an 
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indirect one that is mediated by cytokines or chemokines secreted by 
infected cells (see below), this level of response is very strong. Clearly, 
induction of TLR and especially of TLR3 at the level of mRNA should be 
verified by protein analysis including immunocytochemical staining. This 
should also clarify whether enhanced TLR expression is indeed confined to 
infected cells, or also occurs on uninfected cells. As stated above, it is 
unlikely that TLR induction by HHV-6 infection of the astrocyte cultures is 
mediated indirectly by cytokines or other mediators secreted by infected 
cells. HHV-6-infected astrocyte cultures hardly produce any soluble pro-
inflammatory mediators such as TNF-α that could exert such an effect (see 
Figure 4.1 and Table 4.1).  
The lack of such mediators being triggered in astrocytes by HHV-6 
infection has another interesting implication. Several mediators including 
TNF-α, IL-1β and IL-6 are consistent products of TLR activation in a 
variety of cell types, and traditional products of NF-κB-mediated signaling 
that is activated as a common response to all TLR. In the case of TLR3, also 
type-I interferons including IFN-α and IFN-β are generally activated. The 
fact that over the 48 h-monitoring period mRNA for none of these mediators 
are found at levels that are any higher than in control cultures strongly 
suggests that activation of TLR-mediated signaling does not occur in HHV-
6-infected astrocyte cultures. In turn, this suggests that while HHV-6 
infection does apparently lead to elevated levels of expression of TLR, 
infection does not provide the ligands such as dsRNA to activate these TLR 
in the time frame of the current study. This lack of TLR activation may be at 
least partly explained by the fact that TLR are only expressed on the surface 
of astrocytes whereas the virus is intracellular and no evidence has so far 
been found for viral particles to be relased from infected astrocytes in 
culture. 
Finally, the present study suggests that TLR induction in HHV-6-infected 
astrocyte cultures is altered by the addition of pro-inflammatory cytokines 
in one selective feature, viz. induction of TLR2. While induction levels of 
TLR1, TLR3 and TLR4 remain essentially the same in HHV-6 infected 
astrocyte cultures irrespective of the presence of a mixture of TNF-α, IL1β 
and IFN-γ, induction levels of TLR2 are markedly increased by these 
cytokines. No downregulation of TLR expression was observed under these 
conditions. Again, this phenomenon deserves to be examined more closely 
also at the protein level. It is not immediately obvious which relationship 
HHV-6 could bear to TLR2, especially since TLR2 is known to respond to 
quite a variety of different ligands including lipopeptides, lipoproteins, 
zymosan, peptideoglycan and heat-shock proteins. 
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While representing only a first step towards understanding the role of TLR 
in virus infection in the human CNS, the present study does represent the 
first documentation of the effects of a viral infection on TLR in human adult 
astrocytes. Data on the effects of viruses on TLR in other cell types are 
beginning to emerge and they are revealing complex and sometimes 
opposing effects. Infection of macrophages with influenza A and Sendai 
viruses enhances expression of TLR1, TLR2 and TLR3 (9). Wild-type 
measles virus, human cytomegalovirus (HCMV) and herpes simplex virus 1 
(HSV-1) activate monocytes via TLR2 and trigger inflammatory cytokine 
production (10,11,12). TLR4 plays a role in anti respiratory syncytial virus 
(RSV) responses (13). Vaccina virus (VV) on the other hand inhibits 
multiple TLR pathways to NF-κB and thus suppresses the TLR-mediated 
host immune response (14). Very often, TLR3 is associated with the 
response against viruses since the predominant response to TLR3 ligand is 
production of type-I interferons, which is generally considered as a typical 
anti-viral response. Also, TLR3 is known to be activated by double-stranded 
RNA which is a replication intermediate for several viruses. Nevertheless, 
Edelmann and co-workers recently showed that the susceptibility to 
reovirus, lymphocytic choriomeningitis virus (LCMV), vesicular stomatitis 
virus (VSV) and murine cytomegalovirus (MCMV) was unaffected in 
TLR3-/- mice (15). On the other hand, wild type mice infected peripherally 
with West Nile virus show enhanced BBB breakdown and elevated levels of 
brain infection as compared to TLR3-/- mice (16). 
These observations are only the first sets of data that will ultimately be 
required to gain a full understanding of the interaction between viruses and 
TLR. While requiring confirmation and extension, our current data appear 
to point to TLR3 and TLR2 as being of prime relevance to the interaction 
between HHV-6 and human adult astrocytes, also under inflammatory 
conditions. While HHV-6 most likely leads to marked induction of TLR on 
astrocytes, it appears to fail in directly activating these TLR. This suggests 
that TLR on astrocytes may play alternate roles in the host response to 
infection in the human CNS, different from directly engaging pathogen-
derived components. 
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Abstract 
Brain microglia are highly responsive cells in the central nervous system 
that exert key functions in host defense as well as in neuroprotection and 
regeneration. In this study the gene expression profiles for 268 cytokines, 
chemokines, growth factors and their receptors were examined in cultures of 
purified human adult microglia, using cDNA array profiling.  
Microglia from nine different donors were compared, also following 
challenge of such microglia with the pro-inflammatory cytokines TNF-α 
and IFN-γ. A stable pattern was observed of genes abundantly expressed in 
the different cultures under standard conditions. Genes abundantly 
expressed in all microglia cultures include CCL2 (MCP-1), thymosin beta-
10, migration inhibitory factor-related protein 8 (MRP8), MRP14, 
corticotropin releasing factor receptor 1 and endothelin 2. Abundant gene 
products novel to microglia were neuromodulin (GAP43) and Flt3 ligand. 
Yet, treatment with TNF-α and IFN-γ led to widely different response 
profiles among the different cultures. 
These data show a surprising level of heterogeneity among human adult 
microglia cultures in their response to a pro-inflammatory stimulus despite 
the standardized methodology to examine this response. 
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Introduction  
Microglial cells are derived from CD45+ bone marrow precursors of the 
myeloid lineage, which also give rise to macrophages, dendritic cells and 
granulocytes (1,2,3). Microglia compose approximately 5 to 20 % of all 
cells in the central nervous system (CNS) (4,5). They are the gatekeepers of 
the brain and function as sensor cells that are continuously in surveillance of 
changes or insults in the CNS. Microglia respond to signals from stressed or 
damaged cells as well as to invading pathogens. The adult brain has at least 
two major subsets of resident phagocytic cells. These are resting microglia 
in the parenchyma and perivascular macrophages located in the basal lamina 
of brain vessels and in the choroid plexus (6). The replacement rate of 
perivascular macrophages by blood-derived mononuclear cells is relatively 
fast whereas that of ramified microglia in the parenchyma is very slow. In 
contrast, a high turnover rate has been described for microglia in damaged 
or injured brains (7,8).  
Upon activation by brain damage or injury microglia loose their normal 
ramified shape and acquire a macrophage/monocyte-like rounded 
morphology (9). Under such conditions, microglia proliferate and migrate 
through the brain. Chemokines including CCL2 (MCP-1), CCL3 (MIP-1α) 
and CCL4 (MIP-1β) appear to play important roles in this response (10, 
11,12). Activated microglia participate in the signaling network in the CNS 
during inflammation and consequently, they are involved in the 
pathogenesis and/or regulation of a variety of neurodegenerative disorders 
including multiple sclerosis (MS) (13), Alzheimer’s disease (AD) (14), 
Parkinson’s disease (15) and HIV encephalitis (16). Activated microglia 
increase their phagocytic activity and also express higher levels of major 
histocompatibility complex molecules (MHC) and co-stimulatory molecules 
as compared to resting, ramified microglia. Consequently, they acquire 
antigen-presenting functions (13). The activation of microglia is likely to 
involve a stepwise differentiation program similar to that governing 
dendritic cell maturation (17). Details of this differentiation program, 
however, remain to be clarified. Differentiation, migration and other 
microglia functions thus appear to be governed by complex signaling 
networks involving a variety of mediators including cytokines, chemokines 
and growth factors.  
As a first approach to understanding such networks, in vitro studies of gene 
profile expression in microglia are useful. Whether or not a representative 
and reproducible gene profile can be obtained of human microglia cultured 
from different donors is a question to be answered for such an approach. 
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Isolating and culturing microglia in itself will already trigger some 
activation, given the innate responsiveness of microglia. An important 
question is therefore whether cultured and partly activated microglia reliably 
reflect the behavior of microglia in vivo, and respond in ways that are 
similar to microglia reactions in an intact CNS to trauma, infection or 
inflammation.  
To address this issue, we examined by cDNA array profiling the expression 
pattern of 268 cytokines, chemokines, growth factors and their receptors in 
human adult microglia isolated from post-mortem brain samples of nine 
different donors. In a previous study we have demonstrated in detail the 
reliability and reproducibility of such a comprehensive read-out system, 
applying it to cultured human adult astrocytes (18). Microglia were 
examined under standard culture conditions in the presence of GM-CSF, 
and after treatment with either TNF-α or IFN-γ. When isolated and cultured 
under standard conditions microglia from all donors display a very similar 
pattern of gene expression that is in line with mediators produced in 
(activated) microglia in vivo. Intriguingly, however, pro-inflammatory 
cytokines triggered markedly different responses in different microglia 
cultures. These findings suggest that human adult microglia from different 
sources and/or regions of the CNS may have an innate propensity to respond 
in different ways to a pro-inflammatory insult. 
 
Materials and methods 
 
Donors 
Microglia were obtained from post-mortem sub cortical white matter 
provided by the Netherlands brain bank after rapid autopsy. The 
Netherlands Brain Bank supplies post-mortem material from clinically well 
documented and neuropathologically confirmed cases. Autopsies are 
performed on donors with written informed consent from the donor or from 
direct next of kin. All procedures applied in the experiments described in our 
paper have been approved by the local ethics committee of the free University 
of Amsterdam. Material from nine different donors was used including  two 
control donors (without any neurological disorder), four donors with 
Alzheimer’s disease (AD), one donor with Multiple sclerosis (MS), one 
donor with non-Alzheimer dementia and one donor with dementia with 
senile involutive cortical changes and Lewy bodies. Additional donor 
characteristics are given in Table 6.1. 
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Table 6.1. D
onor characteristics 
 D
onor 
nr 
D
onor# 
Sex 
A
ge 
PM
 delay
a 
C
linical history
b 
C
ause of death 
1 
01-002 
fem
ale 
83 
3h 30m
 
D
em
entia w
ith s.i.c.c./L.b.v. 
cachexia, dehydration 
2 
01-006 
fem
ale 
91 
5h 45m
 
non-dem
ented control 
sudden death, suspected m
yocard infarction 
3 
01-010 
fem
ale 
84 
4h 15m
 
A
D
 
cachexia, dehydration 
4 
01-013 
fem
ale 
68 
4h 51m
 
A
D
 
dehydration 
5 
01-027 
fem
ale 
50 
14h 35m
 
non-alzheim
er dem
entia 
suicide 
6 
01-033 
m
ale 
75 
6h 20m
 
non dem
ented control 
dehydration, pneum
onia 
7 
01-042 
fem
ale 
71 
6h 45m
 
A
D
 
dehydration 
8 
03-052 
m
ale 
53 
5h 30m
 
M
S 
respiratory insufficience 
9 
03-057 
fem
ale 
68 
3h 50m
 
A
D
 
pneum
onia, dehydration 
 a PM
 = post-m
ortem
  
b s.i.c.c. : senile involutive cortical changes; L.b.v.: Lew
y bodies variant no A
lzheim
er's disease or Parkinson's disease ;  
A
D
:  A
lzheim
er's disease; M
S: m
ultiple sclerosis 
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Isolation and in vitro culture of human adult microglia  
Human adult post-mortem microglia were obtained as previously described 
(19,20). Briefly, sub cortical white matter samples were collected and 
meninges and visible blood vessels were removed before mincing the tissue 
into small cubes. The tissue fragments were incubated for 20 min at 37°C in 
0.25 % trypsin (Sigma, St. Louis, MO) and 0.1 mg/mL bovine pancreatic 
DNAse I (Boehringer Mannheim, Germany). After digestion, cell 
suspensions were gently triturated and washed with culture medium 
containing DMEM/HAM-F10 supplemented with 10 % fetal calf serum 
(FCS; Biowhittaker, Verviers, Belgium) and antibiotics. After centrifuging 
for 10 min at 470 g at 20°C the cell suspensions were passed through a 100-
µm nylon filter (Falcon, Franklin Lakes, NJ) and myelin was removed by 
Percoll gradient centrifugation for 30 min at 1,400 g at 20°C. To lyse 
erythrocytes cells were resuspended in a solution containing 155 mM 
NH4Cl, 1 mM KHCO3 and 0.2 % BSA and kept on ice for 20 min. After 
centrifuging for 10 min at 470 g at 20°C the cell pellet was washed once 
with culture medium and microglia were plated in 25 cm2 culture flasks or 
6-well plates (Costar, NY, USA). Recombinant human granulocyte-
macrophage colony stimulating factor (rhGM-CSF; PeproTech Inc, Rocky 
Hill, NJ) promoting in vitro proliferation of microglia (21,22) was added at 
a concentration of 20 ng/mL in fresh culture medium every 3 days. The 
purity of the microglia cultures was verified by staining with murine 
monoclonal anti-human CD68 (DAKO, Glostrup, Denmark) as a microglial 
marker (23), rabbit polyclonal anti-glial fibrillary acidic protein (GFAP; 
ZYMED, San Francisco, CA) as an astrocyte marker, and murine 
monoclonal anti-myelin basic protein (MBP; Boehringer Mannheim, 
Germany) as an oligodendrocyte marker. The microglia cultures were found 
to be essentially 100 % CD68-positive. No cells were found to express 
GFAP or MBP. Microglia were cultured 10 to 14 days and additionally 
treated for 48 h with 500 U/mL of either recombinant human TNF-α or 
IFN-γ (PreproTech Inc, Rocky Hill, NJ). Microglia from donors 1, 2, 6, 7 
and 8 were treated with TNF-α and microglia from donors 4, 5 and 9 were 
treated with IFN-γ. 
 
RNA isolation 
Culture medium was removed and cells were washed with PBS. RNA was 
isolated using RNAzol B (Campro scientific, Veenendaal, The Netherlands) 
according to the manufacturer’s instructions. Briefly, microglia were 
collected in RNAzol B and kept on ice. Chloroform was added to a final 
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concentration of 10 % (Sigma-Aldrich chemie, Steinheim, Germany) and 
cells were shaken firmly and kept on ice for another 5 min and centrifuged 
for 15 min 14,000 g at 4°C. The aqueous solution was transferred to a new 
tube and an equal volume of ice-cold isopropanol (Sigma-Aldrich chemie, 
Steinheim, Germany) was added, precipitation of RNA was carried out 
overnight at 4°C.  After precipitation the samples were centrifuged for 30 
min 14,000 g at 4°C and the pellet was washed with 75 % ethanol and 
centrifuged again. After drying the pellet was dissolved in RNA-se free 
water.  
 
mRNA profiling using cDNA arrays  
Analysis of the mRNA profile of microglia was performed by hybrid 
selection of radioactive labeled cDNA on high-density Clontech Atlas 
arrays of membrane-bound cDNA probes, as previously described (18). 
Briefly, total cellular RNA was extracted from the microglia and poly A+ 
RNA was separated from total RNA. Radioactive cDNA probes were 
prepared by adding dNTP-mix, DTT, MMLV RT and [32P]-dATP and 
incubating for 25 minutes at 50°C. Hybridization of the radioactive cDNA 
probes to the membrane was carried out overnight. Specifically bound 
radioactivity was analyzed and quantitated by phosphor-imaging. The 
hybridization signal for each gene probe, present in duplicate on the array, 
was calculated as the mean of these duplicates, corrected for background 
intensity and quantified using software provided by the manufacturer. 
Relative hybridization signals were calculated by dividing the absolute 
signals by the mean signal for all 9 housekeeping reference genes on the 
corresponding array, and multiplying this ratio by 1,000. Statistical analysis 
was performed using Pearson correlation analysis to compare gene profiles 
from different microglia cultures before and after cytokine treatment. 
 
Results  
 
Gene profiles of human microglia from different donors 
Human adult CD68-positive primary microglia in culture provided with 
GM-CSF developed small cell bodies and a bi-polar morphology over 
periods of 1 to 2 weeks (Figure 6.1).
Chapter 6 
 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this period, microglia did not show the highly ramified morphology that 
typifies resting microglia in an intact CNS but a bi-polar shape, reflecting a 
distinct state of activation induced by isolating and culturing the cells. Gene 
expression profiles were recorded for cultures of microglia derived from 
nine different donors using cDNA arrays that allow monitoring of 268 genes 
encoding cytokines, chemokines, growth factors and their receptors.  
The profiles of the twenty most abundantly expressed genes encoding 
cytokines, chemokines, growth factors and their receptors were very similar 
for the microglia cultures obtained from the different donors. Table 6.2 lists 
those profiles along with standard deviations and coefficients of variation in 
the nine separate analyses. Among the most abundantly expressed genes are 
several chemokines such as CCL2, CCL3 and CXCL8.  Also the migration 
inhibitory factor-related proteins (MRP) 8 and MRP14 are abundantly 
expressed, which are known to be expressed at elevated levels in microglia 
in traumatic brain injury or during cerebral malaria (24,25). Together with 
high expression of chemokines, expression of these MRP markers therefore 
confirm that cultured microglia are different from fully resting microglia, 
consistent with their altered morphology. In addition to the above gene 
products, three family members of bone morphogenetic proteins (BMP) 
including BMP4, BMP2A and BMP2B are highly expressed. These 
 
Figure 6.1. Human adult microglia in culture 
 
Microglia were isolated from sub cortical white matter and cultured for 2 weeks in the 
presence of GM-CSF as described in materials and methods. Microglia displayed a 
uniform morphology typified by small cell bodies and a bipolar shape (A; phase contrast 
microscopy, magnification 10x). Microglia cultures were found to be essentially 100 % 
pure as verified by staining for CD68 (B; magnification 20x). 
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mediators are known to be involved in different stages of neural 
development and exert functions in neuroprotection (26). In fact, several 
other mediators expressed at high levels in microglia also appear to have a 
predominant function in neuroprotection and regeneration. This for example 
also applies to pleiotrophin and its closely related gene HBNF-1 that 
promote growth and neurite extension (27), endothelin-2 (28,29,30), nerve 
growth factor receptor and neuromodulin (or GAP-43) (31). Neuromodulin 
has not been documented before in human microglia, neither has the 
currently documented expression of ribonuclease angiogenin inhibitor and 
Flt3-ligand. Especially the latter novel microglia product is of interest since 
Flt3 and its ligand have recently gained increasing attention as key 
mediators in dendritic cell development (32) and our current data therefore 
suggest that a similar pathway may control also microglia development.  
To validate the results of the gene profiling analysis, we compared our data 
to the set of microglial gene products that have been documented previously 
by others (Table 6.3). To the extent that they were represented on the array, 
all products previously found by others in human microglia in vivo, or in 
cultured human microglia, using varying techniques including 
immunohistochemistry, PCR or ELISA were also detected by the current 
analysis. In all cases, expression levels were at least 10 % of the mean levels 
found for the set of house-keeping genes that served as a reference.  This 
confirms that cultured microglia in their partially activated state are at least 
partially representative for the gene profile of microglia in vivo.  
To compare gene profiles in cultured microglia from different donors the 
degree of similarity between the nine different profiles was investigated by 
a Pearson correlation analysis (33). As shown in Table 6.4, correlation 
coefficients were 0.75 on average, ranging between 0.5 and 0.9, which 
reflects a reasonable level of similarity. The highest correlation coefficient 
of 0.936 was found between the microglia gene profile of donor 8 (MS) and 
that of donor 6 (control). The lowest correlation of 0.521 was found 
between the profiles of donors 8 (MS) and 4 (AD). Together, these data 
indicate that gene profile as established using the current cDNA array is a 
stable feature in all nine microglia cultures. No obvious correlation could be 
discerned between the profiles and several features of the material including 
post-mortem delay, age or sex of the donor or clinical history of CNS 
disease.
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Table 6. 3. Genes previously reported to be expressed in human microglia  
from control donors (without any treatment) 
Name Material Reference mean relative signal intensity 
on array (n=9) 
CXCR1, CXCR2 adult 52 106 
CXCR3, CXCR5 adult 53, 54 not on array 
CXCR4 adult, fetal 55, 56 409 
CCR2 adult, fetal 57 122 
CCR3, CCR5 adult 58 not on array 
CCR4, CCR6 adult 54 not on array 
TNF-α adult 59 686 
TGF-β adult 60 230 
TGF-β1,  -β2,  -β3 adult 61 230 
TGF-βR1, TGF-βR2 adult 61 158 
IL-1 adult 62 446 (α, β variant) 
IL-1α adult 60 177 
IL-1β  adult 60 714 
IL-6 adult 60 682 
IL-1R antagonist adult 60 882 
CD43 adult 63 not on array 
CXCL8 (IL-8) adult, fetal 52, 64 106 
CD40 adult, fetal 65 691 
CCL2 (MCP-1) fetal 12 1415 
CCL3 (MIP-1α) fetal 66 921 
CCL4 (MIP-1β) fetal 66 374 
CCR3, CCR5 fetal 67 not on array 
CX3CR1 fetal 68 not on array 
CSF-1 fetal 69 351 
IL-1β fetal 59 714 
IL-10 fetal 70 296 
IL-12 fetal 70 145 (α, β variant) 
IL-15 fetal 71 118 
IL-16 fetal 72 not on array 
TNFαR1 fetal 73 665 
IL-1RI fetal 70 200 
IL-1RII fetal 70 513 
IL-5R fetal 70 282 
IL-6R fetal 70 220 
IL-9R fetal 70 207 
CD137 fetal 74 not on array 
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The effect of TNF-α or IFN-γ  treatment on microglia gene expression 
profiles 
Next, we investigated the response of cultured human microglia to the pro-
inflammatory cytokines TNF-α and IFN-γ.  Due to the limited numbers of 
microglia isolated from each tissue sample and the relatively large amount 
of RNA required for gene profiling, each culture was treated with only 
one type of stimulation. Five microglia cultures from different donors were 
treated for 48 h with TNF-α, and three cultures with IFN-γ. Microglia 
morphology or proliferation rates were not visibly affected over this 2-day 
treatment period by the addition of either cytokine.  
Tables 6.5 and 6.6 present a summary of the results and highlight which 
genes were either induced or suppressed as compared to the untreated 
microglia in each of the samples. The most striking feature of the results is 
the lack of correspondence between responses in individual microglia 
cultures, contrasting the very similar profiles in each culture when left 
untreated. Taking into account a threshold value of 2 as a meaningful level 
of induction, expression of only two genes was induced in at least three out 
of the five cultures treated with TNF-α. These two genes were the vitamin 
B3 receptor (the G-protein coupled receptor HM74) and the cytokine 
receptor Epstein virus-induced gene 3. No other genes were found to be 
induced in more than two out of the five different cultures. After addition of 
IFN-γ, again only two genes were found to be induced in two out of the 
three cultures treated, viz. stem cell factor and the small inducible cytokine 
A1. None of the other genes expressed at higher levels in a given culture 
displayed a similar induction in other cultures. Some genes were even found 
to be induced in one culture and suppressed in another (e.g. follicle 
stimulating hormone receptor, IL-9 and frizzled-related FrzB) emphasizing 
the remarkable lack of correspondence in the changes observed.  
With regard to genes whose expression was suppressed by either treatment 
the lack of correspondence was even more striking. No single gene product 
was suppressed in at least two different cultures by a factor of at least 2, 
despite the presence of quite a range of gene products that were suppressed 
in individual cultures (Table 6.6).  
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Table 6.5. Genes induced in different microglia cultures after treatment 
with TNF-α and IFN-γ 
name gene code 
donor 
1 
donor 
2 
donor 
6 
donor 
7 
donor 
8 
Induction after TNF-α treatment       
vitamin B3 receptor (HM74) D10923 4.27 1.55 1.57 2.47 2.78 
interleukin-17 (IL-17) U32659 3.40 1.26 0.60 1.53 1.50 
erythroid differentiation protein  (EDF) J03634 3.23 1.34 0.94 2.16 1.45 
CD135 (stem cell tyrosine kinase 1, STK1) U02687 3.20 1.15 1.18 2.12 1.08 
CXCL8 (IL-8) Y00787 3.08 1.23 1.14 1.47 1.24 
glial cell line-derived neurotropic factor (GDNF)  L19063 0.98 0.71 13.07 0.79 1.90 
ciliary neuronotrophic factor (CNTF) isoforms B & C A26792 0.85 0.49 8.72 0.75 0.81 
interleukin-1 alpha  (IL-1α) X02851 0.88 1.31 4.26 1.38 2.00 
colon carcinoma kinase 4 (CCK4)  U33635 1.15 0.65 3.17 1.15 0.59 
follicle stimulating hormone receptor (FSHR) M95489 0.69 0.46 2.77 0.87 0.88 
CXCL6 (granulocyte chemotactic protein 2, GCP 2) X78686 2.31 0.82 1.27 2.82 0.33 
transforming growth factor-beta 3 (TGF-β3) J03241 0.66 0.68 0.87 2.47 0.44 
small inducible cytokine A1 (SCYA1), T-cell-secreted 
protein I-309  
M57502 
 
1.58 
 
1.10 
 
0.69 
 
2.41 
 
1.58 
 
CXCL2  (MIP2-α)  X53799 1.80 1.64 1.16 1.97 5.41 
interleukin-9 (IL-9) X17543 1.15 0.46 1.02 1.03 4.29 
interleukin-13 (IL-13) L06801 0.31 0.91 2.51 0.95 3.60 
Epstein-Barr virus-induced gene 3 (cytokine receptor 
EBI3) 
L08187 
 
2.94 
 
1.10 
 
11.93 
 
2.13 
 
3.51 
 
       
name gene code 
donor 
4 
donor 
5 
donor 
9   
Induction after IFN-γ treatment       
stem cell factor (SCF) M59964 3.09 0.60 3.34   
small inducible cytokine A1 (SCYA1), T-cell-secreted 
protein I-309  
M57502 
 
3.01 
 
1.14 
 
2.75 
   
B-cell growth factor 1 (BCGF1) M15530 2.84 1.52 1.00   
interleukin-7 receptor alpha subunit (IL-7R-α) M29696 2.78 0.92 1.30   
interleukin-3 (IL-3) M14743 2.56 1.75 1.72   
placenta growth factors 1 + 2 (PLGF1 + PLGF2 ) X54936 0.91 2.43 1.26   
transforming growth factor-beta (TGF-β) X02812 1.51 2.06 1.07   
prohibitin (PHB) S85655 1.09 2.00 0.79   
interferon regulatory factor 1 (IRF1) X14454 1.49 0.77 5.33     
vitamin B3 receptor (G-protein-coupled receptor 
HM74) 
D10923 
 
0.70 
 
0.70 
 
3.00 
   
interleukin-1 alpha  (IL-1α) X02851 1.15 1.12 2.49   
Values in bold indicate induction by at least a factor 2 with a signal intensity of at least 150 
in treated cultures. Underscored values in italics indicate suppression by at least a factor 2 
and a signal intensity of at least 150 in untreated cultures. 
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Table 6.6. Genes suppressed in different microglia cultures after treatment  
with TNF- α and IFN-γ 
name gene code 
donor 
1 
donor 
2 
donor 
6 
donor 
7 
donor 
8 
Suppression after TNF-α treatment       
insulin-like growth factor II (IGF2) M29645 0.18 0.70 10.34 2.20 0.74 
interferon gamma (IFN-γ) X01992 0.29 1.27 0.97 1.30 1.05 
interleukin-13 (IL-13) L06801 0.31 0.91 2.51 0.95 3.60 
frizzled-related FrzB (FRITZ) + FrzB + frezzled 
(FRE) 
U91903 + 
U24163  
0.32 
 
1.18 
 
4.35 
 
2.28 
 
1.11 
 
manic fringe U94352 0.33 0.78 0.87 0.54 0.84 
ephrin type-A receptor 2  M59371  0.12 0.25 3.49 1.98 0.83 
kidney epidermal growth factor (EGF) X04571 0.62 0.32 1.56 1.87 0.94 
delta-like protein (DLK) U15979 0.49 0.33 10.54 1.23 0.54 
CD117 (proto-oncogene tyrosine-protein kinase kit) X06182 0.61 0.34 0.36 1.40 0.72 
papillary thyroid carcinoma-encoded protein  M31213  0.86 0.35 5.83 2.12 0.82 
lunatic fringe U94354 1.16 0.85 0.44 0.62 1.33 
interleukin-1 receptor type I  (IL-1R1, CDW121A)  M27492 0.94 0.64 0.46 1.61 1.17 
hepatocyte growth factor activator (HGF activator) D14012 1.52 0.71 0.49 1.06 0.98 
growth inhibitory factor, metallothionein-III (MT-
III) 
D13365 
 
1.10 
 
0.74 
 
0.49 
 
0.58 
 
1.34 
 
CD114 (GCSF-R) M59818 0.68 0.92 0.91 1.30 0.17 
granulocyte-macrophage colony-stimulating factor 
receptor α  
X17648 
 
1.41 
 
0.96 
 
0.86 
 
1.13 
 
0.26 
 
interferon consensus sequence-binding protein 
(ICSBP) 
M91196 
 
0.67 
 
0.63 
 
0.99 
 
1.64 
 
0.29 
 
CXCL6 (granulocyte chemotactic protein 2, GCP 2) X78686 2.31 0.82 1.27 2.82 0.33 
interferon regulatory factor 1 (IRF1) X14454 1.19 1.00 0.85 1.45 0.48 
      
name gene code 
donor 
4 
donor 
5 
donor 
9     
Suppression after IFN-γ treatment      
thrombin receptor (TR) M62424 0.49 1.16 1.50  
TKT (neurotrophic tyrosine kinase receptor-related 
3) 
X74764 
 
0.83 
 
0.38 
 
1.13 
  
CXCL8 (IL-8) Y00787 0.96 0.39 1.26  
teratocarcinoma-derived growth factor 1 (TDGF1) M96955  0.56 0.40 0.64  
interleukin-17 (IL-17) U32659 0.99 0.42 0.91  
insulin-like growth factor binding protein 3 
(IGFBP3) 
M31159 
 
0.98 
 
0.48 
 
0.89 
  
inhibin alpha subunit  (INHA) M13981 1.18 1.59 0.25  
smoothened, GX U84401 0.94 1.60 0.37  
fibroblast growth factor 8 (FGF8) U36223 1.41 0.66 0.37  
Flt3 ligand (SL cytokine)  U04806 0.72 0.69 0.43  
manic fringe U94352 0.55 1.21 0.43   
Values in bold indicate suppression by at least a factor 2 and a signal intensity of at least 
150 in untreated cultures. Underscored values in italics indicate induction by at least a 
factor 2 and a signal intensity of at least 150 in treated cultures. 
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Discussion 
Much remains to be established about the way microglia respond to and 
participate in the communication network of cytokines, chemokines and 
growth factors in the human CNS. Examining cultured microglia from 
human post-mortem brain appears an attractive approach to clarify their cell 
biological functions. So far, however, it has remained unclear to what extent 
such cultured microglia behave in a reproducible manner or to what extent 
they are representative for microglia in an intact CNS in vivo. In this study, 
we attempted to address these issues by a comprehensive analysis of the 
profile of cytokine, chemokine and growth factor gene expression in 
cultured microglia derived from different donors both before and after 
treatment with pro-inflammatory cytokines.  
Both in their morphology and in their gene expression cultured microglia 
reflect a distinct state of activation as compared to resting microglia in vivo. 
Cells are bi-polar and express high levels of the activation-associated 
chemokines CCL2, CCL3 and CXCL8 along with the activation markers 
MRP8 and MRP14, that are undetectable in resting microglia in vivo 
(34,35). Clearly, cultured microglia are different from the highly ramified 
resting microglia in normal brains and spinal cord. This is hardly surprising 
since microglia are highly responsive and will inevitably undergo some 
form of activation as the result of mechanical and metabolic stress during 
isolation, confrontation with serum components and growth factors in the 
culture medium, and of elimination of CNS-borne silencing signals (36). 
The effects for example of GM-CSF (present in our culture medium) on the 
gene profile of macrophages (37) and neonatal murine microglia have 
previously been documented (38).  
Under our standard culture conditions, gene expression profiles of microglia 
from different donors are very similar. This common profile reveals two 
important features of cultured microglia. First, several of the mediators 
expressed at relatively high levels appear to be mediators of neuroprotection 
and regeneration. Expression of neuromodulin, endothelin-2, bone 
morphogenetic proteins 2A, 2B and 4 and pleiotrophin along with the low-
affinity nerve growth factor receptor are clear clues that microglia may very 
well actively participate in signaling functions involved in controlling repair 
rather than only producing a polarized pro-inflammatory reaction. This is 
fully in line with the increased awareness that microglia are not just 
mediators of host defense and antigen-presentation, but exert direct 
protective functions in the CNS as well.  
Secondly, the mediators found at the highest levels fully correspond to gene 
products previously documented by others in human microglia either in vivo 
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or in vitro. Table 6.3 lists cytokines, chemokines and growth factors 
previously reported by others to be expressed in partially activated human 
microglia. To the extent that these products were represented on the array 
used in this study, all products could be readily detected and were found to 
be expressed at levels of at least 10 % of that of the mean of the house-
keeping genes used as reference. This not only confirms the validity of the 
cDNA read-out assay as such, but also indicates that cultured microglia at 
least partially reflect microglia as found in vivo.  
In sharp contrast to the reproducible gene expression patterns of microglia 
from different donors when cultured under standard conditions, treatment 
with the pro-inflammatory cytokines TNF-α or IFN-γ led to a widely 
diverse response in each individual culture. None of the 268 genes displayed 
a consistent induction or suppression in all cultures tested and often, even 
opposing effects were observed in that certain gene expression signals 
increased in one culture while decreasing in another under the same 
experimental condition. Technical issues are highly unlikely to have caused 
this variation since reproducibility of the cDNA array analysis in its own 
right is confirmed not only in the first part of the present study, but has been 
firmly established also in a previous study of gene expression profiles in 
astrocytes using the same technology (18).  
Only limited data on the response of human microglia to TNF-α or IFN-γ 
are available to compare our results to. One of the best documented 
responses to these mediators includes elevated production of IP-10 (39) but 
unfortunately, IP-10 is not represented on the array used here. Hua and Lee 
also reported induction of CXCL8 (IL-8) by TNF-α but not by IFN-γ. This 
appears to be largely in line with our data showing an overall lack of 
induction of CXCL8 by IFN-γ, and marked induction of CXCL8 by TNF-α 
in one donor (3-fold induction) and some induction (up to 1.5-fold) in the 
others. Interestingly, also Hua and Lee already noted marked variation in 
their data between microglia cultures from different donors, yet did not 
elaborate on this issue. A recent cDNA-based analysis of the murine 
microglia response to the combination of TNF-α and IFN-γ has revealed a 
large variety of genes being induced by the stimulus including several genes 
that are also represented on our array (40). The correspondence between 
these data on murine microglia and ours on human microglia is generally 
very poor, in this case possibly also due to species differences. A 
comparison between the response to TNF-α/IFN-γ for murine and human 
microglia, and especially a comparison between the different cultures 
analyzed in this study thus reveal a striking lack of consistency. We 
interpret this to signify real biological variations among the different 
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microglia cultures that only manifest themselves upon a challenge with pro-
inflammatory signals, and that remain latent as long as the microglia are 
kept under standard culture conditions. A very similar set of observations 
have recently been reported for gene profiling studies of activated murine 
microglia (41,42). Again, strikingly heterogeneous gene expression patterns 
were monitored for different activated microglia despite a consistent 
methodological approach. In a study of the effects of the beta amyloid 
peptide 1-42, Walker and co-workers also performed gene profiling analysis 
but in their approach RNA samples from five different microglial cultures 
were pooled prior to the analysis (43), unfortunately leaving open the issue 
of donor-to-donor variations. 
In our study, no obvious link could be discerned between the data and 
several features of the microglia source such as post-mortem delay, age, sex 
or clinical history of the donor. Different anatomical origins of the microglia 
samples are, however, a possible source of the variation. Production of 
neurotrophins and inflammatory mediators including IL-1, IL-6, nitric oxide 
and metallothionein, expression of MHC molecules as well as the response 
to brain insults in vivo differ from one region of the brain to another 
(42,44,45,46,47,48). Along with the fact that microglia densities across the 
CNS can vary considerably (49,50) this contributes to differential 
responsiveness and functionality of different brain regions in infection and 
trauma. The precise anatomical origin of the microglia cultures examined in 
the present study has not been documented in detail thus precluding any 
further analysis of this parameter. Another factor that affects microglia 
functions is age (48,50,51). Yet, the influence of this factor is prominent at 
early stages of mammalian life but much less documented for later stages. 
The way age differences in our donor group between 50 and 90 could have 
affected microglia performance remains to be clarified. Finally, microglia 
from different regions of the brain could proliferate at different rates under 
the culture conditions applied here. This could well lead to a certain level of 
skewing in the final population of cells that are subjected to gene profiling 
after being kept in culture for 1-2 weeks in order to obtain the required level 
of phenotypic purity.  
When taken together our data indicate that cultured human microglia from 
different donors represent populations of partially activated cells with a 
stable gene expression profile, irrespective of the post-mortem delay, 
anatomical origin or clinical features of the donor. Yet, when further treated 
with TNF-α or IFN-γ, microglia from different donors respond very 
differently. This variation does not appear to be a methodological artifact 
but a biological reality that requires further examination.  
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The main goal of the studies described in this thesis was to investigate the 
immune modulatory effects of human herpesvirus-6 (HHV-6) infection on 
cultured human adult glial cells. For many years virus infections have been 
thought to be associated with the development of MS. Among a wide range 
of viruses (as discussed in Chapter 1) HHV-6 and Epstein-Barr virus (EBV) 
have been particularly suspect of an involvement in MS. For HHV-6, 
elevated levels of viral protein have been demonstrated in CNS tissue, 
lymphoid tissues, peripheral blood lymphocytes, serum, saliva and urine 
from MS patients as compared to healthy controls (1,2,3,4,5,6,7,8,9). Yet, 
not all studies have confirmed such a difference between MS patients and 
healthy controls (10,11,12,13,14).  
To understand the possible impact of HHV-6 on CNS inflammation such as 
occurs in MS, it is necessary to clarify the cell-biological effects of viral 
infection on glial cells. These effects may very well involve modulation of 
inflammatory reactions since the HHV-6 genome encodes multiple gene 
products that interfere with chemokine signaling in infected target cells. The 
U12 region of the viral genome encodes a beta chemokine receptor for 
CCL2, CCL3, CCL4 and CCL5, the U51 region encodes a CCL5 receptor 
and the U83 region encodes a chemokine-like CCR2 agonist (15,16,17,18). 
HHV-6 infection might therefore well alter host cell responses to 
inflammation in ways that are dependent on the type of host cell and its state 
of activation. A few examples have already been identified in which HHV-6 
infection changes the behavior of the target cell. Infection of human 
macrophages with HHV-6 impairs the ability of macrophages to produce 
IL-12 in response to IFN-γ (19), most likely by inducing high levels of IL-
10 in the infected macrophages (20). In a T-cell line designated SupT1, 
HHV-6 infection induces expression of several pro-inflammatory genes but 
in this case, suppression of anti-inflammatory gene products including IL-10 
was noted (21). Thus, while HHV-6 does appear to interfere with cytokine 
signaling by the target cell, the way this works out may very well be 
different from one type of cell to another. Essentially nothing is known on 
the effects of HHV-6 on gene expression in glial cells that are key in 
controlling inflammatory reactions in the CNS.  
While the association of HHV-6 with MS is still controversial EBV is 
clearly associated with MS. This association is based on the observations 
that essentially all MS patients (99 to 100 %) are EBV seropositive versus 
90 to 95 % of the general population, and that anti-EBV immunoglobulin 
(Ig) serum titers are higher in MS patients (22,23,24). Furthermore, a 
delayed primary infection with EBV resulting in a history of infectious 
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mononucleosis is associated with a significantly increased risk of MS later 
on in life (25,23). Intriguing is the fact that EBV infection in B cells 
enhances the expression of αB-crystallin, a small stress protein that has 
previously been identified as an immunodominant antigen in CNS myelin of 
MS patients (26). The impact of EBV infection on glial cells is similarly 
still unclear. In our own experiments, human adult astrocytes in culture 
could be infected with EBV but levels of infection (i.e. the percentage of 
infected astrocytes) were too low to allow for a reliable analysis of the 
effects of EBV on the gene profile.  
In present study we focus on the effects of HHV-6 on glial cells. To clarify 
the role of HHV-6 in neurodegenerative diseases such as MS we examined 
its impact on immune regulation of cultured human adult astrocytes. Both 
normal cultured astrocytes were used and astrocytes provoked by a mixture 
of the cytokines TNF-α, IL-1β and IFN-γ that mimics an inflammatory 
microenvironment such as exists in active MS lesions (27). It is well known 
that increased levels of TNF-α, IL-1β and IFN-γ are present in active MS 
lesions, and in MS patients levels of these cytokines in CSF and serum 
correlate with disease progression (28,29,30,31). TNF-α is present in acute 
and chronic active MS lesions but absent from chronic silent lesions (32). 
Increased levels of TNF-α produced by CD4+ T-cells correlate with long-
term increase in lesion load in MS patients as assessed by MRI (33). More 
recently, detailed gene expression analysis have confirmed elevated levels 
of IFN-γ in active MS lesions (34). Thus, examining astrocytes in the 
presence of all three pro-inflammatory cytokines will help reveal how the 
cells might behave under conditions of active inflammation in an intact 
brain.  
 
In vitro studies of human adult glial cells 
The current availability of well characterized post-mortem human brain 
tissue provides the opportunity to culture different human adult glial cell 
types such as astrocytes, microglia and oligodendrocytes. The use of 
primary human adult glial cells offers an advantage over the use of 
transformed immortalized cell lines since primary cells are expected to 
represent more closely the behavior of glial cells in vivo. Obviously, cell 
cultures are different from an intact human brain in lacking a variety of 
intercellular and matrix-derived interactions. Nevertheless, they do provide 
unique possibilities to approach different experimental conditions that are 
impossible to examine in humans notably including experimental virus 
infection. 
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Throughout our studies, we have used cultured human adult post-mortem 
astrocytes and microglia obtained from white matter brain samples as 
described previously (Chapter 2 and 6). Post-confluent monolayers of 
cultured human adult astrocytes were used at passage four. Astrocytes 
cultured up to eight passages show a star-shape morphology and proliferate 
well. After passage eight cells become sensitive to the CD95/CD95L 
apoptosis pathway and tend to enter apoptosis (35). Human microglia were 
grown in medium supplemented with granulocyte macrophage colony-
stimulating factor (GM-CSF) and used within 2 weeks after isolation at a 
time when essentially pure cultures are obtained. The addition of GM-CSF 
as a growth factor may seem artificial but it should be kept in mind that 
GM-CSF is expressed by both human adult astrocytes and microglia. GM-
CSF is also expressed by astrocytes in MS lesions and the growth factor 
therefore represents a biologically relevant stimulus (36). Cultured 
microglia have a bi-polar morphology and represent partly activated cells 
similar to what can be expected during inflammatory activation in the CNS 
such as occurs in MS.  
There are several practical differences between astrocyte and microglia 
cultures that need to be accommodated. The yield of astrocytes, using a 
given quantity of brain tissue, is higher as compared to the yield of 
microglia. Astrocytes proliferate faster and can easily be frozen and thawed 
which makes it possible to culture large numbers of cells. Therefore, it is 
also possible to investigate different experimental conditions using separate 
astrocyte cultures derived from a single donor. Microglia on the other hand 
are more difficult to obtain, they cannot be frozen and the possibilities to 
investigate different stimuli on microglia derived from a single donor are 
limited.  
Communication between glial cells and their environment occurs besides 
physical interactions via a wide range of mediators such as cytokines, 
chemokines, growth factors and their receptors. Rather than focusing on a  
few selected cytokine reporter genes in an attempt to understand the impact 
of viral infection on glial gene profiles, we used a cDNA gene profiling 
array containing 268 gene sequences encoding cytokines, chemokines, 
growth factors and their receptors. Each of these 268 genes represents a part 
of the intricate network of cytokines and chemokines, each of which could 
possibly be influenced by the virus. In this way, a broad view could be 
obtained on the impact of viral infection on glial cell functions without 
having to resolve to high-density arrays which would have posed a serious 
data processing challenge as well as a financial challenge. To allow 
ourselves the more or less routine use of this array as a gene profiling read-
out instrument, we first investigated the reproducibility of the data 
General Discussion 
 153 
generated from repeated astrocyte cultures obtained from a single donor, 
and also from astrocyte cultures from different donors (as described in 
Chapter 2). Apart from the technical performance of the gene array itself, 
major issues to be addressed included whether the gene profiles obtained 
were not only reproducible as such, but also representative for glial 
responses in vivo. Below these issues are discussed to illustrate that in our 
view gene profiling of cultured human glial cells as performed here does 
indeed provide a reliable and representative image of the behavior of the 
cells in the human brain.  
 
Gene profiles of cultured astrocytes and microglia are highly 
reproducible 
To address the issue of reproducibility we first examined gene profiles of 
separately cultured astrocytes samples that had all been derived from a 
single donor. In total, eight of such samples were compared. Furthermore, 
gene profiles were recorded of a further two astrocyte cultures, each from 
two different healthy donors. As described in Chapter 2 the gene expression 
profiles obtained in this exercise show a remarkable agreement both 
amongst the eight separate astrocyte cultures from the same donor as well as 
amongst astrocytes from different donors. This confirms not only that the 
gene profiling technique as such is reproducible, but also indicates that gene 
expression profiles are very similar between astrocyte cultures from 
different donors.  
In Figure 7.1 the coefficient of variation (CV; standard deviation expressed 
in percentage) is plotted against the strength of the gene expression signal 
for each of the 268 genes analyzed in the eight astrocyte cultures from a 
single donor. As can be expected, higher gene expression signals are 
characterized by relatively low CV values and vice versa. It is unlikely that 
the CV values are significantly influenced by variations in the hybridization 
step of the analysis (when radioactive cDNAs are blotted onto the filter) 
since the duplicate gene hybridization signals that we have monitored 
throughout our studies are always extremely reproducible. Most likely, high 
CVs for low signals merely reflect a general relationship between the 
reliability of quantification and the signal-to-noise ratio also since a similar 
curve is obtained for the relationship between CVs and gene expression 
signals in nine different microglia cultures (Figure 7.3). Figure 7.2 shows 
the relationship between the coefficient of variation as observed for gene 
expression signals in astrocytes derived from different donors. Interestingly, 
CV values associated with this comparison tend to be somewhat lower than 
those represented in Figure 7.1. Clearly, it is highly unlikely that gene 
profiles of astrocytes obtained from different donors would resemble each 
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other more than gene profiles of separate astrocyte cultures from a single 
donor. More likely, the difference can be accounted for by the fact that the 
gene profiles on which Figure 7.2 is based were analyzed on the same day 
while the data on which Figure 7.1 is based were collected on different 
days. Thus, slight technical variations will affect the result in a noticeable 
manner, albeit that such variations are not expected to selectively affect a 
few genes only. Nevertheless, critical comparisons of gene profiles are 
therefore best performed using gene profiles analyzed in parallel at the same 
time. In particular in Figure 7.1, reflecting a comparison of eight astrocyte 
gene profiles obtained from a single donor, a few genes deviate markedly 
from the general relationship between CV and gene expression signal 
strength. These few genes, whose detection is accompanied by relatively 
large coefficients of variation, include IL-4, IL-6, BMP2A and endothelin-2. 
Interestingly, these genes are highly inducible in astrocytes. BMP2A is 
induced upon TNF-α treatment, as described in Chapter 2, while IL-6 is 
induced upon cytokine treatment of HHV-6-infected astrocytes, as 
described in Chapter 4. Also data from others - as reviewed in Chapter 2 - 
confirm that IL-4, IL-6 and BMP-2A are easily inducible in human 
astrocytes (37,38). Therefore, it is likely that these particularly inducible 
genes easily respond to subtle variations in cell culturing conditions or cell 
density which results in the unusually high coefficients of variation. Such an 
apparent intrinsic variability for certain genes in certain types of cells is 
useful to keep in mind when comparing the effects of certain stimuli on 
gene profiles.
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Figure 7.1. mean relative signal intensities and their coefficients of variation of 
268 genes from eight array experiments using astrocytes from one single donor 
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Figure 7.2. mean relative signal intensities and their coefficients of variation of 268 
genes expressed in astrocytes from three different donors 
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Figure 7.3. mean relative signal intensities and their coefficients of variation of 268 
genes expressed in microglia from nine different donors 
 
 
 
Another important issue to consider is the question to what extent the 
changes we have observed in gene profiles of cultured glial under various 
conditions cells mirror the behavior of astrocytes and microglia in vivo. First 
of all, the changes in the expression of cytokines and chemokines we have 
monitored are very similar to what others have observed in cultured human 
glial cells, while using different samples and different analytical techniques. 
Almost without exception, genes that have been reported by others to be 
induced in cultured glial cells and that are included on the array, are also 
found to be induced by our approach. This comparison is elaborated on in 
detail in Chapters 2 and 6. Clearly, validating the results of any gene 
profiling study could be performed by verifying certain gene induction data 
using RT-PCR, or by establishing increased protein levels by ELISA or 
immunocytochemistry. Yet, in an approach such as ours the question arises 
for how many genes the expression data should be verified for any 
validation to be sufficiently thorough. In view of the above excellent 
correspondence between our data and those reported by others, we made no 
attempts to validate individual gene expression signals by alternative 
technologies. We feel strengthened in this attitude by comparing our data to 
all the available data that have been published on cytokine and chemokine 
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expression by astrocytes and microglia in (inflamed) human brain tissue. A 
variety of studies, using different brain samples and different analytical 
techniques and reagents provides a relatively broad framework of data to 
compare our results to. As elaborated in detail in Chapters 2 and 6, this 
comparison shows that essentially all cytokines or chemokines that have 
been documented by others to be expressed by glial cells in inflamed human 
brains, and that are represented on the cDNA array, are also found in 
cultured and partially activated glial cells. This consideration goes beyond 
the question of technical validation and appears supportive for the idea that 
cultured glial cells indeed mirror the behavior of glial cells in an intact 
(inflamed) human brain to a sufficient extent to be considered as a useful 
model.  
As an extension to the above statement, it should be noted that the data in 
Chapter 6 do reveal an unexpected and interesting aspect of microglia 
cultures. Despite the fact that microglia cultures from different donors 
appear to have similar gene profiles under standard culturing conditions, 
their response to a pro-inflammatory signal varies widely (see also below). 
It is unknown as yet to what extent this may reflect actual differences 
between microglia residing in different parts of the brain, or being derived 
from different donors. We do not consider it to be an experimental artifact 
and take this observation as an encouragement to more closely examine the 
possibility of regional differences in microglial responses also in an intact 
brain. 
When taken together, our data appear supportive for the idea that cultured 
human astrocytes and microglia largely behave reproducibly, except for the 
unusual diversity in microglia responses to pro-inflammatory signals. The 
use of a low-density cDNA array as described by us produces data that are 
very much in line with data obtained by others and, more importantly, they 
are very much in line with data on astrocyte and microglia responses in an 
intact human brain. Using cell culture models, therefore, relevant data may 
be obtained that will help understand the way glial cells behave in an intact 
brain under a variety of conditions.    
 
Detection of astrocyte signaling genes as well as novel gene products  
The twenty most abundantly expressed genes in astrocytes (described in 
Chapter 2) include genes that are mediators primarily involved in 
proliferation, growth  and differentiation as well as their receptors. These 
are the low affinity nerve growth factor receptor (NGFR), insulin-like 
growth factor binding protein 2 (IGFBP2), thymosin beta-10 (TMSB10), 
pleiotrophin (PTN, involved in growth and migration), connective tissue 
growth factor (CTGF), vascular endothelial growth factor (VEGF) and its 
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receptor, insulin receptor (INSR) and epidermal growth factor receptor 
(EGFR). Furthermore, TNF-α and IL-6 are abundantly expressed consistent 
with their role in growth and neuronal survival, apart from their 
involvement in inflammatory reactions (39). The chemokine CCL2 is also 
abundantly expressed in astrocytes, along with its receptor. This expression 
is consistent with a key role of CCL2 as an autocrine migratory factor for 
astrocytes during gliosis (40). As also explained below, this emphasizes that 
post-confluent astrocyte cultures such as the ones used in our studies can be 
considered to mimic a state of gliosis in vitro.  
The data collected by us reveal expression of several genes that to the best 
of our knowledge have not previously been documented for astrocytes.  
These novel astrocyte gene products include IL-17, CD70 (CD27 ligand), 
CD147 (basigin, neurothelin), BIGH3, UFO/Axl receptor tyrosine kinase 
and TEK/TIE-2 receptor tyrosine kinase. Especially the astroglial 
expression of IL-17 is an interesting observation since this cytokine has 
hitherto been regarded as a powerful pro-inflammatory mediator that is 
specifically expressed by memory T-cells (41). That IL-17 in MS lesions 
would be produced by such memory T-cells is already questionable since 
IL-17 is expressed at much higher levels in chronic inactive MS plaques as 
compared to early active lesions, inconsistent with T-cells being the prime 
source (34). Our data suggest that astrocytes could in fact be responsible for 
marked IL-17 production at these late stages of MS plaques. The presence 
of IL-17 in inactive plaques (but not active plaques) along with the notion 
that at this stage astrocytes are primarily involved in controlling 
inflammation appears at odds with a strictly pro-inflammatory character of 
IL-17.  More likely, astrocyte-derived IL-17 may play a role in down-
regulating inflammation and/or promoting repair. Together, our data 
therefore suggest that IL-17 may not only be produced by cells other than 
just memory T-cells, but also that it may have dual functions dependent on 
its context. The recent interest in IL-17 as a target for therapy in MS 
maytherefore require revision.  
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Impact of pro-inflammatory cytokines on astrocyte gene profiles: 
Limited synergistic effects  
In Chapter 2, we described the effects of an inflammatory mimic consisting 
of TNF-α, IL-1β or IFN-γ on the astrocyte gene profile. Cytokine treatment 
of post-confluent astrocyte monolayers had no effect on the morphology of 
the astrocytes. In general, TNF-α and -to a lesser extent- IL-1β lead to 
induction of several genes whereas IFN-γ has very little impact on 
expression levels of the set of 268 genes represented on the array used. As a 
rule, any effect of these cytokines involved gene induction and no genes 
were found to become down-regulated by any of the cytokines.  
TNF-α treatment of astrocytes resulted in increased expression of several 
chemokines including CCL2 (MCP-1), CCL4 (MIP-1β), CCL5 (RANTES), 
CXCL6 (GCP 2) CXCL8 (IL-8) and CXCL9 (MIG). Furthermore, growth 
and neuroprotective factors were induced such as BMP-2A, BMP-3, 
neuromodulin (GAP43), BDNF and G-CSF and receptors including the 
CRF-receptor, the calcitonin receptor (CTR) and TKT. The response to IL-
1β involves largely the same range of genes, but responses were blunted in 
comparison to the response upon TNF-α treatment. One of the more 
prominent responses of astrocytes to either cytokine is production of 
strongly increased quantities of CXCL8. As a matter of exception, we 
verified increased CXCL8 expression under such conditions by confirming 
elevated levels of CXCL8 in the culture medium using ELISA (data not 
shown). CXCL8 is an interesting response marker of astrocytes that is 
activated by a variety of stimuli and appears to contribute to the resistance 
of astrocytes to CD95/CD95L (Fas/Fas ligand)-mediated apoptosis. Upon 
triggering CD95 on astrocytes CXCL8 and its receptor CXCR2 are both 
induced and they are associated with an increased resistance to apoptosis, 
apparently as part of a self-defense response by astrocytes (42).  
Astrocytes treated with a mixture of all three cytokines together displayed 
responses that are largely similar to those found in response to TNF-α or IL-
1β alone and little indication was obtained for any synergistic effects, 
despite reports by others that appear to indicate otherwise (43,44,45,46). We 
observed only a few apparently synergistic effects in that IGFBP3, CXCL2 
(MIP2-α), ephrin A3, follistatin-related protein, neurotrophin-3, IL-11, IGF-
2 and erythropoietin receptor were found to be induced by the mixture of 
cytokines while being less affected by each of the cytokines individually. 
Most of these effects, however, were rather modest. The cytokine IL-11 for 
example, which is discussed below in more detail since it is strongly 
induced upon cytokine treatment of HHV-6-infected astrocytes, was 
Chapter 7 
 160 
induced by a factor of only 3 by the cytokine mixture, and by a factor of 1.4 
by IL-1β alone. Overall, responses to the mixture of cytokines were 
quantitatively less as compared to responses to either TNF-α or IL-1β alone, 
for reasons that are not fully understood.  
Lack of any striking synergy between the three pro-inflammatory cytokines 
appears consistent with a number of astrocyte features observed in our 
studies. First of all, treatment of astrocytes with the individual cytokines as 
well as with the cytokine mixture had no influence on expression levels of 
the receptors for TNF-α, IL-1β or IFN-γ, indicating that their sensitivity 
towards each cytokine remains similar. Secondly, astrocytes respond rather 
slowly to any stimulus, rendering it unlikely that any indirect effect 
mediated by a responsive gene can exert its influence within the 48 h-time 
frame of most experiments. As detailed in Chapter 2, changes in astrocyte 
mRNA levels upon cytokine treatment develop and accumulate over periods 
of days rather than hours. This repeated observation is fully in line with 
previous reports by others in which cytokine-induced chemokine responses 
in human fetal astrocytes at the level of mRNA consistently took 48 to 72-h 
periods to fully develop (46). Therefore, while synergistic effects between 
cytokine-induced changes may well occur at later stages, they do not appear 
to influence astrocyte responsiveness in the first 2 days. 
 
HHV-6 infection impacts marginally on the astrocyte gene profile  
So far only four studies have been published documenting experimental 
HHV-6 infection in cultured human glial cells including primary astrocytes, 
oligodendrocytes and microglia (47,48,49,50). In these studies glial cells 
were infected using HHV-6-infected T-cell lines as well as cell-free HHV-6 
(free from any viable cells or sub cellular particles). He et al. reported that 
infecting human fetal astrocytes using a HHV-6-infected T-cell carrier line 
in stead of cell-free virus resulted in more rapid formation of syncytia (47).  
In these previously reported studies on HHV-6-infected glial cells the 
percentages of infected cells have remained undocumented. Yet, to reliably 
study the impact of infection on astrocyte gene profiling it is important to 
have a substantial part of the cultured astrocytes stably infected with HHV-
6. In our studies, we succeeded to achieve reproducible and stable infection 
of up to 35 % of all cells in a given astrocyte culture as determined by 
staining for HHV-6 protein, as described in Chapter 3. Improving on this 
level of infection by co-culturing larger numbers of infected carrier T-cells, 
or by culturing the infected astrocytes for periods longer than 3 days proved 
impossible. Culturing the HHV-6-infected astrocytes for longer periods for 
example resulted in rapid expansion of uninfected astrocytes since these 
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proliferate faster than infected ones. Since the effectiveness of infection was 
quite different between the two T-cell lines used as a source of virus, 
increased levels may perhaps be obtained using yet other T-cell lines. 
Alternatively, it is conceivable that HHV-6-infected astrocytes may be 
separated from uninfected ones by selecting for increased cell size that 
typifies syncytia, or by employing certain flowcytometric markers. 
When examining the effects of HHV-6 on astrocytes, the first striking 
observation in our studies was that HHV-6 infection impacted only 
marginally on the cytokine and chemokine profile of the astrocytes. After 
HHV-6 infection of cultured astrocytes only leukocyte interferon-inducible 
peptide, CCL5, IGFBP6 and VEGF-C were markedly induced. Furthermore, 
a few genes were suppressed including trk-T3, IGFBP complex acid labile 
chain, ephrin type-A receptor 5, ephrin-B2, TGF-β3, colon carcinoma 
kinase 4 and transmembrane receptor PTK7. In our view, it is unlikely that 
these findings would have been much different if the analysis would have 
been performed at times different from our more less standard 48-h analysis 
time. Also in monocytes for example, cytokine responses to HHV-6 
infection (if any) required 2 to 5 days to develop (51). Furthermore, as 
stated above already, astrocyte responses to any stimulus develop at the 
level of mRNA at a time scale of days rather than hours. One could argue 
that the lack of any major response to HHV-6 infection largely reflects the 
fact that only 30-35 % of the cells are infected and that any potential 
response is diluted by gene expression signals of uninfected astrocytes. Yet, 
when this is corrected for by using a threshold of an induction factor of 1.6 
rather than 2.0 to evaluate changes, still no marked changes are observed. 
Also, the response of infected astrocyte cultures to cytokines, as described 
below, demonstrate that even when representing a minority of the cells, 
HHV-6 infected astrocytes can very well impact in quite a dominant way on 
(changes in) the overall gene profile.  
It is of interest to compare our data on the gene profile in HHV-6-infected 
astrocytes to changes in HHV-6-infected T-cell lines. This comparison that 
is presented in Chapter 4 reveals striking cell-specific features, also by 
revealing that none of the changes in gene expression induced by HHV-6 in 
the SupT1 T-cell line (21) could be reproduced in the HSB-2 T-cell line 
used by us. Studies by others indicate that expression of CCL2, CCL3, 
CXCL8, IL-10, IL-12 and IFN-γ is enhanced in HHV-6-infected human 
endothelial cells, hepatoma cell line or monocytes as assessed by PCR and 
ELISA (20,51,52,53,54). Yet, none of these genes were induced in infected 
astrocytes. Clearly, HHV-6 has widely different effects in different types of 
target cells.  
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Inflammatory conditions change the silent HHV-6 infection  
In strong contrast to the limited impact of HHV-6 infection on the astrocyte 
gene profile is the dramatic impact of infection on the response by 
astrocytes to pro-inflammatory cytokines. While hardly or not at all induced 
by pro-inflammatory cytokines in normal astrocytes, infected astrocytes 
displayed strongly elevated levels of IL-10 and IL-11, both powerful anti-
inflammatory cytokines. Apart from its well-known immune-regulatory 
effects on T-cells IL-10 also regulates the cytokine network in microglia by 
inhibiting expression of the pro-inflammatory cytokines IL-1β and TNF-α 
as well as of the receptors for IL-2 and IL-6 (55). Both IL-10 and the 
similarly anti-inflammatory IL-11 are known to down-regulate expression 
of the co-stimulatory molecules CD80, CD86 and CD40 as well as MHC 
class II on microglia, thus frustrating their ability to activate infiltrated T-
cells (56,57,58,59). Also, a remarkable collection of chemokines are 
induced in HHV-6 infected astrocytes by TNF-α, IL-1β and IFN-γ, different 
from uninfected cells. These genes including CCL3, CCL5, CXCL2 and 
CXCL6 are important mediators in the communication between astrocytes 
and microglia and play key roles in their migration. Cytokine treatment of 
HHV-6-infected astrocytes also resulted in induction of type I interferon 
response regulating genes such as leukocyte interferon-inducible peptide, 
interferon regulatory factor 1 and interferon consensus sequence binding 
protein. Induction of these genes is consistent with the notion that a type I 
interferon response is generally geared towards combating viral infection, 
though not necessarily involving an adaptive immune response. 
Furthermore, many growth-related genes were induced such as neuregulin, 
VEGF, metallothionein along with the growth- and immune-modulatory 
genes IL-1β and IL-6. As elaborated in Chapter 4, the set of growth-related 
genes that are induced in infected astrocytes was completely different from 
the one induced in uninfected astrocytes.  
Still much is to be learned on how certain cytokines, chemokines and 
growth factors influence glial cells functioning, and how they could 
influence each other in this respect. Therefore, it is near to impossible to 
judge the overall significance of the changes effected by HHV-6 at face 
value. Yet, we consider it to be quite remarkable that at least two of the best 
known anti-inflammatory cytokines, viz. IL-10 and IL-11, with proven 
immune down-regulatory qualities are among the products triggered in 
HHV-6-infected cytokines by a pro-inflammatory stimulus. We therefore 
interpret this as an indication that HHV-6 infection of astrocytes is more 
likely to result in local immune-regulatory reactions rather than pro-
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inflammatory reactions. In other words: based on these data HHV-6 
infection of astrocytes is not very likely to activate a local inflammatory 
response but rather tends to down-regulate any response that might emerge 
as the result of other factors. Or in yet other words: in astrocytes HHV-6 
promotes an immunologically suppressive environment.  
It is remarkable that HHV-6 infection accounts for such a dramatic change 
in gene profiles after cytokine treatment despite the fact that only about 30 
% of the astrocytes are infected. It is unlikely that gene expression data are 
influenced by viral spread upon cytokine treatment or other indirect effects. 
First of all, no signs of virus release from infected astrocytes are visible in 
culture and it is known that in oligodendrocyte cultures such also does not 
occur (48). Infected astrocytes engage in syncytium formation and can all be 
stained for HHV-6 protein. No individual astrocytes outside syncytia were 
ever found to contain HHV-6 protein and cytokine treatment had no visible 
impact on these features over the 48-h monitoring period. Secondly, it is 
unlikely that any newly released virus would effectively infect novel target 
cells since our experience with cell-free HHV-6 preparations as described in 
Chapter 3 indicates such cell-free virus to be highly ineffective in this 
respect. Thirdly, indirect effects on gene expression caused by mediators 
from the infected astrocytes are also unlikely to occur, given the timeframe 
of astrocyte responses. Given these considerations, we take the data on gene 
expression profiles in HHV-6-infected cultures to indeed reflect changes in 
the 30-35 % infected cells only. The impact of cytokine treatment on these 
gene profiles is therefore much stronger as compared to uninfected 
astrocytes and essentially overrules them, in all three experiments 
performed. This was also found with infected astrocytes treated with the 
individual cytokines separately as described in Chapter 4 which produced 
consistent data and again pointed to very limited synergistic effects between 
these cytokines.  
 
HHV-6 infection and cytokine treatment impact on TLR expression in 
astrocytes  
To explore the role of TLR in the host response to neurotropic infections we 
investigated the impact of HHV-6 infection as well as the pro-inflammatory 
cytokines TNF-α, IL-1β and IFN-γ on expression in astrocytes of the TLR 
family members 1 through 4. These family members were monitored since 
previous data thought us that TLR5 to 10 are hardly expressed at all in 
astrocytes. Also, the combination of HHV-6 infection and cytokine 
treatment was examined for its effects since in Chapter 4 it is illustrated that 
HHV-6 exerts very different effects on astrocytes under normal versus pro-
inflammatory culturing conditions. In agreement with our previous studies 
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(60) we found that also in the cultures studied in the present context 
astrocytes express high levels of TLR4 while TLR3 was less abundantly 
expressed, followed by TLR1 and TLR2. HHV-6 infection of astrocytes led 
to a preferential and strong increase (10- to 200-fold) in expression levels of 
TLR3-encoding mRNA while the expression levels of TLR1, TLR2 and 
TLR4 were only modestly increased (less than 10-fold). Infection of the 
astrocytes with HHV-6 did not result in any suppression of TLR expression. 
Treatment of astrocytes with either IL-1β, TNF-α or IFN-γ, as well as with 
a mixture of these cytokines resulted in changes in TLR expression levels 
similar to those triggered by HHV-6  infection and again, in preferential 
induction of TLR3. Interestingly, the combined effects of cytokine 
stimulation and HHV-6 infection appeared to induce higher levels not only 
of TLR3 again (5- to 100-fold), but in this case induction was observed also 
of TLR2, between 10- to 100-fold. Changes in TLR1 or TLR4 expression 
were much less marked. The data, however, also reveal significant donor to 
donor variations that render it difficult to draw any far-reaching conclusions 
based on the more or less preliminary set of data generated in the current 
study. Extension of our data by analyses of more astrocyte samples will be 
required to confirm preferential induction of TLR3 by both HHV-6 and 
cytokines, and the additional induction of TLR2 by cytokines in infected 
astrocytes. 
Intuitively, one might expect viral infection to trigger enhanced expression 
of TLR that are specifically suited to recognize viral structures and help 
mount a host defense response against it. In this case, however, such does 
not seem to be the case. Generally, engagement of TLR including TLR3 and 
TLR2 activates intracellular signaling pathways that trigger enhanced 
production of IL-1β, TNF-α and IL-6, among a variety of other responses. 
While different TLR do activate different sets of responses, these mediators 
are invariably part of these responses, notably also in astrocytes (Bsibsi et 
al, unpublished data).  As described in Chapter 4 however, HHV-6 infection 
of astrocytes does not result in any significant induction of either one of 
these common TLR-responsive gene products, whereas they would be 
expected to become detectable at least to some extent in the 48-h time frame 
of the experiment in case they were triggered. This strongly suggests that 
while HHV-6 does induce elevated levels of TLR3, the virus does not 
trigger its activation within the time frame of the experiment. This appears 
to be in line with the current knowledge on TLR3 agonists. So far, only 
double-stranded RNAs (and certain double-stranded segments of mRNAs or 
siRNAs) are known to activate TLR3 and it is not obvious how HHV-6 
infection could provide these ligands to surface-exposed TLR3 receptors on 
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astrocytes. Intriguingly, therefore, HHV-6 infection of astrocytes appears to 
prime the infected cells to become responsive to TLR3 ligands that are 
probably not derived from HHV-6 itself.  
 
Differences in microglia gene profiles upon inflammatory cytokines 
treatment  
Apart from studies on astrocyte gene profiles, part of the work described in 
this thesis focused on microglia. The main observation in this part was that 
while gene expression profiles were very similar among cultures of 
microglia derived from different donors, the changes triggered by pro-
inflammatory cytokines differ widely among different cultures, for reasons 
not fully understood at present.  
Microglia cultured under standardized conditions show abundant expression 
of the chemokines CCL2, CCL3 and CXCL8 that each plays key roles in 
glial cell migration. Receptors for these chemokines are expressed not only 
in microglia themselves, but also on astrocytes. Also pleiotrophin, a 
molecule with anti-apoptotic, mitogenic, angiogenic and chemotactic 
activities is abundantly expressed. Interestingly, CCL2 and pleiotrophin are 
also expressed at high levels in astrocytes suggesting that they are important 
mediators in the intercellular communication by glial cells (see also below). 
Along with pleiotrophin, that has distinct neuroprotective qualities, also the 
known neuroprotectants neuromodulin (GAP-43, a novel microglia gene), 
endothelin-2, and several members of the bone morphogenetic protein 
family (BMP2A, BMP2B and/or BMP4) are expressed at high levels by 
microglia. These molecules share a variety of activities that promote 
neuronal growth and neurite extension and mediate neural development. 
Expression of these genes involved in neuroprotection and regeneration 
indicates that microglia actively participate in protective functions in the 
CNS. This is consistent with the generally growing awareness that microglia 
are not just destructive cells that limit themselves to phagocytosing cell 
debris and pathogens, but are active also in promoting neuronal survival and 
repair. 
As stated before, while these abundantly expressed genes are consistently 
found in different microglia cultures, the way these cultures respond to pro-
inflammatory stimuli including TNF-α or IFN-γ turned out to be very 
different each time we performed an analysis. None of the differences 
appeared to correlate with known parameters of the donor samples used to 
generate the microglial cultures including post-mortem delay, age, sex or 
clinical history of the donor. Variations in the outcome of well-controlled 
experiments are obviously frustrating to researchers but in this particular 
case, we strongly believe that the variation in microglia responses is not the 
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result of experimental artifacts or methodological flaws, but reflects a real 
biological difference amongst the different cultures. Interestingly, similar 
experiences by others can be tracked in a few papers. Hua and Lee for 
example, also noted marked variation in chemokine responses to cytokine or 
LPS stimulation between human microglia cultures from different donors, 
but somehow did not show any data on this variation nor elaborated on the 
issue (61). In a study on the effects of the amyloid-beta peptide on human 
microglia gene profiles, the researchers pooled mRNA samples from five 
different human samples rather than analyze individual samples, possibly 
again to accommodate individual variations (62). Also in murine microglia 
variations occur in the response monitored in different preparations, as 
reported by Carson and colleagues in their attempts to identify microglial 
activation markers (63).  
One factor that might help explain the above variations includes regional 
differences in microglia features. For example it has recently been reported 
that expression of the TREM-2 receptor on murine microglia differs quite 
markedly from one region of the brain to the next (64). Also other features 
of microglia may be differentially developed dependent on the architectural 
context of the cells. A challenge remains to understand this remarkable 
heterogeneity in human adult microglia gene profiles upon activation. 
 
Communication between astrocytes and microglia 
As explained above, the cell culture models for either astrocytes or 
microglia that we have examined in our studies do not really represent fully 
resting cells as one would expect to find in a normal healthy brain. 
Astrocytes as well as microglia are proliferating and they are stimulated not 
only by the mere act of culturing but also by serum-derived factors or 
exogenous growth factors such as GM-CSF. Their morphology is consistent 
with cells being taken to a certain state of activation. For astrocytes, this 
state may be comparable to the state of gliosis. Likewise, microglia in 
culture do not fully resemble the highly ramified resting microglia that are 
seen in normal brain tissue, but display clear signs of activation as well. In 
both cases, cells may be considered to reflect glial cells as they will behave 
immediately following trauma, infection or damage.  
It is of interest to consider the mediators that according to our gene profiling 
studies now emerge as the most dominantly expressed gene products in 
either type of cell under these partially activated states. Figure 7.4 
summarizes the soluble mediators that are amongst these dominant products 
(indicated by bold “production“ arrows) and separates them into two 
groups. The first is composed of mediators that are relevant to regulating 
growth and differentiation of surrounding neurons and endothelial cells, and 
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include well-known growth factors such as VEGF, GAP-43 and 
pleiotrophin. The second group includes primarily mediators of growth and 
migration for astrocytes and microglia themselves; receptors for these 
molecules are expressed by either type of glial cell (indicated by thin 
“receptor” arrows in Figure 7.4). Well-known mediators that emerge as 
dominant players in the cross-talk between astrocytes and microglia include 
IL-1β and TNF-α, consistent with a wealth of previous data on these key 
mediators. Microglia are particularly active in producing IL-1β while 
astrocyte are strong TNF-α producers. Yet, a few other equally dominant 
mediators emerged from our studies that are less well known as mediators 
of glial cell interaction. These include CCL2 (formerly known as MCP-1) 
that our data reveal as a dominant product of both cultured astrocytes and 
microglia, and for which the receptor is also expressed by either type of cell. 
Also bone morphogenetic protein 2A (BMP-2A) is amongst the mediators 
produced at high levels by both cell types. While BMPs are known to affect 
the developmental program of astrocytes, their effects on microglia remain 
to be established. Interestingly another BMP family member, viz. BMP2B 
and/or BMP4 (the gene probe on the array does not discriminate between 
these two) is a major microglia product indicating that BMPs are mediators 
in glial cell communication.  
A final point that could be made when reflecting on the data that are 
summarized in Figure 7.4 is the notion that several chemokines are involved 
in the intercellular communication between astrocytes and microglia, along 
with being autocrine mediators. Chemokines are often regarded as 
molecules that primarily serve to recruit hematogenous lymphocytes and 
thus promote inflammation. Yet, it should be kept in mind that also glial 
cells themselves - more close neighbours - are very well capable of binding 
and responding to several chemokines (65). Several chemokines, especially 
CCL2, CCL3 and CXCL8, may thus well be primarily aimed at guiding 
local glial cell responses rather than recruit macrophages or T-cells.
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Possible role of HHV-6 in MS 
In Chapter 1 of this thesis we discussed general mechanisms by which virus 
infection could conceivably promote an autoimmune response against 
myelin, and thus trigger or facilitate the development of MS. Such potential 
mechanisms include molecular mimicry and determinant spreading. To the 
best of our knowledge, only one report suggests a possibility for molecular 
mimicry to be operational in the case of HHV-6 by identifying a 7-amino 
acid peptide sequence in the U24 region of HHV-6 that is identical to the 
myelin basic protein sequence 96-102 (66). While cross-reactivity of T-cell 
clones could be demonstrated at the level of reactivity to synthetic peptides, 
no evidence exists to suggest that such cross-reactivity occurs at the 
biologically relevant level of reactivity to protein antigens. Also given other 
considerations, such as for example the widespread character of HHV-6 
infection in humans, it seems unlikely that such cross-reactivity is relevant 
to understanding a possible involvement of HHV-6 in MS. Likewise, a 
mechanism of determinant spreading (viral infection triggers novel response 
cascades against autoantigens from the infected tissue) does not appear to be 
a likely one in the case of HHV-6. As explained before, our collective data 
on the impact of HHV-6 on astrocytes does not appear to be supportive at 
all to the idea that HHV-6 infection would spark a local inflammatory 
reaction, at least not after infecting astrocytes. Instead, the reverse is much 
more likely in that HHV-6 infection counteracts local inflammation.  
HHV-6 infection of astrocytes clearly does not lead to production of factors 
that could activate T-cells such as IL-12 or high levels of TNF-α. One of the 
few pro-inflammatory mediators induced at all is CCL5 (RANTES) which 
may assist in recruitment of T-cells into the CNS. Yet, it should be kept in 
mind that the several different receptors for CCL5 are also expressed on 
glial cells themselves and the modest increase in CCL5 production in HHV-
6-infected astrocytes may easily be absorbed by neighbouring cells before it 
could lead to levels of CCL5 that would attract T-cells from the blood. Even 
when an inflammatory reaction would start for another reason, the presence 
of HHV-6 in astrocytes would help down-regulate T-cell activity by 
triggering production of the anti-inflammatory mediators IL-10 and IL-11, 
as already elaborated above and in Chapter 4.  
Apart from activating T-cells, HHV-6 infection could also lead to activation 
of microglia, which is the very first step in the formation of an MS lesion 
and a key element in its continued development. Potent activators of resting 
microglia including IL-1β, TNF-α and GM-CSF, however, are not induced 
in astrocytes by HHV-6 in any detectable way. Only when inflammation has 
already started (mimicked in our experiments by the addition of exogenous 
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TNF-α and IL-1β) increased production of IL-1β and GM-CSF was 
observed, a response that would further stimulate microglia activation and 
proliferation under such conditions. It should be noted, however, that at this 
stage microglia produce distinct neuroprotective mediators and no longer 
represent polarized destructive elements (67,68). Also (as noted before), the 
mediators IL-10 and IL-11 that are released by infected astrocytes under 
these conditions are known to down-regulate expression of the major co-
stimulatory molecules CD40, CD80 and CD86 as well as MHC class II on 
microglia, impairing their ability to activate T-cells (56,57,58,59). Thus, our 
data suggest that HHV-6 infection of astrocytes will not easily lead to 
activation of surrounding microglia in resting tissue. When another factor 
has already triggered a local inflammatory reaction HHV-6-infected 
astrocytes can further promote microglia activation but at the same time 
inhibit their antigen-presenting ability.  
More subtle ways for HHV-6 to influence pathogenic autoimmune 
responses in MS could include effects on apoptosis-induction pathways, a 
central mechanism for astrocytes to eliminate undesirable (autoimmune) T-
cell activity from the CNS. This mechanism is important in protecting the 
CNS from immune-mediated damage. Human adult astrocytes express both 
CD95 (Fas) and CD95L (Fas ligand) both of which can induce apoptotic 
death in infiltrating T-cells by binding to their counterparts CD95L and 
CD95, respectively, that are expressed on T-cells. Upon infection by HHV-
6, no change in astrocyte expression was observed of any of the apoptosis-
related genes represented on the cDNA arrays including CD95, CD95L,  
Fas soluble protein Apo 1, secreted apoptosis related protein 1 (SARP1), 
SARP3 or apoptosis-related protein TFAR15. These genes were all 
expressed at low but detectable levels in uninfected astrocytes and their 
expression levels remained unchanged upon infection.  
A recent paper by Dietrich and co-workers has suggested yet another way 
by which HHV-6 could influence the development of MS lesions and this is 
by interfering with repair. When oligodendrocyte precursor cells were 
experimentally infected with HHV-6, their proliferation and development 
was markedly impaired (49). If this would also be the case in vivo, an 
obvious effect could be interference with the natural process of myelin 
repair. An inhibiting effect of HHV-6 on the growth and development of 
such oligodendrocyte precursors is in line with our own observation that 
HHV-6 slows down growth in astrocytes as well. Yet in the case of 
astrocytes, diminished growth could be regarded as a positive side effect 
since reduced proliferation of astrocytes (gliosis) may in fact allow for more 
opportunity to repair myelin rather than turning a lesion into an eternally 
dysfunctional scar. In whatever way the net effect of HHV-6 of growth of 
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glial cells may work out in vivo, it still does not represent a likely 
mechanism that could explain a role of HHV-6 as an initial trigger for lesion 
formation in MS.  
When taken together, our data and considerations give us little reason to 
strengthen any suspicion towards HHV-6 as an etiological agent in MS. 
Although we are far from fully understanding all effects that the virus may 
have on CNS functioning, the currently collected pieces of the puzzle all 
point to a more immune-regulatory effect of HHV-6 infection rather than a 
clear-cut pro-inflammatory effect, at least after infection of astrocytes. As 
reviewed above, also no clues were found for other and more subtle ways 
for the virus to promote T-cell mediated autoimmune reactions in the CNS, 
not even under pre-existing inflammatory conditions. The fact in itself that 
HHV-6 is a common infection whereas MS is not a common disease, does 
not necessarily rule out a contributing role of the virus. Like in the case of 
EBV which is also a common infection, multiple ways exist to 
accommodate a virus as a crucial co-factor in the pathogenesis of disease 
without viral infection being equally rare as the disease itself.  
We showed that cultured human astrocytes and microlgia present a unique 
system to examine in detail their response to defined stimuli and virus 
infection. It is our conviction that this will help to understand the way glial 
cells behave in an intact brain under a variety of conditions. The major gene 
products in astrocytes and microglia cultured under standardized conditions 
are genes involved in growth processes. Microglia from different donors 
treated with pro-inflammatory cytokines show a widely diverse gene 
response in each individual culture. In addition the data as described in this 
thesis indicate that infection of astrocytes with HHV-6 is silent, the virus 
has no impact on the astrocyte gene profile. Furthermore, pro-inflammatory 
cytokine treatment of HHV-6-infected astrocytes resulted in an anti-
inflammatory gene response. In conclusion all the data collected by us 
indicate that HHV-6 is highly unlikely to play a pathogenic role in the 
development of MS. 
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Nederlandse Samenvatting 
Virus infectie (met HHV-6) en het cytokinen profiel in menselijke 
hersencellen (glia cellen) 
Doel van het onderzoek 
Het ophelderen van de rol van het humane herpes virus 6 in de hersenen van 
de mens bij de ontwikkeling van multiple sclerose (MS) 
 
MS is een chronische ontstekingsziekte van het centrale zenuwstelsel (CZS) 
met onbekende oorzaak, en waarvoor momenteel geen genezing bestaat. Het 
is de meest invaliderende ziekte van het CZS onder jong volwassenen, de 
ziekteverschijnselen worden meestal tussen de leeftijd van 20 en 40 jaar 
duidelijk. Bij MS patienten raakt de myeline, de witte stof in de hersenen en 
ruggenmerg die zorgt voor overdracht van zenuwprikkels, beschadigd door 
ontstekingen. MS gaat gepaard met vele ziekteverschijnselen, variërend van 
tinteling in de ledematen en tijdelijk slecht zien tot ernstige beperkingen in 
lichaamsbewegingen en tevens vermoeidheid en depressiviteit. Helaas 
ervaren mensen met MS nog vaak onbegrip uit hun omgeving, voortkomend 
uit de onbekendheid van de ziekte. Er is weinig bekend over het ontstaan 
van de ziekte. Door bestudering van de verspreiding van MS weet men dat 
zowel omgevingsfactoren als erfelijkheid de kans op MS beïnvloeden. 
Omgevingsfactoren zoals zonlicht, voeding en infectie met virussen of 
bacteriën kunnen naast het risico op MS ook het beloop ervan beïnvloeden. 
Virussen zijn beruchte micro-organismen. Ze leven in en vaak ten koste van 
andere organismen en passen zich snel aan. Virussen worden van oudsher 
verondersteld een rol te spelen bij het ontstaan en het beloop van MS. In de 
laatste decennia hebben vele onderzoeken de betrokkenheid van virussen bij 
MS ondersteund. Toch ontbreekt het nog aan inzicht over de precieze relatie 
tussen virussen en MS. Immers, de meeste virussen waarvan we vermoeden 
dat ze een rol spelen, zijn vrij normale virussen die het merendeel van de 
bevolking infecteren en allerminst specifiek zijn voor mensen met MS. Hoe 
kunnen deze virussen dan toch een rol spelen? Er is nog nauwelijks iets 
bekend over het gevolg van een infectie op het functioneren van 
hersencellen. Eén van de virussen die verondersteld worden een rol te 
spelen bij MS is humaan herpes virus-6 (HHV-6). Ook bij dit virus is het zo 
dat het niet specifiek is voor de ziekte en in de bevolking veel voorkomt, 
dus ook bij gezonde mensen. Toch wijzen sommige studies erop dat het 
virus vaker en actiever voorkomt in de hersenen van MS patiënten. Daarbij 
wordt vaak zonder meer verondersteld dat de aanwezigheid van het virus de 
ontstekingen verder stimuleert, maar harde gegevens hierover ontbreken. 
Mijn onderzoek was er op gericht om vast te leggen welk effect HHV-6 
infectie nu precies heeft op menselijke hersencellen. Het is natuurlijk niet 
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mogelijk experimentele infecties met HHV-6 in de mens uit te voeren. Een 
goed alternatief lijkt het werken met gekweekte cellen uit hersenmateriaal, 
verkregen na het overlijden van donoren. Dit gebeurde in samenwerking 
met de Nederlandse Hersenbank. Hersencellen kunnen zelfs na de dood heel 
goed worden gekweekt door ze te voorzien van een kweekvloeistof met 
voedingsstoffen, voldoende zuurstof en een juiste temperatuur.  
Wat valt er nu zoal te onderzoeken aan hersencellen in kweek? Gekweekte 
hersencellen kunnen blootgesteld worden aan zelfgekozen virusinfecties en 
verschillende ontstekingsbevorderende stoffen. (wat natuurlijk onmogelijk 
is bij proefpersonen). Op die manier is het dan mogelijk om in detail de 
effecten daarvan te leren begrijpen. Een groot voordeel van gekweekte 
hersencellen is dat er heel nauwkeurig, en per celtype afzonderlijk, gemeten 
kan worden welke stoffen geproduceerd worden. Een belangrijke groep 
stoffen die hersencellen maken is bijvoorbeeld de groep van 
ontstekingsstoffen. Door deze stoffen te maken en vanuit de cel de 
omgeving in te sturen kan een hersencel andere cellen beïnvloeden in hun 
groei, bewegingsrichting en andere activiteiten. Zulke stoffen noemen we 
cytokines en chemokines. Andere belangrijke stoffen die gemaakt worden 
kunnen zenuwcellen beschermen tegen schade, of een nabijgelegen 
bloedvatwand laten openen of juist sluiten. Een hersencel produceert dit 
soort stoffen niet voortdurend, maar pas als daarvoor de juiste prikkels 
worden ontvangen. Vaak is een hersencel daarbij gevoelig voor prikkels die 
gegeven worden door precies dezelfde stoffen die het zelf weer maakt om 
andere cellen te beïnvloeden. Zo ontstaat dus een netwerk van honderden 
stoffen die gezamenlijk en in wisselende samenstelling de ingewikkelde 
activiteiten van allerlei celtypen binnen het zenuwstelsel nauwkeurig sturen. 
Zo kan dan ook een passende reactie verzorgd worden op schade of infectie. 
Gegeven de ingewikkeldheid van dit soort boodschapper-netwerken is een 
goed begrip van de werking ervan afhankelijk van een meetmethode waarbij 
de aanmaak van vele stoffen tegelijkertijd kan worden gevolgd. In het 
onderzoek is daarom gebruik gemaakt van een zogenaamde cDNA array 
profileringstechniek. Bij deze techniek worden filters gebruikt waarop 
“malletjes” zitten voor het gelijktijdig registreren van de aanmaak van 268 
verschillende stoffen. Genetisch materiaal (cDNA) uit de gekweekte 
hersencellen dat die aanmaak van stoffen weerspiegelt wordt radioactief 
gemaakt en op zo’n filter gebracht. Als de cel veel van dit radioactieve 
productie-materiaal oplevert, betekent dat vrijwel zonder uitzondering dat er 
ook veel van die bepaalde stof wordt gemaakt. De honderden verschillende 
“mallen” op de filter kunnen op deze manier gebruikt worden om van even 
zovele stoffen de productie nauwkeurig te meten. Een volledig overzicht, 
ook wel expressieprofiel genoemd, is dan het resultaat.  
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De menselijke hersenen en ruggenmerg bevatten twee belangrijke celtypen, 
neuronen (zenuwcellen) en glia cellen. Neuronen zijn betrokken bij 
informatie overdracht zowel binnen het CZS als in communicatie met de 
rest van het lichaam. Glia cellen ondersteunen en voeden neuronen en doen 
ook mee in bepaalde informatie-circuits. Daarnaast spelen glia cellen een 
heel belangrijke rol in het constant houden van het interne milieu van 
hersenen en ruggenmerg, en het regelen van bloedvatfuncties in het CZS. 
Daarbij hoort ook het regelen van ontstekingsreacties die als regel volgen op 
infecties, zuurstoftekort of andersoortige schade. Glia cellen zijn onder te 
verdelen in astrocyten, microglia en oligodendrocyten. In dit proefschrift is 
gebruik gemaakt van gekweekte menselijke astrocyten (hoofdstuk 2 t/m 
hoofdstuk 5) en gekweekte menselijke microglia (hoofdstuk 6). Astrocyten 
zijn de meest voorkomende cellen in het CZS. Ze zijn vooral betrokken bij 
het ondersteunen en voeden van andere cellen, ze communiceren direct met 
zenuwcellen en bloedvaten en na schade –zoals na een ontsteking tijdens 
MS- zijn ze primair verantwoordelijk voor de vorming van litteken weefsel. 
Microglia zorgen in eerste instantie voor het bevechten van infecties en het 
opruimen van restmateriaal dat ontstaat bij schade, celdood of ontstekingen. 
Ze spelen daarnaast ook een aanvullende rol in herstelprocessen. 
In hoofdstuk 2 is onderzocht of de hierboven beschreven cDNA array 
techniek geschikt is voor het meten van stoffen in gekweekte menselijke 
astrocyten. Dit is eerst gedaan met cellen in een normale kweek, en 
vervolgens met cellen die geactiveerd werden door een paar van de meest 
belangrijke signaalstoffen voor ontstekingen. Deze signaalstoffen zijn 
eerder door anderen gevonden in de ontstekingshaarden van MS en het is 
daarom bekend dat ermee een redelijke nabootsing kan worden verkregen 
van het actieve milieu van zulke haarden. In beide situaties is met de cDNA 
array techniek de aanmaak van een groot aantal boodschapperstoffen door 
astrocyten gevolgd. De array techniek bleek prima geschikt te zijn voor de 
beoogde metingen. Wanneer een populatie astrocyten afkomstig van één 
donor op verschillende tijdstippen in kweek werd genomen en geanalyseerd 
op hun productieprofiel, was het resultaat steeds hetzelfde. Ook wanneer 
astrocyten uit hersenen van andere donoren werden gekweekt werd 
wederom hetzelfde profiel gemeten, ten teken dat de kweek- en 
meetmethode voldoende stabiel en betrouwbaar was en dat astrocyten uit de 
hersenen van verschillende donoren sterk op elkaar lijken. Met de methode 
werd vervolgens in kaart gebracht welk van de honderden verschillende 
stoffen nu precies reageerden op de ontstekingssignalen. Van veel stoffen 
was de productie sterk verhoogd, van sommige stoffen ging de productie 
juist omlaag. Hoofdstuk 2 geeft een compleet overzicht van alle reacties. 
Echt interessant werd het natuurlijk toen ook het virus erbij werd betrokken. 
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In hoofdstuk 3 en 4 is onderzocht wat nu precies het effect is van HHV-6 
infectie op astrocyten. In hoofdstuk 3 is vastgesteld op welke manier zoveel 
mogelijk astrocyten in kweek konden worden geïnfecteerd. Daarbij werd 
onderzocht welke hoeveelheid van het virus het meest geschikt was, en hoe 
lang gewacht moest worden voordat effecten zichtbaar zijn. Na het testen 
van allerlei variaties bleek het maximaal haalbare een benadering waarbij na 
2 dagen ongeveer eenderde van alle astrocyten met HHV-6 geïnfecteerd 
was. Dit was eenvoudig zichtbaar omdat geïnfecteerde astrocyten met elkaar 
versmelten tot één grote reuzencel met vele kernen waarin viraal eiwit 
zichtbaar is. Langer wachten dan 2 dagen, of een grotere hoeveelheid virus 
leidde er slechts toe dat de astrocyten snel doodgingen, hetgeen uiteraard 
niet de bedoeling was. In hoofdstuk 4 is het effect van zo’n experimentele 
infectie op astrocyten bepaald, met gebruikmaking van de cDNA array 
techniek. Verrassend was dat na infectie van de astrocyten er helemaal niets 
veranderde aan de productie van de honderden stoffen gemeten met de 
array. Klaarblijkelijk weet het virus de astrocyt te infecteren zonder dat de 
cel een signaal afgeeft dat er iets aan de hand is. Het is goed denkbaar dat 
dit vermogen van HHV-6 tot “sluipmoord” de doorslag geeft bij zijn succes 
om bij veel mensen het CZS te infecteren zonder direct kwalijke gevolgen. 
Het virus bleek nog verder te gaan. Wanneer er ontstekingssignalen werden 
toegevoegd aan de geïnfecteerde astrocyten, net zoals eerder was gedaan 
met de gewone gezonde astrocyten, bleken de geïnfecteerde astrocyten heel 
anders te reageren. Veel meer beschermende en herstellende stoffen werden 
aangemaakt dan in gezonde cellen, en zelfs een paar uitzonderlijke stoffen 
die ontstekingen krachtig remmen. Hoewel de interpretatie van dit alles niet 
eenvoudig is zonder nog meer proeven te doen, lijkt het profiel dat werd 
gemeten heel sterk te wijzen op de mogelijkheid dat de HHV6 infectie van 
astrocyten veel eerder een ontsteking in het CZS afremt dan bevordert.  
Hoofdstuk 5 (het laatste hoofdstuk gewijd aan astrocyten) beschrijft een 
serie verkennende proeven naar het voorkomen van Toll-like receptoren 
(TLR) in reactie op een HHV-6 infectie. TLR zijn eiwitten die we vanaf de 
geboorte hebben, ze zitten op het oppervlak van cellen om binnendringende 
virussen en bacteriën te herkennen. Er zijn in de mens tenminste tien van 
dergelijke TLR beschreven en op dit moment wordt er wereldwijd veel 
onderzoek gedaan naar hun werking. Meestal worden TLR onderzocht in 
weefsels die speciaal met afweer te maken hebben, zoals lymfeklieren en 
milt. Welke van de tien TLR in het CZS van belang zijn, en of ze betrokken 
zouden kunnen zijn bij herkenning van HHV-6 zijn de eerste vragen die 
opkomen. In de eerste proeven is gevonden dat HHV-6 infectie van 
astrocyten leidt tot verhoging van de aanmaak van sommige TLR. Dit zou 
men wellicht verwachten als een reactie op infectie, aannemend dat die 
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bepaalde TLR dan ook het virus herkennen. Daar bleek evenwel nog niets 
van. De signalen die astrocyten afgeven zodra TLR worden geactiveerd 
traden namelijk niet op. De vraag blijft dus of het virus überhaupt wel door 
TLR kan worden opgepikt en, als dat niet zo zou zijn, waarom de astrocyte 
dan de moeite neemt TLR verhoogd te produceren in reactie op het virus. 
Het is mogelijk dat het virus methoden heeft om binnen de cel de signalen 
van een TLR te blokkeren, en zo afweerreacties te saboteren. 
Hoofdstuk 6 gaat over een ander belangrijk celtype in het CZS, de 
microglia. Microglia zijn lastiger te bestuderen omdat ze niet goed houdbaar 
zijn en alleen direct na hun zuivering uit hersenweefsel onderzocht kunnen 
worden. Anders dan astrocyten kunnen ze niet bevroren bewaard worden. 
Allereerst werd met de cDNA profileringsmethode bekeken of microglia uit 
verschillende donorhersenen een stabiel expressieprofiel hebben. Dat bleek 
inderdaad het geval. Opmerkelijk was dat microglia gestimuleerd met 
ontstekingsstoffen die ook bij de astrocyt waren toegepast, sterk wisselende 
profielen hadden. Microglia uit verschillende bronnen gaven verschuivingen 
in het profiel van de honderden stoffen. Momenteel blijft dit wisselvallige 
gedrag van microglia wat raadselachtig, maar in eerder gepubliceerde 
resultaten van andere onderzoekers vonden we aanwijzingen dat ook zij 
nogal eens geplaagd zijn door wispelturige microglia. Samen met de 
overtuiging dat de meetmethode geen bron van de wisselende resultaten kan 
zijn, gaan we er van uit dat microglia inderdaad nogal wisselend gedrag 
kunnen vertonen wanneer ze geprikkeld raken. Dit heeft mogelijk te maken 
met de precieze plaats in de hersenen waaruit de cellen zijn gezuiverd (was 
niet voor elke proef dezelfde), of met klinische variabelen van de donoren. 
Met dit wisselend microglia gedrag dient in toekomstig werk rekening 
gehouden te worden. Het maakt het werken met gekweekte microglia een 
stukje lastiger dan het werken met astrocyten, maar zeker zo interessant. 
In hoofdstuk 7 (algemene discussie) worden de resultaten kort beschouwd 
en met elkaar in verband gebracht. Natuurlijk zijn er nog geen 
eindconclusies te trekken. Wanneer is onderzoek helemaal af? De vraag of 
HHV-6 een rol speelt in MS blijft open, maar de resultaten uit dit 
proefschrift geven aan dat niet voetstoots mag worden aangenomen dat 
infectie met HHV-6 de ziekte zou verergeren. Integendeel, HHV-6 lijkt veel 
meer een remmende factor te zijn wanneer het in een ontstekingshaard zit. 
Effecten kunnen anders zijn bij infectie van andere celtypen. Met gekweekt 
menselijk hersenmateriaal is dit verder te onderzoeken, maar bij gebruik van 
gekweekte microglia is dus wel enige voorzichtigheid geboden, gezien het 
wispelturige karakter van deze cellen. Maar juist dit karakter, en dat van 
andere celtypen in de menselijke hersenen blijkt zeer toegankelijk te zijn 
met de nu verder ontwikkelde onderzoeksmethoden. 
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